{
    "questions": [
        {
            "body": "Do brown fat cells produce heat?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23834768",
                "http://www.ncbi.nlm.nih.gov/pubmed/26910308",
                "http://www.ncbi.nlm.nih.gov/pubmed/22796012",
                "http://www.ncbi.nlm.nih.gov/pubmed/21196229",
                "http://www.ncbi.nlm.nih.gov/pubmed/23818608",
                "http://www.ncbi.nlm.nih.gov/pubmed/6148836",
                "http://www.ncbi.nlm.nih.gov/pubmed/3083882",
                "http://www.ncbi.nlm.nih.gov/pubmed/26496384",
                "http://www.ncbi.nlm.nih.gov/pubmed/26322018",
                "http://www.ncbi.nlm.nih.gov/pubmed/15058310",
                "http://www.ncbi.nlm.nih.gov/pubmed/6819159",
                "http://www.ncbi.nlm.nih.gov/pubmed/21982742",
                "http://www.ncbi.nlm.nih.gov/pubmed/26912151",
                "http://www.ncbi.nlm.nih.gov/pubmed/27528872",
                "http://www.ncbi.nlm.nih.gov/pubmed/8042786",
                "http://www.ncbi.nlm.nih.gov/pubmed/25642708",
                "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                "http://www.ncbi.nlm.nih.gov/pubmed/27528697",
                "http://www.ncbi.nlm.nih.gov/pubmed/27552974",
                "http://www.ncbi.nlm.nih.gov/pubmed/1550210",
                "http://www.ncbi.nlm.nih.gov/pubmed/25068090",
                "http://www.ncbi.nlm.nih.gov/pubmed/2039657",
                "http://www.ncbi.nlm.nih.gov/pubmed/21123942",
                "http://www.ncbi.nlm.nih.gov/pubmed/9277366",
                "http://www.ncbi.nlm.nih.gov/pubmed/24129212",
                "http://www.ncbi.nlm.nih.gov/pubmed/5262992",
                "http://www.ncbi.nlm.nih.gov/pubmed/24046370",
                "http://www.ncbi.nlm.nih.gov/pubmed/24567786",
                "http://www.ncbi.nlm.nih.gov/pubmed/6315457",
                "http://www.ncbi.nlm.nih.gov/pubmed/541897",
                "http://www.ncbi.nlm.nih.gov/pubmed/25466254",
                "http://www.ncbi.nlm.nih.gov/pubmed/16594742",
                "http://www.ncbi.nlm.nih.gov/pubmed/26749900",
                "http://www.ncbi.nlm.nih.gov/pubmed/22654830",
                "http://www.ncbi.nlm.nih.gov/pubmed/19641492"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0018837",
                    "o": "Heat"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0018837",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0066521"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0066521",
                    "o": "Heat"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0018837",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18591807"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18591807",
                    "o": "heat"
                }
            ],
            "ideal_answer": [
                "Yes, brown fat cells produce heat."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002001",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052437",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006359",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005223"
            ],
            "type": "yesno",
            "id": "58ca906a02b8c6095300002e",
            "snippets": [
                {
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 512,
                    "text": "WAT and BAT are both involved in energy balance. WAT is mainly involved in the storage and mobilization of energy in the form of triglycerides, whereas BAT specializes in dissipating energy as heat during cold- or diet-induced thermogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24567786",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 76,
                    "offsetInEndSection": 288,
                    "text": "Because brown adipose\u00a0tissue (BAT) dissipates energy in the form of heat, increasing energy expenditure by augmenting BAT-mediated thermogenesis may represent an approach to counter obesity and its complications.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25466254",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "text": "Classic brown fat and inducible beige fat both dissipate chemical energy in the form of heat through the actions of mitochondrial uncoupling protein 1. This nonshivering thermogenesis is crucial for mammals as a defense against cold and obesity/diabetes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 105,
                    "offsetInEndSection": 245,
                    "text": "Mitochondrial uncoupling protein 1 in brown fat cells produces heat by dissipating the energy generated by fatty acid and glucose oxidation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22654830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 36,
                    "text": "Brown fat biology and thermogenesis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Brown fat (brown adipose tissue, BAT) primary function is to produce heat. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 353,
                    "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1226,
                    "offsetInEndSection": 1487,
                    "text": "Calorimetric measurements from cell suspensions showed that ATP increased basal heat production of isolated brown fat cells by approximately 40% but had no effect on the greater than fivefold increase in heat production seen with maximal adrenergic stimulation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9277366",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Classic brown fat and inducible beige fat both dissipate chemical energy in the form of heat through the actions of mitochondrial uncoupling protein 1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Brown adipocytes oxidize fatty acids to produce heat in response to cold or to excessive energy intake; stimulation of brown fat development and function may thus counteract obesity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21982742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1032,
                    "offsetInEndSection": 1285,
                    "text": "The occurrence of Types 1 and/or 6 cells that has been revealed in 65 out of the total 180 samples (36%), suggests that the oxidation of fat for the thermogenesis proceeds in the brown fat tissue and that brown fat cells partially undergo fat depletion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 354,
                    "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 333,
                    "text": "In response to cold, both classical brown fat and the newly identified \"beige\" or \"brite\" cells are activated by \u03b2-adrenergic signaling and catabolize stored lipids and carbohydrates to produce heat via UCP1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "The ability of brown adipocytes (fat cells) to dissipate energy as heat shows great promise for the treatment of obesity and other metabolic disorders",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496384",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Inappropriate heat dissipation ignites brown fat thermogenesis in mice with a mutant thyroid hormone receptor \u03b11",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24046370",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Brown fat and vascular heat dissipation: The new cautionary tail",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25068090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 458,
                    "text": "Brown adipose produces heat as a defense against hypothermia and obesity, and the appearance of brown-like adipocytes within white adipose tissue depots is associated with improved metabolic phenotypes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21123942",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1764,
                    "offsetInEndSection": 1902,
                    "text": "In the same manner, marked ability to produce a considerable amount of heat was evidenced in  brown fat tissue of children and teenagers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 355,
                    "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1616,
                    "offsetInEndSection": 1739,
                    "text": "It is inferred that brown-adipose-tissue heat production is reduced during (and probably also some time after) anesthesia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8042786",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Parallel measurements of heat production and thermogenin content in brown fat cells during cold acclimation of rats.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3083882",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 39,
                    "offsetInEndSection": 287,
                    "text": "The classical white adipose tissue builds up energy in the form of triglycerides and is useful for preventing fatigue during periods of low caloric intake and the brown adipose tissue instead of inducing fat accumulation can produce energy as heat.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528872",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 334,
                    "text": "In response to cold, both classical brown fat and the newly identified \"beige\" or \"brite\" cells are activated by \u03b2-adrenergic signaling and catabolize stored lipids and carbohydrates to produce heat via UCP1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 245,
                    "text": "White adipose tissue stores energy reserves as fat, whereas the metabolic function of brown adipose tissue is lipid oxidation to produce heat.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "The main function of brown adipose tissue (BAT) is to produce heat in response to cold.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6148836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Brown adipocytes oxidize fatty acids to produce heat in response to cold or caloric overfeeding.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129212",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Brown fat (brown adipose tissue, BAT) primary function is to produce heat.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 293,
                    "text": "Adipose tissue plays an active role in energy balance because it is not only a lipid storing and mobilizing tissue but consists of functionally specialized tissues able to produce heat (in brown adipose tissue) and to produce or release a vast number of so called adipokines or adipocytokines.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15058310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Brown adipose tissue (BAT), a specialized fat that dissipates energy to produce heat, plays an important role in the regulation of energy balance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25642708",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Brown adipose cells are specialized to dissipate chemical energy in the form of heat, as a physiological defence against cold and obesity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641492",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1430,
                    "text": "In the present study, the thermogenesis of human brown fat tissue was suggested chiefly with regard to the occurrence of Types 1 and/or 6 cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1764,
                    "offsetInEndSection": 1901,
                    "text": "In the same manner, marked ability to produce a considerable amount of heat was evidenced in  brown fat tissue of children and teenagers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Adult humans have heat-producing and energy-consuming brown adipose tissue in the clavicular region of the neck.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26749900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "Brown and beige adipocytes expend chemical energy to produce heat and are therefore important in regulating body temperature and body weight.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2005,
                    "offsetInEndSection": 2203,
                    "text": "In human perirenal brown fat tissue, darkly stained fat-depleted cells (D) occupy, with other cell types (CR, CR'), an important part in the reversible heat production cycle of the brown fat tissue.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2039657",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Brown fat is a specialized fat depot that can increase energy expenditure and produce heat.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26912151",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Stat4 a transcription factor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25178516",
                "http://www.ncbi.nlm.nih.gov/pubmed/25829541",
                "http://www.ncbi.nlm.nih.gov/pubmed/25798064",
                "http://www.ncbi.nlm.nih.gov/pubmed/25852285"
            ],
            "ideal_answer": [
                "Yes, Stat4 is a transcription factor.\nStat4 is a member of the signal transducer and activator of transcription (STAT) family of molecules that localizes to the cytoplasm. STAT4 regulates various genes expression as a transcription factor after it is phosphorylated, dimerizes and translocates to the nucleus."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "58bc58c302b8c60953000001",
            "snippets": [
                {
                    "offsetInBeginSection": 713,
                    "offsetInEndSection": 750,
                    "text": "transcription factors T-bet and STAT4",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25829541",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272,
                    "text": "STAT4 is a member of the signal transducer and activator of transcription (STAT) family of molecules that localizes to the cytoplasm. STAT4 regulates various genes expression as a transcription factor after it is phosphorylated, dimerizes and translocates to the nucleus. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25798064",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "STAT4 is a latent cytosolic factor that encodes a transcription factor transmitting signals stimulated by cytokines. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25178516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 168,
                    "text": " To investigate the role of signal transduction and activation of transcription 4 (STAT4) in the development and progression of human hepatocellular carcinoma (HCC)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852285",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is subdural empyema a complication of sinusitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16462969",
                "http://www.ncbi.nlm.nih.gov/pubmed/7810468",
                "http://www.ncbi.nlm.nih.gov/pubmed/17182345",
                "http://www.ncbi.nlm.nih.gov/pubmed/9217340",
                "http://www.ncbi.nlm.nih.gov/pubmed/30014307",
                "http://www.ncbi.nlm.nih.gov/pubmed/22030191",
                "http://www.ncbi.nlm.nih.gov/pubmed/12521560",
                "http://www.ncbi.nlm.nih.gov/pubmed/28806018",
                "http://www.ncbi.nlm.nih.gov/pubmed/25437686",
                "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                "http://www.ncbi.nlm.nih.gov/pubmed/29404826",
                "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                "http://www.ncbi.nlm.nih.gov/pubmed/12402493",
                "http://www.ncbi.nlm.nih.gov/pubmed/29682134",
                "http://www.ncbi.nlm.nih.gov/pubmed/29131135"
            ],
            "ideal_answer": [
                "Yes, subdural empyema can be a complication of sinusitis"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ca0c81eecadf2e73f000047",
            "snippets": [
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 180,
                    "text": "Acute and chronic sinusitis can give rise to a wide array of intracranial and orbital complications. These complications include brain abscess, subdural empyema,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 323,
                    "text": " A computed tomography scan showed bilateral paranasal sinus disease, and magnetic resonance imaging showed a right frontal abscess and subdural empyema.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Frontal sinusitis complicated by a brain abscess and subdural empyema.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 292,
                    "text": "In older children, sinusitis and otitis media are usually the source for subdural empyem",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30014307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Subdural empyema as a complication of sinusitis in the pediatric population.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2077,
                    "offsetInEndSection": 2182,
                    "text": "Second, subdural empyema appears to arise in the setting of subacute rather than acute frontal sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 358,
                    "offsetInEndSection": 514,
                    "text": "Subdural empyema is a rare but potentially life-threatening complication following paranasal sinusitis and should be considered as a neurological emergency.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "[Subdural empyema as a complication of sinusitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "INTRODUCTION\nSubdural empyema is an uncommon but serious complication of sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 318,
                    "text": "Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 471,
                    "text": "Subdural empyema is a rare complication of sinusitis although very severe.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402493",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Subdural empyema is a rare complication of sinusitis in children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Subdural empyema is a rare but serious complication of paranasal sinusitis which may result in death or permanent disability in a significant proportion of cases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9217340",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 850,
                    "text": "We report a case of subdural empyema secondary to frontal sinusitis in an otherwise healthy immunocompetent adolescent boy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22030191",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 309,
                    "text": "Subdural empyema is a rare but life-threatening complication of paranasal sinusitis, otitis media, or mastoid disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Wolf in Sheep's Clothing Subdural Empyema: A Rare Complication of Acute Sinusitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806018",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Interhemispheric and Infratentorial Subdural Empyema with Preseptal Cellulitis as Complications of Sinusitis: A Case Report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Subdural empyema as a complication of sinusitis in the pediatric population.<AbstractText Label=\"OBJECTIVE\" NlmCategory=\"OBJECTIVE\">Sinusitis is a rare cause of intracranial infection in children. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "[Subdural empyema as a complication of sinusitis. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 335,
                    "text": "Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "text": "Streptococcus pluranimalium: A novel human pathogen?<AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">We present the first case of a subdural empyema caused by Streptococcus pluranimalium, in a healthy adolescent male as a possible complication of subclinical frontal sinusitis. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437686",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1283,
                    "text": "<AbstractText Label=\"DISCUSSION\" NlmCategory=\"CONCLUSIONS\">The diagnosis of subdural empyema as a complication of asymptomatic sinusitis in an immunocompetent patient with no history of fever or upper respiratory symptoms was unanticipated. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437686",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2329,
                    "offsetInEndSection": 2434,
                    "text": "Second, subdural empyema appears to arise in the setting of subacute rather than acute frontal sinusitis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Bifrontal decompressive craniectomy for acute subdural empyema.<AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Subdural empyema is an uncommon but serious complication of sinusitis. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 638,
                    "text": "Subdural empyema is a rare but potentially life-threatening complication following paranasal sinusitis and should be considered as a neurological emergency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 530,
                    "text": "We present a patient with subdural empyema in whom the diagnosis was delayed, followed by a discussion of suppurative complications of sinusitis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17182345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 607,
                    "text": "<AbstractText Label=\"CASE REPORT\" NlmCategory=\"METHODS\">We report an unusual case of sinusitis-associated acute subdural empyema in a 13-year-old patient, presenting in a catastrophic manner with acutely raised intracranial pressure. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 475,
                    "text": "The symptoms of subdural empyema may be mild and may be the same as those associated with sinusitis, or the infection may result in alteration of the level of consciousness and focal neurologic deficits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7810468",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 335,
                    "text": "We report the clinical and radiological course of an adolescent with a subdural empyema secondary to sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 602,
                    "text": "We report two cases of subdural empyema secondary to sinusitis in persons without impaired immunity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 48,
                    "text": "Subdural empyema as a complication of sinusitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 246,
                    "text": "Furthermore, subdural empyema usually is related to sinus infections, particularly those caused by Streptococcus milleri, an anaerobic organism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Subdural empyema is an uncommon but serious complication of sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can mitochondria transfer from cell to cell?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29158129",
                "http://www.ncbi.nlm.nih.gov/pubmed/29357914"
            ],
            "ideal_answer": [
                "Yes,\nthe recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c9e738decadf2e73f000037",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Interest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29158129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2055,
                    "offsetInEndSection": 2160,
                    "text": "We show evidence that mitochondria transfer from Jurkat cells to MSCs, which is mediated by cell adhesion",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1589,
                    "offsetInEndSection": 1721,
                    "text": "This process of mitochondria transfer is mediated by tunneling nanotubes, which are protrusions that extend from the cell membrane .",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357914",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is triadin involved in cardiac function?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                "http://www.ncbi.nlm.nih.gov/pubmed/17890426",
                "http://www.ncbi.nlm.nih.gov/pubmed/15191886",
                "http://www.ncbi.nlm.nih.gov/pubmed/15023559"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/440"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/440",
                    "o": "Cardiac muscle"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://linkedlifedata.com/resource/#_51323838323000B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51323838323000B",
                    "o": "Triadin"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/440",
                    "o": "Heart muscle"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/445"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://linkedlifedata.com/resource/#_503832313739006"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503832313739006",
                    "o": "Triadin"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/445",
                    "o": "Cardiac"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/445",
                    "o": "Cardiac tissue"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/445",
                    "o": "Heart"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://linkedlifedata.com/resource/#_503832313739009"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_503832313739009",
                    "o": "TRDN"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://linkedlifedata.com/resource/#_51313330363100E"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://linkedlifedata.com/resource/#_51313330363100B"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51313330363100E",
                    "o": "TRDN"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51313330363100B",
                    "o": "Triadin"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://linkedlifedata.com/resource/#_51323838323000E"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51323838323000E",
                    "o": "TRDN"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/440"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/445"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/go/0006936"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/go/0006936",
                    "o": "http://www.geneontology.org/go#GO:0006936"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/go/0006936",
                    "o": "muscle contraction"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/keywords/703"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/keywords/703",
                    "o": "Sarcoplasmic reticulum"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/keywords/703"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/keywords/703"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0006936"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0006936",
                    "o": "muscle contraction"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/933",
                    "o": "Skeletal muscle"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/933",
                    "o": "Striated muscle"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/933"
                }
            ],
            "ideal_answer": [
                "Yes, triadin is involved in the regulation of cardiac excitation-contraction coupling."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/TRDN_RABIT",
                "http://www.uniprot.org/uniprot/TRDN_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0060048",
                "http://www.uniprot.org/uniprot/TRDN_CANFA"
            ],
            "type": "yesno",
            "id": "52b2f09f4003448f55000008",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 349,
                    "text": "Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle. Within this complex, calsequestrin, triadin, and JCN appear to be critical for normal regulation of ryanodine receptor-mediated calcium (Ca) release.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 873,
                    "text": "Recent studies have uncovered functional roles of both JCN and triadin in the mouse heart, using transgenic overexpression strategies, which exhibit varying phenotypes including mild SR structural alterations, prolongation of Ca transient decay, impaired relaxation, and cardiac hypertrophy and/or heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Triadin is involved in the regulation of cardiac excitation-contraction coupling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1686,
                    "offsetInEndSection": 1792,
                    "text": "Thus the maintenance of triadin expression is essential for normal SR Ca cycling and contractile function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 215,
                    "text": "Ca2+ release from the cardiac junctional sarcoplasmic reticulum (SR) is regulated by a complex of proteins, including the ryanodine receptor (RyR), calsequestrin (CSQ), junctin (JCN), and triadin 1 (TRD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15023559",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 287,
                    "text": "Impaired sarcoplasmic reticulum (SR) Ca release has been suggested to contribute to the depressed cardiac function in heart failure. The release of Ca from the SR may be regulated by the ryanodine receptor, triadin, junctin, calsequestrin, and a histidine-rich, Ca-binding protein (HRC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15191886",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is patisiran currently (November 2017) in clinical phase II trials?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
                "http://www.ncbi.nlm.nih.gov/pubmed/28893208"
            ],
            "ideal_answer": [
                "No, patisiran is in phase 3 clinical studies.",
                "No, patisiran is in clinical phase 3 trials"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5a735c143b9d13c708000003",
            "snippets": [
                {
                    "offsetInBeginSection": 435,
                    "offsetInEndSection": 728,
                    "text": "This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 726,
                    "text": " patisiran (phase 3)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 484,
                    "text": " Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Are long non coding RNAs as conserved in sequence as protein coding genes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21112873",
                "http://www.ncbi.nlm.nih.gov/pubmed/23467124",
                "http://www.ncbi.nlm.nih.gov/pubmed/22955988",
                "http://www.ncbi.nlm.nih.gov/pubmed/22844254",
                "http://www.ncbi.nlm.nih.gov/pubmed/22708672",
                "http://www.ncbi.nlm.nih.gov/pubmed/23463798",
                "http://www.ncbi.nlm.nih.gov/pubmed/23028352",
                "http://www.ncbi.nlm.nih.gov/pubmed/20428234",
                "http://www.ncbi.nlm.nih.gov/pubmed/20624288",
                "http://www.ncbi.nlm.nih.gov/pubmed/22707570",
                "http://www.ncbi.nlm.nih.gov/pubmed/21622663",
                "http://www.ncbi.nlm.nih.gov/pubmed/20587619",
                "http://www.ncbi.nlm.nih.gov/pubmed/23454638"
            ],
            "ideal_answer": [
                "No. Most long non coding RNAs  (lncRNAs) are under lower sequence constraints than protein-coding genes."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "51757bbb8ed59a060a00002e",
            "snippets": [
                {
                    "offsetInBeginSection": 101,
                    "offsetInEndSection": 265,
                    "text": "Most lncRNAs are under lower sequence constraints than protein-coding genes and lack conserved secondary structures, making it hard to predict them computationally.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21622663",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 981,
                    "offsetInEndSection": 1166,
                    "text": "hey are under stronger selective pressure than neutrally evolving sequences-particularly in their promoter regions, which display levels of selection comparable to protein-coding genes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1243,
                    "text": "bout one-third seem to have arisen within the primate lineage.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is PLK2 involved in alpha-synuclein phosphorylation in Parkinson disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                "http://www.ncbi.nlm.nih.gov/pubmed/21050448",
                "http://www.ncbi.nlm.nih.gov/pubmed/19004816"
            ],
            "ideal_answer": [
                "PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assayThese results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.",
                "Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy-diseased brains, interacts with, phosphorylates and enhances \u03b1-synuclein autophagic degradation in a kinase activity-dependent manner. These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.",
                "Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system  "
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "551910fa622b19434500000b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "An increase in \u03b1-synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 540,
                    "text": "Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy-diseased brains, interacts with, phosphorylates and enhances \u03b1-synuclein autophagic degradation in a kinase activity-dependent manner.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Polo-like kinase 2 regulates selective autophagic \u03b1-synuclein clearance and suppresses its toxicity in vivo",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1004,
                    "offsetInEndSection": 1219,
                    "text": "Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of \u03b1-synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 845,
                    "text": " \u03b1-Synuclein increased PLK2 levels and GSK-3\u03b2 activity and increased the levels of phosphorylated \u03b1-Synuclein and Tau",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21050448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of alpha-synuclein phosphorylated at Ser-129 (p-Ser-129)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 293,
                    "offsetInEndSection": 477,
                    "text": "Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to alpha-synuclein phosphorylation at Ser-129 in neurons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 566,
                    "text": "PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assay",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 859,
                    "offsetInEndSection": 975,
                    "text": "These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does metformin interfere thyroxine absorption?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26191653"
            ],
            "ideal_answer": [
                "No. There are not reported data indicating that metformin reduce with thyroxine absorption."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008687",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000042"
            ],
            "type": "yesno",
            "id": "51406e6223fec90375000009",
            "snippets": [
                {
                    "offsetInBeginSection": 1418,
                    "offsetInEndSection": 1481,
                    "text": "LT4 absorption is unchanged by concomitant metformin ingestion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 302,
                    "text": "It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is NicVAX vaccine effective for smoking cessation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22895958",
                "http://www.ncbi.nlm.nih.gov/pubmed/22229310",
                "http://www.ncbi.nlm.nih.gov/pubmed/21270788",
                "http://www.ncbi.nlm.nih.gov/pubmed/23496672",
                "http://www.ncbi.nlm.nih.gov/pubmed/24894625"
            ],
            "ideal_answer": [
                "No. NicVAX vaccine failed to meet the primary endpoint in two large phase III studies, although the correlation of higher abstinence rates in subjects with higher immunity to nicotine was observed. The nicotine vaccine, NicVAX, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e4b639c6d0a277941000027",
            "snippets": [
                {
                    "offsetInBeginSection": 1480,
                    "offsetInEndSection": 1643,
                    "text": "CONCLUSION: The nicotine vaccine, NicVAX, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 290,
                    "text": " First efficacy results of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) showed that only a subgroup of the top 30% antibody responders achieved higher abstinence rates than placebo. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1479,
                    "text": "FINDINGS: There was no difference in abstinence rates between NicVAX and placebo from weeks 9 to 52 [27.7 versus 30.0%, odds ratio (OR)\u2009=\u20090.89, 95% confidence interval (CI)\u2009=\u20090.62-1.29] or weeks 37 to 52 (33.8 versus 33.2%, OR\u2009=\u20091.03, 95% CI\u2009=\u20090.73-1.46). The top 30% antibody responders, compared to the placebo group, showed a non-significant tendency towards higher abstinence rates from weeks 37 to 52 (42.2 versus 33.2%, OR\u2009=\u20091.47, 95% CI\u2009=\u20090.89-2.42)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1002,
                    "offsetInEndSection": 1218,
                    "text": "Unfortunately, the only vaccine tested in two large, randomized Phase\u00a0III trials, 3'-amino-methyl-nicotine r-exoprotein A conjugate vaccine (NicVAX(\u00ae), Nabi Biopharmaceuticals, MD, USA), did not demonstrate efficacy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3042,
                    "offsetInEndSection": 3365,
                    "text": "The RR for 12 month cessation in active and placebo groups was 1.35 (95% Confidence Interval (CI) 0.82 to 2.22) in\u00a0the trial of NIC002\u00a0and 1.74 (95% CI 0.73 to 4.18) in one NicVAX trial. Two Phase III NicVAX trials, for which full results were not available, reported similar quit rates of approximately 11% in both groups.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895958",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4355,
                    "offsetInEndSection": 4467,
                    "text": "AUTHORS' CONCLUSIONS: There is currently no evidence that nicotine vaccines enhance long-term smoking cessation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895958",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 837,
                    "text": "3'AmNic-rEPA recipients with the highest serum antinicotine Ab response (top 30% by area under the curve (AUC)) were significantly more likely than the placebo recipients (24.6% vs. 12.0%, P = 0.024, odds ratio (OR) = 2.69, 95% confidence interval (CI), 1.14-6.37) to attain 8 weeks of continuous abstinence from weeks 19 through 26. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21270788",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1149,
                    "text": "Recently, the most advanced candidate vaccine, NicVAX, failed to meet the primary endpoint in two large phase III studies, although the correlation of higher abstinence rates in subjects with higher immunity to nicotine was observed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22229310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1492,
                    "offsetInEndSection": 1655,
                    "text": "CONCLUSION\n\nThe nicotine vaccine, NicVAX, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 289,
                    "text": "First efficacy results of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) showed that only a subgroup of the top 30% antibody responders achieved higher abstinence rates than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1480,
                    "offsetInEndSection": 1642,
                    "text": "CONCLUSION The nicotine vaccine, NicVAX, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 271,
                    "text": "First efficacy results of the nicotine vaccine 3'-AmNic-rEPA ( NicVAX ) showed that only a subgroup of the top 30 % antibody responders achieved higher abstinence rates than placebo",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 289,
                    "text": "First efficacy results of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) showed that only a subgroup of the top 30% antibody responders achieved higher abstinence rates than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1033,
                    "offsetInEndSection": 1288,
                    "text": "FINDINGS\nThere was no difference in abstinence rates between NicVAX and placebo from weeks 9 to 52 [27.7 versus 30.0%, odds ratio (OR)\u2009=\u20090.89, 95% confidence interval (CI)\u2009=\u20090.62-1.29] or weeks 37 to 52 (33.8 versus 33.2%, OR\u2009=\u20091.03, 95% CI\u2009=\u20090.73-1.46).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1492,
                    "offsetInEndSection": 1655,
                    "text": "CONCLUSION\nThe nicotine vaccine, NicVAX, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894625",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are cyclophilins proteins that bind to prolines?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24831536",
                "http://www.ncbi.nlm.nih.gov/pubmed/12358793",
                "http://www.ncbi.nlm.nih.gov/pubmed/18823995",
                "http://www.ncbi.nlm.nih.gov/pubmed/25967372"
            ],
            "ideal_answer": [
                "Cyclophilins are ubiquitously expressed proteins that bind to prolines."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56f6a63d09dd18d46b00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Cyclophilins are ubiquitously expressed proteins that bind to prolines and can catalyse cis/trans isomerization of proline residues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25967372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 593,
                    "offsetInEndSection": 722,
                    "text": "a characteristic of the cyclophilin family of proteins that bind prolines and often act as cis-trans peptidyl-prolyl isomerases. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823995",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "The cyclophilins are widely expressed enzymes that catalyze the interconversion of the cis and trans peptide bonds of prolines. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24831536",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1468,
                    "offsetInEndSection": 1564,
                    "text": " an immunophilin on the isomerization of critical prolines that are found in the tCHT1 sequence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12358793",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can RNAPolII function as an RNA-dependent RNA-polymerase?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17855633",
                "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                "http://www.ncbi.nlm.nih.gov/pubmed/18004386",
                "http://www.ncbi.nlm.nih.gov/pubmed/17132145",
                "http://www.ncbi.nlm.nih.gov/pubmed/20943989",
                "http://www.ncbi.nlm.nih.gov/pubmed/15964997",
                "http://www.ncbi.nlm.nih.gov/pubmed/15827195",
                "http://www.ncbi.nlm.nih.gov/pubmed/16624367"
            ],
            "ideal_answer": [
                "RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity. Pol II can use a homopolymeric RNA template, can extend RNA by several nucleotides in the absence of DNA, and has been implicated in the replication of the RNA genomes of hepatitis delta virus (HDV) and plant viroids. The RdRP activity of Pol II provides a missing link in molecular evolution, because it suggests that Pol II evolved from an ancient replicase that duplicated RNA genomes.",
                "There is, however, evidence that Pol II also possesses RNA-dependent RNA polymerase (RdRP) activity. Here we show the intrinsic RdRP activity of Pol II with only pure polymerase, an RNA template-product scaffold and nucleoside triphosphates (NTPs). RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity. We conclude that influenza A virus replication requires RNAP-II activity not just to provide capped mRNA substrates but also to facilitate nuclear export of selected viral mRNAs.",
                "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012319"
            ],
            "type": "yesno",
            "id": "571696d9cb4ef8864c000009",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 913,
                    "text": ". Our studies provide compelling evidence that mammalian Pol II acts as an RdRP to control the stability of a cellular RNA by extending its 3'-end.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 407,
                    "text": "here is, however, evidence that Pol II also possesses RNA-dependent RNA polymerase (RdRP) activity. Pol II can use a homopolymeric RNA template, can extend RNA by several nucleotides in the absence of DNA, and has been implicated in the replication of the RNA genomes of hepatitis delta virus (HDV) and plant viroids.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18004386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1171,
                    "offsetInEndSection": 1341,
                    "text": "The RdRP activity of Pol II provides a missing link in molecular evolution, because it suggests that Pol II evolved from an ancient replicase that duplicated RNA genomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18004386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 1017,
                    "text": "The present findings provide a framework for further studies to elucidate the mechanistic principles of transcription by a viral RNA polymerase and have implications for the regulation of Pol II activities in infected cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827195",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "Influenza A virus transcribes its segmented negative sense RNA genome in the nuclei of infected cells in a process long known to require host RNA polymerase II (RNAP-II).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17132145",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1385,
                    "text": "We conclude that influenza A virus replication requires RNAP-II activity not just to provide capped mRNA substrates but also to facilitate nuclear export of selected viral mRNAs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17132145",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 985,
                    "text": "Thus, influenza virus specifically interferes with Pol II elongation, but not Pol II initiation. We propose that influenza virus RNA polymerase, by binding to the CTD of initiating Pol II and subsequent cleavage of the capped 5' end of the nascent transcript, triggers premature Pol II termination.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16624367",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 737,
                    "text": "We show that RNA polymerase II (RNAPolII) preinitiation complex recruitment and H3 Lys 4 (H3-K4) methylation at the Xist promoter form the basis of the Xist expression profiles that drives both imprinted and random XCI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15964997",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 1096,
                    "text": "Identification of these ENL-associated proteins (EAPs) by mass spectrometry revealed enzymes with a known role in transcriptional elongation (RNA polymerase II C-terminal domain kinase [RNAPolII CTD] positive transcription elongation factor b [pTEFb]), and in chromatin modification (histone-H3 methyltransferase DOT1L) as well as other frequent MLL partners (AF4, AF5q31, and LAF4), and polycomb group members (RING1, CBX8, and BCoR).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17855633",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Association of the influenza A virus RNA-dependent RNA polymerase with cellular RNA polymerase II.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827195",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 290,
                    "text": "It is also well established that viral RNA-dependent RNA polymerase (vRNP) associates with cellular RNA polymerase II (Pol II), on which viral replication depends. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20943989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 317,
                    "text": "RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity. Natural cellular RNA substrates of mammalian Pol II, however, have not been identified and the cellular function of the Pol II RdRP activity is unknown.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does Uc.160 promote cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                "http://www.ncbi.nlm.nih.gov/pubmed/20802525"
            ],
            "ideal_answer": [
                "No. Uc.160+ is a T-UCR reported to be downregulated in human cancer. In addition, Uc.160+ could possibly have a tumor suppressive role in gastric cancer."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:162",
                "https://meshb.nlm.nih.gov/record/ui?ui=D009369"
            ],
            "type": "yesno",
            "id": "5a6d2558b750ff4455000036",
            "snippets": [
                {
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 1592,
                    "text": "We previously discovered the downregulation of T-UCR expression in gastric cancer (GC), indicating that T-UCRs could play an important role in GC biology. Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.METHODS: We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs. We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.RESULTS: On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach. Cancer-specific DNA methylation in the promoter region of Uc.160 was observed by bisulfite genomic DNA sequencing analysis. The effect of DNA methylation on Uc.160+ expression was further confirmed by reporter gene assay. We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.CONCLUSIONS: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 841,
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.<br><b>METHODS</b>: We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1391,
                    "offsetInEndSection": 1636,
                    "text": "We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.<br><b>CONCLUSIONS</b>: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 842,
                    "offsetInEndSection": 1168,
                    "text": "We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.<br><b>RESULTS</b>: On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1597,
                    "text": "CONCLUSIONS These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 490,
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1494,
                    "text": "Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20802525",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 479,
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1465,
                    "offsetInEndSection": 1553,
                    "text": "These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there Conserved Noncoding Elements (CNEs) in invertebrate genomes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24282393",
                "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                "http://www.ncbi.nlm.nih.gov/pubmed/17274809",
                "http://www.ncbi.nlm.nih.gov/pubmed/23357263",
                "http://www.ncbi.nlm.nih.gov/pubmed/18402933"
            ],
            "ideal_answer": [
                "Yes.",
                "Yes. Conserved Noncoding Elements (CNEs) have also been found in invertebrate genomes."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "553a6a9fbc4f83e82800001c",
            "snippets": [
                {
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 708,
                    "text": "Here, we use genome-wide comparisons between C. intestinalis and C. savignyi to identify putative urochordate cis-regulatory sequences. Ciona conserved non-coding elements (ciCNEs) are associated with largely the same key regulatory genes as vertebrate CNEs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24282393",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "We have identified Conserved Non-coding Elements (CNEs) in the regulatory region of Caenorhabditis elegans and Caenorhabditis briggsae ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18402933",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 781,
                    "text": "Here we report that nematode genomes contain an alternative set of CNEs that share sequence characteristics, but not identity, with their vertebrate counterparts. CNEs thus represent a very unusual class of sequences that are extremely conserved within specific animal lineages yet are highly divergent between lineages",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274809",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1280,
                    "text": "A core set of genes that regulate development is associated with CNEs across three animal groups (worms, flies and vertebrates)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274809",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "The genomes of vertebrates, flies, and nematodes contain highly conserved noncoding elements (CNEs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "text": "The genomes of vertebrates, flies, and nematodes contain highly conserved noncoding elements (CNEs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can valproic acid act as an activator of AMPK?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24105977",
                "http://www.ncbi.nlm.nih.gov/pubmed/23889921"
            ],
            "ideal_answer": [
                "Yes, valproic acid canact as an activator of AMPK.",
                "VPA is a novel activator of AMP-activated protein kinase (AMPK)"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031588",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055372",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004679",
                "http://www.uniprot.org/uniprot/AAKB1_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:2000479",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014635",
                "http://www.biosemantics.org/jochem#4271063",
                "http://www.uniprot.org/uniprot/AAPK2_HUMAN"
            ],
            "type": "yesno",
            "id": "52f89ee42059c6d71c00004d",
            "snippets": [
                {
                    "offsetInBeginSection": 89,
                    "offsetInEndSection": 261,
                    "text": "Here we demonstrate that VPA is a novel activator of AMP-activated protein kinase (AMPK), a key regulator of cellular metabolism, using primary mouse and human hepatocytes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24105977",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1407,
                    "offsetInEndSection": 1503,
                    "text": "These studies are the first to establish VPA and its metabolites as in vitro activators of AMPK.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24105977",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a sequence bias in MNase digestion patterns?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22310051",
                "http://www.ncbi.nlm.nih.gov/pubmed/23458408",
                "http://www.ncbi.nlm.nih.gov/pubmed/21206756",
                "http://www.ncbi.nlm.nih.gov/pubmed/26080409",
                "http://www.ncbi.nlm.nih.gov/pubmed/22559821",
                "http://www.ncbi.nlm.nih.gov/pubmed/27185945"
            ],
            "ideal_answer": [
                "The cutting preference of MNase in combination with size selection generates a sequence-dependent bias in the resulting fragments.",
                "yes",
                "Micrococcal nuclease does not substantially bias nucleosome mapping. Signal variation in these simulations reveals an important DNA sampling bias that results from a neighborhood effect of MNase digestion techniques."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a4e1882966455904c00000f",
            "snippets": [
                {
                    "offsetInBeginSection": 1127,
                    "offsetInEndSection": 1211,
                    "text": "In addition, unlike MNase, MPE-Fe(II) cleaves nuclear DNA with little sequence bias.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1423,
                    "offsetInEndSection": 1600,
                    "text": "These findings collectively indicate that MPE-seq provides a unique and straightforward means for the genome-wide analysis of chromatin structure with minimal DNA sequence bias.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "text": "Micrococcal nuclease does not substantially bias nucleosome mapping.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310051",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 432,
                    "offsetInEndSection": 565,
                    "text": "MNase has hitherto been very widely used to map nucleosomes, although concerns have been raised over its potential to introduce bias.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310051",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1403,
                    "offsetInEndSection": 1534,
                    "text": "These results indicate that biases in nucleosome positioning data collected using MNase are, under our conditions, not significant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310051",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1066,
                    "offsetInEndSection": 1213,
                    "text": "Signal variation in these simulations reveals an important DNA sampling bias that results from a neighborhood effect of MNase digestion techniques.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Standardized collection of MNase-seq experiments enables unbiased dataset comparisons.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 409,
                    "text": "Here, we show that the cutting preference of MNase in combination with size selection generates a sequence-dependent bias in the resulting fragments.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206756",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1210,
                    "text": "We propose that combined MNase/exoIII digestion can be applied to in situ chromatin for unbiased genome-wide mapping of nucleosome positions that is not influenced by DNA sequences at the core/linker junctions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23458408",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1067,
                    "offsetInEndSection": 1214,
                    "text": "Signal variation in these simulations reveals an important DNA sampling bias that results from a neighborhood effect of MNase digestion techniques.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1193,
                    "text": "Signal variation in these simulations reveals an important DNA sampling bias that results from a neighborhood effect of MNase digestion techniques.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1403,
                    "offsetInEndSection": 1535,
                    "text": "These results indicate that biases in nucleosome positioning data collected using MNase are, under our conditions, not significant..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310051",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 69,
                    "text": "Micrococcal nuclease does not substantially bias nucleosome mapping.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310051",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 390,
                    "offsetInEndSection": 561,
                    "text": "We find that maize MNase-hypersensitive (MNase HS) regions localize around active genes and within recombination hotspots, focusing biased gene conversion at their flanks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27185945",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any urine biomarkers for chronic kidney disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20425065",
                "http://www.ncbi.nlm.nih.gov/pubmed/24315007",
                "http://www.ncbi.nlm.nih.gov/pubmed/24281781",
                "http://www.ncbi.nlm.nih.gov/pubmed/23758910",
                "http://www.ncbi.nlm.nih.gov/pubmed/21286212",
                "http://www.ncbi.nlm.nih.gov/pubmed/24065527",
                "http://www.ncbi.nlm.nih.gov/pubmed/23617441",
                "http://www.ncbi.nlm.nih.gov/pubmed/21151537",
                "http://www.ncbi.nlm.nih.gov/pubmed/23339563",
                "http://www.ncbi.nlm.nih.gov/pubmed/24133923",
                "http://www.ncbi.nlm.nih.gov/pubmed/24308223",
                "http://www.ncbi.nlm.nih.gov/pubmed/24224012",
                "http://www.ncbi.nlm.nih.gov/pubmed/24152229",
                "http://www.ncbi.nlm.nih.gov/pubmed/23344473",
                "http://www.ncbi.nlm.nih.gov/pubmed/22189039",
                "http://www.ncbi.nlm.nih.gov/pubmed/21538916",
                "http://www.ncbi.nlm.nih.gov/pubmed/23061738",
                "http://www.ncbi.nlm.nih.gov/pubmed/22914685",
                "http://www.ncbi.nlm.nih.gov/pubmed/21816077",
                "http://www.ncbi.nlm.nih.gov/pubmed/24205707"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/pubmed/keyword/CHRONIC+DISEASE%2Furine",
                    "o": "CHRONIC DISEASE/urine"
                }
            ],
            "ideal_answer": [
                "Chronic kidney disease (CKD), is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experiencing a reduced appetite. Often, chronic kidney disease is diagnosed as a result of screening of people known to be at risk of kidney problems, such as those with high blood pressure or diabetes and those with a blood relative with chronic kidney disease. Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis. It is differentiated from acute kidney disease in that the reduction in kidney function must be present for over 3 months.",
                "Yes, there is a number of urine biomarkers used for early detection of chronic kidney disease."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:784",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0002678",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012079",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007674",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0002676",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0002677",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007672",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014556",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014554",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007676",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category",
                "http://www.disease-ontology.org/api/metadata/DOID:3265",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0002544",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002908",
                "http://www.disease-ontology.org/api/metadata/DOID:2975",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051437",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051436",
                "http://www.disease-ontology.org/api/metadata/DOID:557",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003928",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007668",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054316"
            ],
            "type": "yesno",
            "id": "52fa73c62059c6d71c000058",
            "snippets": [
                {
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 726,
                    "text": "Kidney and urine proteomic biomarkers are considered as promising diagnostic tools to predict CKD progression early in diabetic nephropathy, facilitating timely and selective intervention that may reduce the related health-care expenditures.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21538916",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1028,
                    "text": "Both blood and urine biomarkers are reviewed in this paper and offer a considerable opportunity to enhance the understanding of the pathophysiology and known epidemiology of these recently defined syndromes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21286212",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 314,
                    "text": "Cardiorenal syndromes (CRS) have been subclassified as five defined entities which represent clinical circumstances in which both the heart and the kidney are involved in a bidirectional injury and dysfunction via a final common pathway of cell-to-cell death and accelerated apoptosis mediated by oxidative stress.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21286212",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "There is a strong association between both acute and chronic dysfunction of the heart and kidneys with respect to morbidity and mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1265,
                    "offsetInEndSection": 1452,
                    "text": "Both blood and urine biomarkers, including the assessment of catalytic iron, a critical element to the generation of oxygen-free radicals and oxidative stress, are reviewed in this paper.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 1225,
                    "text": "Identification of urine biomarkers has proven to be beneficial in recent years because of ease of handling, stability, and the ability to standardize the various markers to creatinine or other peptides generally already present in the urine. Recent markers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin have garnered a lot of attention. The emergence of these and other biomarkers is largely because of the evolution of novel genomic and proteomic applications in investigations of acute kidney injury and chronic kidney disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425065",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is LDB1-mediated enhancer looping dependent on cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28520978"
            ],
            "ideal_answer": [
                "No. LDB1-mediated enhancer looping can be established independent of mediator and cohesin."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0061774",
                "http://amigo.geneontology.org/amigo/term/GO:0061780",
                "http://amigo.geneontology.org/amigo/term/GO:0008278",
                "http://amigo.geneontology.org/amigo/term/GO:0001205",
                "http://amigo.geneontology.org/amigo/term/GO:0071921",
                "http://amigo.geneontology.org/amigo/term/GO:1905309",
                "http://amigo.geneontology.org/amigo/term/GO:0071923",
                "http://amigo.geneontology.org/amigo/term/GO:0071922",
                "http://amigo.geneontology.org/amigo/term/GO:1905339",
                "http://amigo.geneontology.org/amigo/term/GO:1905338",
                "http://amigo.geneontology.org/amigo/term/GO:0003705",
                "http://amigo.geneontology.org/amigo/term/GO:0071733",
                "https://meshb.nlm.nih.gov/record/ui?ui=D004742",
                "http://amigo.geneontology.org/amigo/term/GO:0001206"
            ],
            "type": "yesno",
            "id": "5a6e49a4b750ff445500004b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "LDB1-mediated enhancer looping can be established independent of mediator and cohesin.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1167,
                    "offsetInEndSection": 1488,
                    "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs. Thus, lineage specific factors largely mediate enhancer-promoter looping in erythroid cells independent of mediator and cohesin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1167,
                    "offsetInEndSection": 1359,
                    "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1364,
                    "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "LDB1-mediated enhancer looping can be established independent of mediator and cohesin.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is apremilast effective for psoriasis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27376729",
                "http://www.ncbi.nlm.nih.gov/pubmed/26923915",
                "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
                "http://www.ncbi.nlm.nih.gov/pubmed/22712800",
                "http://www.ncbi.nlm.nih.gov/pubmed/26243735",
                "http://www.ncbi.nlm.nih.gov/pubmed/26644232",
                "http://www.ncbi.nlm.nih.gov/pubmed/26806620",
                "http://www.ncbi.nlm.nih.gov/pubmed/26549249",
                "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                "http://www.ncbi.nlm.nih.gov/pubmed/23663752",
                "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                "http://www.ncbi.nlm.nih.gov/pubmed/26954311",
                "http://www.ncbi.nlm.nih.gov/pubmed/26357944",
                "http://www.ncbi.nlm.nih.gov/pubmed/20419594",
                "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
                "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
                "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
                "http://www.ncbi.nlm.nih.gov/pubmed/26892034",
                "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                "http://www.ncbi.nlm.nih.gov/pubmed/27538241",
                "http://www.ncbi.nlm.nih.gov/pubmed/26660203",
                "http://www.ncbi.nlm.nih.gov/pubmed/26820148",
                "http://www.ncbi.nlm.nih.gov/pubmed/26837052",
                "http://www.ncbi.nlm.nih.gov/pubmed/27021239",
                "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
                "http://www.ncbi.nlm.nih.gov/pubmed/26792812"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0033860",
                    "o": "psoriasis"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0033860",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0487662"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0487662",
                    "o": "psoriasis"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1678805",
                    "o": "APREMILAST"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1678805",
                    "o": "http://linkedlifedata.com/resource/umls/label/A15589751"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15589751",
                    "o": "apremilast"
                }
            ],
            "ideal_answer": [
                "Yes, apremilast is effective for treatment of psoriasis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:8893",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011565"
            ],
            "type": "yesno",
            "id": "589a246d78275d0c4a000033",
            "snippets": [
                {
                    "offsetInBeginSection": 1630,
                    "offsetInEndSection": 1698,
                    "text": "CONCLUSION: Apremilast reduces the severity of nail/scalp psoriasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26549249",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1638,
                    "offsetInEndSection": 1834,
                    "text": "CONCLUSIONS: Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52\u2005weeks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 634,
                    "offsetInEndSection": 910,
                    "text": "In those that involved doses of 30 mg twice daily, a significantly greater percentage of patients receiving apremilast (28.8% to 40.9%) compared with placebo (5.3% to 5.8%) achieved at least 75% improvement from baseline in Psoriasis Area and Severity Index score at 16 weeks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1605,
                    "text": "CONCLUSIONS: Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis. At this time, apremilast should be reserved for patients unable to take disease-modifying antirheumatic drugs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "text": "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 938,
                    "offsetInEndSection": 1338,
                    "text": "More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1664,
                    "text": "No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period.Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Apremilast was effective in moderate to severe plaque psoriasis.<CopyrightInformation>Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 596,
                    "text": "Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production.Assess apremilast efficacy and safety in moderate to severe plaque psoriasis.Phase II, 12-week, multicenter, double-blind, placebo-controlled, parallel-group, dose-comparison study of 259 subjects randomized 1 : 1 : 1 to placebo, apremilast 20 mg QD or apremilast 20 mg BID.More subjects receiving apremilast 20 mg BID achieved \u2265 75% reduction in Psoriasis Area and Severity Index (PASI-75) vs. placebo (24.4% vs. 10.3%; P = 0.023)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 449,
                    "text": "Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production.Apremilasts effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized, controlled trial (NCT00773734).In this 16-week, placebo-controlled study, 352 patients with moderate to severe plaque psoriasis received placebo or apremilast (10, 20, or 30 mg BID)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663752",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1278,
                    "offsetInEndSection": 1517,
                    "text": "Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1343,
                    "text": "More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1601,
                    "offsetInEndSection": 1813,
                    "text": "No deaths or opportunistic infections were reported.Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis.<CopyrightInformation>\u00a9 2012 The Authors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 934,
                    "text": "In addition, GlaxoSmithKline plc is developing 256066, an inhaled formulation of a PDE4 inhibitor that has demonstrated efficacy in trials in asthma, and apremilast from Celgene Corp has been reported to be effective for the treatment of psoriasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20419594",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1278,
                    "offsetInEndSection": 1518,
                    "text": "Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1665,
                    "text": "No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period.Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Apremilast was effective in moderate to severe plaque psoriasis.<CopyrightInformation>Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</C",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1161,
                    "offsetInEndSection": 1344,
                    "text": "Several drug peculiarities, such as the low frequency of adverse events and the oral route of administration, make apremilast an innovative treatment for moderate-to-severe psoriasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243735",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 673,
                    "text": "Two new oral medications, apremilast and tofacitinib, have been developed for their immunomodulatory properties, and their potential efficacy in treating psoriasis is being evaluated.We reviewed phase III randomized, placebo-controlled clinical trial results for apremilast and tofacitinib for efficacy and safety in psoriasis.Psoriasis Area and Severity Index (PASI) 75 after 16 weeks for apremilast was between 28.8% and 33.1%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1476,
                    "offsetInEndSection": 1541,
                    "text": "Apremilast was effective in moderate to severe plaque psoriasis..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1009,
                    "offsetInEndSection": 1109,
                    "text": "Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1516,
                    "offsetInEndSection": 1612,
                    "text": "Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52\u00a0weeks..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357944",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1064,
                    "text": "Apremilast is an effective and well-tolerated option in treating moderate-to-severe plaque psoriasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376729",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1407,
                    "text": "Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1651,
                    "offsetInEndSection": 1772,
                    "text": "Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 43,
                    "text": "Apremilast for the treatment of psoriasis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243735",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 309,
                    "text": "Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27021239",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does surgery for ovarian endometriomas improve fertility?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11526777",
                "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
                "http://www.ncbi.nlm.nih.gov/pubmed/8737616",
                "http://www.ncbi.nlm.nih.gov/pubmed/7202738",
                "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
                "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
                "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
                "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
                "http://www.ncbi.nlm.nih.gov/pubmed/21679474",
                "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
                "http://www.ncbi.nlm.nih.gov/pubmed/23759693",
                "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
                "http://www.ncbi.nlm.nih.gov/pubmed/24231199",
                "http://www.ncbi.nlm.nih.gov/pubmed/12419041",
                "http://www.ncbi.nlm.nih.gov/pubmed/17399914",
                "http://www.ncbi.nlm.nih.gov/pubmed/2943896"
            ],
            "ideal_answer": [
                "Yes, endometrioma surgery seems to improve the success rates of fertility treatment."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "54f088ee94afd61504000015",
            "snippets": [
                {
                    "offsetInBeginSection": 1490,
                    "offsetInEndSection": 1764,
                    "text": "CONCLUSION: Endometriomas per se appear to be the main cause of the reduced long-term reproductive performance of the affected patients, with little or no contribution from surgery. Furthermore, endometrioma surgery seems to improve the success rates of fertility treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 572,
                    "offsetInEndSection": 711,
                    "text": "Amongst the 38 women desiring pregnancy after endometrioma surgery, 19 (50%) achieved a spontaneous pregnancy during the follow-up period. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1248,
                    "offsetInEndSection": 1325,
                    "text": "Of 33 women who wished to conceive, 67% became pregnant, spontaneously in 59%",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23759693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1604,
                    "offsetInEndSection": 1753,
                    "text": "CONCLUSIONS: Recurrence and pregnancy rates are encouraging in that they seem comparable to the best reported results after endometrioma cystectomy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23759693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 291,
                    "text": "While laparoscopic excision is known to improve fertility, recurrence can cause significant ovarian damage and adverse affects on fertility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 252,
                    "text": "Surgery is considered to play a role within the framework of the therapeutic options to cure infertile women with the disease even though its effectiveness is generally modest. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 760,
                    "offsetInEndSection": 962,
                    "text": "Randomized controlled trials showed that the excision technique is associated with a higher pregnancy rate and a lower rate of recurrence although it may determine severe injury to the ovarian reserve. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 258,
                    "text": "Surgical treatment is associated with a high recurrence rate and its employment for women undergoing assisted conception has recently been challenged.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 990,
                    "offsetInEndSection": 1114,
                    "text": "Laparoscopic excision of ovarian endometrioma prior to IVF does not offer any additional benefit over expectant management. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2521,
                    "offsetInEndSection": 2723,
                    "text": "For those women subsequently attempting to conceive it was also associated with a subsequent increased spontaneous pregnancy rate in women who had documented prior sub-fertility (OR 5.21 CI 2.04-13.29).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2959,
                    "offsetInEndSection": 3173,
                    "text": "here is insufficient evidence to favour excisional surgery over ablative surgery with respect to the chance of pregnancy after controlled ovarian stimulation and intra-uterine insemination (OR 1.40 CI 0.47-4.15) . ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1875,
                    "offsetInEndSection": 2223,
                    "text": "CONCLUSIONS: These findings suggest that in a context of more than one year infertility only related to endometriosis, it is reasonable to offer these patients a complete operative laparoscopic treatment of their lesions, which enables 65% of them to be pregnant within a 8.5 months post-surgical median time to pregnancy and spontaneously in 60%. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17399914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2173,
                    "offsetInEndSection": 2632,
                    "text": " It was also associated with a subsequent increased rate of spontaneous pregnancy women who had documented prior sub-fertility (OR 5.21 CI 2.04-13.29). AUTHORS' CONCLUSIONS: There is some evidence that excisional surgery for endometriomata provides for a more favourable outcome than drainage and ablation, with regard to the recurrence of the endometrioma, recurrence of symptoms and subsequent spontaneous pregnancy in women who were previously subfertile. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 58,
                    "offsetInEndSection": 186,
                    "text": "Surgery is an option for treatment, but there is no convincing evidence that it promotes a significant improvement in fertility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12419041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1539,
                    "offsetInEndSection": 1717,
                    "text": "In conclusion, ovarian surgery for the treatment of endometriosis reduces the ovarian outcome in IVF/ICSI cycles in women >35 years old, and might also decrease pregnancy rates. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12419041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 489,
                    "offsetInEndSection": 577,
                    "text": "Improvement of pain symptoms occurred in 87% of the patients and fertility rate was 45%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8737616",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 429,
                    "offsetInEndSection": 609,
                    "text": "The long-term results, especially the fertility outcome, have been promising: 12 of 20 women (60%) achieved a term pregnancy following a laparoscopic endometrioma procedure alone. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 301,
                    "text": "Among this group, 115 patients (54%) conceived following surgery; of these conceptions, 109 resulted in a living child.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7202738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2259,
                    "offsetInEndSection": 2523,
                    "text": "WIDER IMPLICATIONS OF THE FINDINGS: Despite the available evidence that surgery for endometriomas does not improve the outcome of ART and may damage ovarian reserve, it seems that the majority of gynaecologists in the UK offer ovarian cystectomy to their patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "Ovarian endometriomas does not exclude fertility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11526777",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Removal of endometriomas before in vitro fertilization does not improve fertility outcomes: a matched, case-control study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 356,
                    "text": "Conclusion(s): Laparoscopic cystectomy for endometriomas before commencing an IVF cycle does not improve fertility outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "Despite the available evidence that surgery for endometriomas does not improve the outcome of ART and may damage ovarian reserve, it seems that the majority of gynaecologists in the UK offer ovarian cystectomy to their patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1281,
                    "offsetInEndSection": 1430,
                    "text": "Furthermore, laparoscopic removal of endometriomas does not improve IVF results, but may cause a decrease of ovarian responsiveness to gonadotropins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21679474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1629,
                    "offsetInEndSection": 1721,
                    "text": "Furthermore, endometrioma surgery seems to improve the success rates of fertility treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 828,
                    "text": "Laparoscopic cystectomy for endometriomas before commencing an IVF cycle does not improve fertility outcomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is TENS machine effective in pain?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7644247",
                "http://www.ncbi.nlm.nih.gov/pubmed/17333874"
            ],
            "ideal_answer": [
                "Transcutaneous electrical nerve stimulation is widely used in pain management"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018710",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010146",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059350",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004561"
            ],
            "type": "yesno",
            "id": "535d75ab7d100faa09000004",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Transcutaneous electrical nerve stimulation is widely used in pain management but its effectiveness depends on the stimulation being targeted appropriately",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333874",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 36,
                    "offsetInEndSection": 146,
                    "text": "hypoalgesic effects of transcutaneous electrical nerve stimulation upon experimentally induced ischaemic pain.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7644247",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1174,
                    "offsetInEndSection": 1416,
                    "text": "The results of this study have provided evidence of the hypoalgesic effects of TENS upon experimental ischaemic pain which were found to be frequency specific with the lower frequency used here (4 Hz) demonstrating the only significant effect",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7644247",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are mouse chromosomes acrocentric?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9177778",
                "http://www.ncbi.nlm.nih.gov/pubmed/8896561",
                "http://www.ncbi.nlm.nih.gov/pubmed/6177004",
                "http://www.ncbi.nlm.nih.gov/pubmed/6538846",
                "http://www.ncbi.nlm.nih.gov/pubmed/100785",
                "http://www.ncbi.nlm.nih.gov/pubmed/3248380",
                "http://www.ncbi.nlm.nih.gov/pubmed/2767161",
                "http://www.ncbi.nlm.nih.gov/pubmed/7606923"
            ],
            "ideal_answer": [
                "yes",
                "Mouse chromosomes are acrocentric and of similar size."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a89537cfcd1d6a10c000002",
            "snippets": [
                {
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 950,
                    "text": " Based on combined fluorescence in situ hybridization and linkage mapping, the gene order on CFA9 is similar to that of the homologous genes on HSA17q and mouse chromosome 11 (MMU11), but in the dog the gene order is inverted with respect to the centromere. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9177778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 435,
                    "text": "In murine models of human carcinogenesis, however, karyotype analysis is technically demanding because mouse chromosomes are acrocentric and of similar size.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8896561",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 359,
                    "text": "The minor satellite is closer to the short arms of the acrocentric chromosomes than the major satellite",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2767161",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 584,
                    "text": " These cells contain Robertsonian translocated chromosomes 1 and 7 as the only submetacentric chromosome in an otherwise acrocentric genome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3248380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 452,
                    "text": " The resulting metacentric chromosomes are very different in size and in morphology from normal mouse acrocentric chromosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 552,
                    "text": " Because of 35 independent primary hybrids used in this study were derived from two types of feral mice, each with a different combination of Robertsonian translocation chromosomes, as well as from mice with a normal complement of acrocentric chromosomes, analysis of 16 selected mouse enzyme markers provided data on the segregation of all 20 mouse chromosomes in these hybrids",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6177004",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 416,
                    "text": "The two mouse stocks exhibit karyotypes consisting of nine pairs of metacentric chromosomes as a result of centric fusions of acrocentric chromosomes in different combinations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/100785",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "Physical gene mapping by in situ hybridization is a difficult task in an all-acrocentric mouse karyotype, because all of the chromosomes are morphologically very similar.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 452,
                    "text": "The resulting metacentric chromosomes are very different in size and in morphology from normal mouse acrocentric chromosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1673,
                    "text": "murine models of human carcinogenesis are exceedingly valuable tools to understand genetic mechanisms of neoplastic growth the identification of recurrent chromosomal rearrangements by cytogenetic techniques serves as an initial screening test for tumour specific aberrations in murine models of human carcinogenesis however karyotype analysis is technically demanding because mouse chromosomes are acrocentric and of similar size fluorescence in situ hybridization fish with mouse chromosome specific painting probes can complement conventional banding analysis although sensitive and specific fish analyses are restricted to the visualization of only a few mouse chromosomes at a time here we apply a novel imaging technique that we developed recently for the visualization of human chromosomes to the simultaneous discernment of all mouse chromosomes the approach is based on spectral imaging to measure chromosome specific spectra after fish with differentially labelled mouse chromosome painting probes utilizing a combination of fourier spectroscopy ccd imaging and conventional optical microscopy spectral imaging allows simultaneous measurement of the fluorescence emission spectrum at all sample points a spectrum based classification algorithm has been adapted to karyotype mouse chromosomes we have applied spectral karyotyping sky to chemically induced plasmocytomas mammary gland tumours from transgenic mice overexpressing the c myc oncogene and thymomas from mice deficient for the ataxia telangiectasia atm gene results from these analyses demonstrate the potential of sky to identify complex chromosomal aberrations in mouse models of human carcinogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8896561",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does smoking increase risk for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2319291",
                "http://www.ncbi.nlm.nih.gov/pubmed/17372252",
                "http://www.ncbi.nlm.nih.gov/pubmed/19568697",
                "http://www.ncbi.nlm.nih.gov/pubmed/19022673",
                "http://www.ncbi.nlm.nih.gov/pubmed/21742680",
                "http://www.ncbi.nlm.nih.gov/pubmed/19494549",
                "http://www.ncbi.nlm.nih.gov/pubmed/20487573",
                "http://www.ncbi.nlm.nih.gov/pubmed/16217772",
                "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
                "http://www.ncbi.nlm.nih.gov/pubmed/15685439"
            ],
            "ideal_answer": [
                "No. Smoking does not increase risk for glioblastoma."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012907",
                "http://www.disease-ontology.org/api/metadata/DOID:3073",
                "http://www.disease-ontology.org/api/metadata/DOID:3068"
            ],
            "type": "yesno",
            "id": "550e7d6aa103b7801600000e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Glioma risk has consistently been inversely associated with allergy history but not with smoking history despite putative biologic plausibility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1159,
                    "offsetInEndSection": 1380,
                    "text": "No relation was observed between glioma risk and smoking (odds ratio = 0.92, 95% confidence interval: 0.77, 1.10; P = 0.37), and there were no interactions for glioma risk of smoking history with any of the risk alleles. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1654,
                    "offsetInEndSection": 1926,
                    "text": "Non-smokers with G/A and A/A genotype showed increased glioma risk compared with G/G genotype (adjusted OR = 1.72, 95%CI: 1.29-2.30, p = 0.0002 and adjusted OR = 1.81, 95%CI: 1.10-2.99, p = 0.020, respectively). This association was not found in ever- or current-smokers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20487573",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1256,
                    "offsetInEndSection": 1363,
                    "text": "There was no significant association between glioma and alcohol consumption, smoking and mobile phone use. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19494549",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1565,
                    "text": "RESULTS: We found no associations between the GSTM3, GSTP1, NQO1, CYP1A1, GSTM1, or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C (Val-Ala) GSTP1 105/114 haplotype and glioma [odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.54, 0.99], nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17372252",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 1029,
                    "text": "We did not find any evidence for an association with life-style characteristics such as cigarette smoking, alcohol consumption, use of drugs of any kind, or dietary intake of cured or smoked meat or fish.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2319291",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1230,
                    "text": "No relation was observed between glioma risk and smoking (odds ratio = 0",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Glioma risk has consistently been inversely associated with allergy history but not with smoking history despite putative biologic plausibility",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1608,
                    "offsetInEndSection": 1824,
                    "text": "Compared with nonsmokers, duration of cigarette smoking, number of cigarettes smoked per day and pack-years of smoking were associated with increased glioma risk, although the increases in risk were relatively modest",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 989,
                    "offsetInEndSection": 1210,
                    "text": "Among ever smokers, women who reported having quit smoking had a 51% increase in risk of glioma compared with never smokers (HR = 1.51, 95% CI = 0.97-2.34), while current smokers did not appear to have an increase in risk",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217772",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does HER2 under-expression lead to favorable response to trastuzumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22711713",
                "http://www.ncbi.nlm.nih.gov/pubmed/20392785",
                "http://www.ncbi.nlm.nih.gov/pubmed/23082154",
                "http://www.ncbi.nlm.nih.gov/pubmed/11148461",
                "http://www.ncbi.nlm.nih.gov/pubmed/19606230",
                "http://www.ncbi.nlm.nih.gov/pubmed/12503030",
                "http://www.ncbi.nlm.nih.gov/pubmed/21709140",
                "http://www.ncbi.nlm.nih.gov/pubmed/18534031",
                "http://www.ncbi.nlm.nih.gov/pubmed/19435924",
                "http://www.ncbi.nlm.nih.gov/pubmed/22580986",
                "http://www.ncbi.nlm.nih.gov/pubmed/19624808",
                "http://www.ncbi.nlm.nih.gov/pubmed/19920112",
                "http://www.ncbi.nlm.nih.gov/pubmed/22658319"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00072",
                    "o": "Trastuzumab"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0728747",
                    "o": "http://linkedlifedata.com/resource/umls/label/A10771788"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10771788",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1545807",
                    "o": "trastuzumab"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8438296",
                    "o": "TRASTUZUMAB"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1545806",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                }
            ],
            "ideal_answer": [
                "No, trastuzumab is effective only in cancers where Her2 is over-expessed."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018734",
                "http://www.disease-ontology.org/api/metadata/DOID:0060079",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020869",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010467",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0038128",
                "http://www.biosemantics.org/jochem#4002084",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005176",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786",
                "http://www.disease-ontology.org/api/metadata/DOID:0060080"
            ],
            "type": "yesno",
            "id": "51542eacd24251bc05000084",
            "snippets": [
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 331,
                    "text": "over-expression of HER2 is reported in approximately 20% of gastric tumours, challenging the use of targeted therapies. ",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 802,
                    "text": "In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. Addition of trastuzumab to chemotherapy did not increase the incidence of adverse events.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 408,
                    "text": "treatment of HER2-overexpressing breast cancer: trastuzumab,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658319",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 354,
                    "text": "Trastuzumab has demonstrated clinical activity in several types of HER2-overexpressing epithelial tumors, such as breast and metastatic gastric or gastroesophageal junction cancer. ",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580986",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1621,
                    "offsetInEndSection": 1817,
                    "text": "An example is the established benefit of trastuzumab as adjuvant therapy for breast cancer; a clear definition of HER2-positivity and the assay reproducibility have, however, remained unanswered. ",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392785",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 136,
                    "text": "Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920112",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 350,
                    "text": "Human epidermal growth factor receptor 2 (HER2/neu) is an important target for the treatment of the breast cancers in which it is overexpressed. However, no approved anti-HER2/neu therapy is available for the majority of breast cancer patients, who express HER2/neu at low levels (with scores of 1+ or 2+/fluorescence in situ hybridization-negative).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435924",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 146,
                    "text": "The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) is useful in the treatment of ErbB2-overexpressing breast cancers,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 280,
                    "text": "HercepTestTM (DAKO A/S, Glostrup, Denmark) is an immunohistochemical assay that detects HER2/neu gene products, and evaluates the overexpression status of the HER2/neu protein in determining eligibility for the Trastuzumab (HerceptinR, Genentech, San Francisco, CA, USA) therapy. ",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148461",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is vemurafenib used for thyroid cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                "http://www.ncbi.nlm.nih.gov/pubmed/27554612",
                "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                "http://www.ncbi.nlm.nih.gov/pubmed/24987354",
                "http://www.ncbi.nlm.nih.gov/pubmed/23489023",
                "http://www.ncbi.nlm.nih.gov/pubmed/26751190",
                "http://www.ncbi.nlm.nih.gov/pubmed/24756795",
                "http://www.ncbi.nlm.nih.gov/pubmed/26735176",
                "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
                "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
                "http://www.ncbi.nlm.nih.gov/pubmed/26636651",
                "http://www.ncbi.nlm.nih.gov/pubmed/27127178",
                "http://www.ncbi.nlm.nih.gov/pubmed/24262022",
                "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                "http://www.ncbi.nlm.nih.gov/pubmed/25467940"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220",
                    "o": "VEMURAFENIB"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C3192263",
                    "o": "http://linkedlifedata.com/resource/umls/label/A20020623"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A20020623",
                    "o": "VEMURAFENIB"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220",
                    "o": "http://linkedlifedata.com/resource/rxnorm/label/4224011"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/rxnorm/label/4224011",
                    "o": "VEMURAFENIB"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/chembl/synonym/691867_Vemurafenib_USAN",
                    "o": "Vemurafenib"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C3192263",
                    "o": "http://linkedlifedata.com/resource/umls/label/A19613644"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A19613644",
                    "o": "Vemurafenib"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C3192263",
                    "o": "http://linkedlifedata.com/resource/umls/label/A19649207"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A19649207",
                    "o": "Vemurafenib"
                }
            ],
            "ideal_answer": [
                "Yes. Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3963",
                "http://www.disease-ontology.org/api/metadata/DOID:1781",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013964"
            ],
            "type": "yesno",
            "id": "58848ea5e56acf517600000e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 117,
                    "offsetInEndSection": 314,
                    "text": "Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2338,
                    "offsetInEndSection": 2559,
                    "text": "INTERPRETATION: Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1685,
                    "offsetInEndSection": 1840,
                    "text": "CONCLUSIONS: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 459,
                    "text": "The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30-40%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Use of vemurafenib in anaplastic thyroid carcinoma: a case report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1212,
                    "offsetInEndSection": 1361,
                    "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 399,
                    "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 361,
                    "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 400,
                    "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1220,
                    "offsetInEndSection": 1369,
                    "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1237,
                    "offsetInEndSection": 1415,
                    "text": "Metformin or rapamycin adjuvant treatment may provide clinical benefits with minimal side effects to BRAFV600E-positive advanced thyroid cancer patients treated with vemurafenib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 362,
                    "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1727,
                    "text": "Our data demonstrate that vemurafenib induces ER stress response-mediated autophagy in thyroid cancer and autophagy inhibition may be a beneficial strategy to sensitize BRAF-mutant thyroid cancer to vemurafenib..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 729,
                    "text": "Combination of vemurafenib and metformin decreased cell viability and increased apoptosis in both BCPAP papillary thyroid cancer cells and 8505c anaplastic thyroid cancer cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1092,
                    "text": "Vemurafenib induced a high level of autophagy in BRAF-mutant thyroid cancer cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can tetracycline affect tooth formation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/6829791",
                "http://www.ncbi.nlm.nih.gov/pubmed/1410257",
                "http://www.ncbi.nlm.nih.gov/pubmed/5447715",
                "http://www.ncbi.nlm.nih.gov/pubmed/737550",
                "http://www.ncbi.nlm.nih.gov/pubmed/3855899"
            ],
            "ideal_answer": [
                "Tetracycline is incorporated in the teeth during their formation and leads to their permanent staining. A definite relationship between total dosage and staining and duration of administration and staining was established; the condition occurred with greater frequency (in more than one-third of the children) when the total dosage exceeded 3 g. or the duration of treatment was longer than 10 days."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4272839",
                "http://www.disease-ontology.org/api/metadata/DOID:1091",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013752",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013754",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014070",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014071",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014076"
            ],
            "type": "yesno",
            "id": "530cf4fe960c95ad0c000009",
            "snippets": [
                {
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 379,
                    "text": "he results of that study, reported earlier (Rebich et al., 1983), indicated that over one-fifth of the American Indian children had discoloration of the dentition due to ingestion of tetracycline during the years of tooth formatio",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3855899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 184,
                    "text": "ale Wistar rats prelabeled with tetracycline to mark surfaces of bone and tooth formation-mineralization were placed into orbit for 18.5 days aboard the Soviet COSMOS-1129 Biosatellit",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6829791",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 360,
                    "text": "It was concluded that the increased tetracycline incorporation reflected a higher rate of mineralization associated with faster tooth formation in the unimpeded toot",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/737550",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 237,
                    "text": "n this investigation an attempt has been made to determine the relationship between the staining of permanent teeth by tetracycline administered during the period of tooth formation with the dosage of the drug and the duration of therap",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/5447715",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 787,
                    "text": " definite relationship between total dosage and staining and duration of administration and staining was established; the condition occurred with greater frequency (in more than one-third of the children) when the total dosage exceeded 3 g. or the duration of treatment was longer than 10 days",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/5447715",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 292,
                    "text": "This case report suggests the possibility that discoloration from tetracycline may not be limited to tooth development in the child, but may also affect the adult dentition",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1410257",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is low T3 syndrome a prognostic marker in patients with renal insufficiency?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/958900",
                "http://www.ncbi.nlm.nih.gov/pubmed/21189433",
                "http://www.ncbi.nlm.nih.gov/pubmed/22419237",
                "http://www.ncbi.nlm.nih.gov/pubmed/18211669",
                "http://www.ncbi.nlm.nih.gov/pubmed/17908160",
                "http://www.ncbi.nlm.nih.gov/pubmed/999108",
                "http://www.ncbi.nlm.nih.gov/pubmed/7385804",
                "http://www.ncbi.nlm.nih.gov/pubmed/19367004",
                "http://www.ncbi.nlm.nih.gov/pubmed/21389695",
                "http://www.ncbi.nlm.nih.gov/pubmed/20178724",
                "http://www.ncbi.nlm.nih.gov/pubmed/16230785",
                "http://www.ncbi.nlm.nih.gov/pubmed/23857979",
                "http://www.ncbi.nlm.nih.gov/pubmed/17082213",
                "http://www.ncbi.nlm.nih.gov/pubmed/16775599",
                "http://www.ncbi.nlm.nih.gov/pubmed/22260378",
                "http://www.ncbi.nlm.nih.gov/pubmed/22881233"
            ],
            "ideal_answer": [
                "Low fT3 is an independent predictor of death in chronic kidney disease, in particular in dialised patients at end-stage renal diseases."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011379",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005067",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058186",
                "http://www.disease-ontology.org/api/metadata/DOID:784",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051437",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051436"
            ],
            "type": "yesno",
            "id": "5325de7d9b2d7acc7e000029",
            "snippets": [
                {
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 723,
                    "text": "Low T3 was particularly common (44.3 %), and clearly associated with increased 6- and 12-month mortality and decreased overall survival (log rank test, P=0.007). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22881233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 955,
                    "offsetInEndSection": 1131,
                    "text": "Increased rT3 may be more common in ESRD patients than previously described, and together with decreased T3 it may serve as an indicator of poor prognosis in subsequent months.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22881233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2451,
                    "offsetInEndSection": 2568,
                    "text": "The presence of TFT alterations seems to not be associated with clinical and prognostic implications in AKI patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419237",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 783,
                    "offsetInEndSection": 939,
                    "text": "Multivariate analysis, according to receiver operating characteristic (ROC) curves, showed that mortality was best predicted by total triiodothyronine (T3).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17908160",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1132,
                    "offsetInEndSection": 1364,
                    "text": "Finally, low T3 but not low free triiodothyronine was associated with worse all-cause (Likelihood ratio = 45.4; P < 0.0001) and cardiovascular mortality (Likelihood ratio = 47.8; P < 0.0001) after adjustment for confounding factors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17908160",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1423,
                    "text": " In Cox analyses, fT3 was a significant predictor of mortality independent of the main traditional as well as non-traditional risk factors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17082213",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1774,
                    "text": "All-cause and CV mortality rates were significantly higher in patients with 'lower' T3 levels than in the 'higher' T3 group (113.4 vs 18.2 events per 1000 patient-years, P<0.001, and 49.8 vs 9.1 events per 1000 patient-years, P=0.001, respectively). The Kaplan-Meier analysis also showed significantly worse cumulative survival rates in the 'lower' T3 group (P<0.001). In the Cox regression analysis, low T3 was an independent predictor of all-cause mortality even after adjusting for traditional risk factors (hazard ratio=3.76, P=0.021). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23857979",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1411,
                    "offsetInEndSection": 1566,
                    "text": "In CKD patients with proteinuria, low T3 concentration predicted all-cause mortality and cardiovascular event independently of the severity of proteinuria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1096,
                    "offsetInEndSection": 1344,
                    "text": "Low-T3 syndrome is a frequent finding among HD patients, but it does not predict outcome. However, serum fT3 level is a strong and inverse mortality predictor, in part explained by its underlying association with nutritional state and inflammation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21389695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1289,
                    "offsetInEndSection": 1435,
                    "text": "These data suggest that low FT3 levels are not predictive for mortality in a subgroup of stable HD patients who could survive more than 12 months.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20178724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1246,
                    "offsetInEndSection": 1438,
                    "text": "Low fT3 is an independent predictor of death in hemodialysis patients. These data lend support to the hypothesis that thyroid dysfunction is implicated in the high risk of the ESRD population.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775599",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is macitentan an ET agonist?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22862294",
                "http://www.ncbi.nlm.nih.gov/pubmed/23830395",
                "http://www.ncbi.nlm.nih.gov/pubmed/25539851",
                "http://www.ncbi.nlm.nih.gov/pubmed/24797866",
                "http://www.ncbi.nlm.nih.gov/pubmed/23984728",
                "http://www.ncbi.nlm.nih.gov/pubmed/24769543",
                "http://www.ncbi.nlm.nih.gov/pubmed/23900878",
                "http://www.ncbi.nlm.nih.gov/pubmed/23077657",
                "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
                "http://www.ncbi.nlm.nih.gov/pubmed/24297706",
                "http://www.ncbi.nlm.nih.gov/pubmed/25060980",
                "http://www.ncbi.nlm.nih.gov/pubmed/24998329",
                "http://www.ncbi.nlm.nih.gov/pubmed/21403842",
                "http://www.ncbi.nlm.nih.gov/pubmed/25457902",
                "http://www.ncbi.nlm.nih.gov/pubmed/24906252",
                "http://www.ncbi.nlm.nih.gov/pubmed/25226600",
                "http://www.ncbi.nlm.nih.gov/pubmed/25604973",
                "http://www.ncbi.nlm.nih.gov/pubmed/23353592",
                "http://www.ncbi.nlm.nih.gov/pubmed/25131455",
                "http://www.ncbi.nlm.nih.gov/pubmed/25084082",
                "http://www.ncbi.nlm.nih.gov/pubmed/23568224",
                "http://www.ncbi.nlm.nih.gov/pubmed/25012164",
                "http://www.ncbi.nlm.nih.gov/pubmed/22348175",
                "http://www.ncbi.nlm.nih.gov/pubmed/22189899",
                "http://www.ncbi.nlm.nih.gov/pubmed/20730702",
                "http://www.ncbi.nlm.nih.gov/pubmed/22525377",
                "http://www.ncbi.nlm.nih.gov/pubmed/25377471",
                "http://www.ncbi.nlm.nih.gov/pubmed/24582812",
                "http://www.ncbi.nlm.nih.gov/pubmed/23997048"
            ],
            "ideal_answer": [
                "No, macitentan is anendothelin receptor antagonist."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065128",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065131",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065130"
            ],
            "type": "yesno",
            "id": "56c863385795f9a73e000015",
            "snippets": [
                {
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1036,
                    "text": "Administration of an ET receptor antagonist, either bosentan or macitentan, markedly attenuated PD-induced MMT, fibrosis, angiogenesis, and peritoneal functional decline. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012164",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 453,
                    "text": "Macitentan is an oral, once-daily, dual endothelin (ET)A and ETB receptor antagonist with high affinity and sustained receptor binding that was approved in the USA, Europe, Canada, and Switzerland for the treatment of PAH.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25604973",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Macitentan (Opsumit\u00ae) is a novel dual endothelin receptor antagonist (ERA) with sustained receptor binding properties developed by Actelion Pharmaceuticals Ltd.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297706",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 520,
                    "text": "Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N'-propylaminosulfonamide], is a new dual ET(A)/ET(B) endothelin (ET) receptor antagonist designed for tissue targeting. Selection of macitentan was based on inhibitory potency on both ET receptors and optimization of physicochemical properties to achieve high affinity for lipophilic milieu. In vivo, macitentan is metabolized into a major and pharmacologically active metabolite, ACT-132577. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 1183,
                    "text": "Macitentan and its metabolite antagonized the specific binding of ET-1 on membranes of cells overexpressing ET(A) and ET(B) receptors and blunted ET-1-induced calcium mobilization in various natural cell lines, with inhibitory constants within the nanomolar range. In functional assays, macitentan and ACT-132577 inhibited ET-1-induced contractions in isolated endothelium-denuded rat aorta (ET(A) receptors) and sarafotoxin S6c-induced contractions in isolated rat trachea (ET(B) receptors). In rats with pulmonary hypertension, macitentan prevented both the increase of pulmonary pressure and the right ventricle hypertrophy, and it markedly improved survival. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1362,
                    "offsetInEndSection": 1689,
                    "text": "In conclusion, macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats. This profile makes macitentan a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525377",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 498,
                    "text": "Here we investigated the effects of macitentan, an orally-active, tissue-targeting dual ET receptor antagonist on chronic complications in type 2 diabetes.MAIN METHODS: db/db mice and their age- and sex-matched controls were examined after 2 and 4 months of diabetes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 314,
                    "text": "Macitentan is a novel dual ETA/ETB receptor antagonist with enhanced tissue distribution and sustained receptor binding properties designed to achieve a more efficacious ET receptor blockade. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24582812",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 867,
                    "text": "Recently oral prostacyclin receptor agonists have shown encouraging results. Many clinical studies targeting the vasoconstrictor ET-1 pathway with receptor antagonists like bosentan and ambrisentan have shown strong results, even more optimism coming from macitentan, the newest drug.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23997048",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is lenvatinib effective for renal cell carcinoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27467136",
                "http://www.ncbi.nlm.nih.gov/pubmed/27267515",
                "http://www.ncbi.nlm.nih.gov/pubmed/24190702",
                "http://www.ncbi.nlm.nih.gov/pubmed/27690664",
                "http://www.ncbi.nlm.nih.gov/pubmed/27047959",
                "http://www.ncbi.nlm.nih.gov/pubmed/24387233",
                "http://www.ncbi.nlm.nih.gov/pubmed/26482279",
                "http://www.ncbi.nlm.nih.gov/pubmed/27339111",
                "http://www.ncbi.nlm.nih.gov/pubmed/27621699"
            ],
            "ideal_answer": [
                "Yes, combination of lenvatinib and everolimus is approved to treat advanced or metastatic renal cell carcinoma."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002292",
                "http://www.disease-ontology.org/api/metadata/DOID:4450",
                "http://www.disease-ontology.org/api/metadata/DOID:4451"
            ],
            "type": "yesno",
            "id": "589a245778275d0c4a000024",
            "snippets": [
                {
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 406,
                    "text": "However, the combination of lenvatinib, a multitargeted agent that inhibits VEGF as well as FGF receptors, and everolimus demonstrated promising results in a randomized phase II trial. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27047959",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267515",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1386,
                    "offsetInEndSection": 1642,
                    "text": "Moreover, a recent Phase II study demonstrated a significant benefit for the second-line combination treatment with everolimus plus lenvatinib (a novel TKI) in terms of progression-free survival and overall survival compared to the single-agent everolimus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 1030,
                    "text": "We then discuss two recently approved growth factor receptor antagonists i.e. cabozantinib and lenvatinib, and a recently approved checkpoint inhibitor, nivolumab, and issues pertaining to drug development, and future directions in treatment of metastatic RCC. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690664",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2654,
                    "offsetInEndSection": 2878,
                    "text": "INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26482279",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339111",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339111",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Are hepadnaviral minichromosomes free of nucleosomes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3023620",
                "http://www.ncbi.nlm.nih.gov/pubmed/8649399",
                "http://www.ncbi.nlm.nih.gov/pubmed/1337883",
                "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                "http://www.ncbi.nlm.nih.gov/pubmed/8380890",
                "http://www.ncbi.nlm.nih.gov/pubmed/21331901"
            ],
            "ideal_answer": [
                "Nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned.",
                "In vitro assembled minichromosomes were able to replicate efficiently in vitro, when the DNA was preincubated with T-antigen, a cytosolic S100 extract and three deoxynucleoside triphosphates prior to chromatin assembly, indicating that the origin has to be free of nucleosomes for replication initiation. The transcriptionally inactive locus is covered by an array of positioned nucleosomes extending over 1,400 bp. In minichromosomes with a (mu)LCR or DNase I-hypersensitive site 2 (HS2) which actively transcribe the epsilon-globin gene, the nucleosome at the promoter is altered or disrupted while positioning of nucleosomes in the rest of the locus is retained. Viral minichromosomes were found to exist in at least two defined structures covered with 11 or 12 nucleosomes, leaving open gaps accessible for interactions with other host factors. Minichromosomes from both preparations contain the full complement of nucleosomes, but salt treatment removes histone H1 and a fraction of nonhistone chromatin proteins. This double-stranded DNA serves as a template for replication as well as transcription and is assembled into host nucleosomes, yielding circular viral minichromosomes. In contrast, the replicated untreated minichromosomes were found to be densely packed with nucleosomes, indicating that an assembly of new nucleosomes occurred during in vitro replication.",
                "Several nucleosome-protected sites in a region of the DHBV genome [nucleotides (nt) 2000 to 2700], known to harbor various cis transcription regulatory elements, were consistently identified in all DHBV-positive liver samples. In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings.",
                "nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned. In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "58e3d1743e8b6dc87c000001",
            "snippets": [
                {
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 782,
                    "text": "Several nucleosome-protected sites in a region of the DHBV genome [nucleotides (nt) 2000 to 2700], known to harbor various cis transcription regulatory elements, were consistently identified in all DHBV-positive liver samples.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 783,
                    "offsetInEndSection": 1024,
                    "text": "In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1054,
                    "offsetInEndSection": 1160,
                    "text": "nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 593,
                    "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 554,
                    "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 497,
                    "text": "Mature SV40 minichromosomes are estimated to contain about 27 nucleosomes (error +/- 2), except for those molecules with a nucleosome-free gap, which are interpreted to contain 25 nucleosomes (error +/- 2).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3023620",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 591,
                    "offsetInEndSection": 791,
                    "text": "In vitro replication in the presence of protein-free competitor DNA shows that replicating trypsinized minichromosomes do not lose nucleosomes and replicating competitor DNA does not gain nucleosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649399",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 595,
                    "offsetInEndSection": 795,
                    "text": "In vitro replication in the presence of protein-free competitor DNA shows that replicating trypsinized minichromosomes do not lose nucleosomes and replicating competitor DNA does not gain nucleosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649399",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 793,
                    "text": "We conclude that in both cases parental nucleosomes are transferred to progeny DNA, and, in addition, that an assembly of new nucleosomes occurs during the replication of native minichromosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1337883",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 845,
                    "text": "In contrast, the replicated untreated minichromosomes were found to be densely packed with nucleosomes, indicating that an assembly of new nucleosomes occurred during in vitro replication.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8380890",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 593,
                    "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 554,
                    "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 555,
                    "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 595,
                    "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are integrins part of the extracellular matrix?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25220424",
                "http://www.ncbi.nlm.nih.gov/pubmed/26029690",
                "http://www.ncbi.nlm.nih.gov/pubmed/26096733",
                "http://www.ncbi.nlm.nih.gov/pubmed/25631868",
                "http://www.ncbi.nlm.nih.gov/pubmed/24965068",
                "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
                "http://www.ncbi.nlm.nih.gov/pubmed/25605337",
                "http://www.ncbi.nlm.nih.gov/pubmed/25886986",
                "http://www.ncbi.nlm.nih.gov/pubmed/25759527",
                "http://www.ncbi.nlm.nih.gov/pubmed/25460334",
                "http://www.ncbi.nlm.nih.gov/pubmed/26089687"
            ],
            "ideal_answer": [
                "Yes, \tintegrins are a central family of extracellular matrix receptors."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56e83a2342442bac75000001",
            "snippets": [
                {
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 451,
                    "text": "Several constituents of the ECM provide adhesive cues, which serve as binding sites for cell trans-membrane receptors, such as integrins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029690",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1129,
                    "text": "We also determined that blocking \u03b21integrins, the major class of receptors for all ECM proteins tested,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 298,
                    "text": "Here, we elucidate a cross-scale mechanism for tissue assembly and ECM remodeling involving Cadherin 2, the ECM protein Fibronectin, and its receptor Integrin \u03b15. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26096733",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 604,
                    "text": "due to the diverse functions and variable expression of proteoglycans, matrix proteins, and integrins, it is rather difficult to identify a comprehensive therapeutic target among ECM components.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Integrin-dependent cell-extracellular matrix (ECM) adhesion is a determinant of spindle orientation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605337",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "The extracellular matrix component periostin is a secreted protein that functions as both a cell attachment protein and an autocrine or paracrine factor that signals through the cell adhesion molecule integrins \u03b1v\u03b23 and \u03b1v\u03b25. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759527",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Integrin receptors connect the extracellular matrix to the cell cytoskeleton to provide essential forces and signals. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25460334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 839,
                    "text": " the integrin, talin, and actin filament form a linear complex of which both ends are typically anchored to the extracellular matrices via integrins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965068",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 338,
                    "text": "Integrins, a central family of cellular ECM receptors, have been implicated in these processes but their specific role in ES cell self-renewal remains unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25886986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 446,
                    "text": "Attachment to the extracellular matrix is mediated by a complex of adhesion proteins, including integrins, signaling molecules, actin and actin-binding proteins, and scaffolding proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25631868",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Beta 1 integrin binding plays a role in the constant traction force generation in response to varying stiffness for cells grown on mature cardiac extracellular matrix.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220424",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is autism one of the characteristics of Moebius syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15736079",
                "http://www.ncbi.nlm.nih.gov/pubmed/22832772",
                "http://www.ncbi.nlm.nih.gov/pubmed/20621443",
                "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
                "http://www.ncbi.nlm.nih.gov/pubmed/2929356"
            ],
            "ideal_answer": [
                "Moebius syndrome is a rare congenital disorder usually defined as a combination of facial weakness with impairment of ocular abduction. A strong association of Moebius syndrome with autism spectrum disorders (ASDs) has been suggested in early studies with heterogenous age groups."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5727b6410fd6f91b6800001b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 410,
                    "text": "The diagnosis of Moebius syndrome, a rare congenital disorder, is primarily based on congenital facial and abducent nerve palsy. Involvement of other cranial nerves is also common. Occasionally the V, X, XI, and XII cranial nerves are involved, resulting in a difficulty to chew, swallow, and cough, which often leads to respiratory complications. Mental retardation and autism have been reported in some cases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22832772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 281,
                    "text": "Moebius sequence is a rare congenital disorder usually defined as a combination of facial weakness with impairment of ocular abduction. A strong association of Moebius sequence with autism spectrum disorders (ASDs) has been suggested in earlier studies with heterogenous age groups",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 1069,
                    "text": "Certain genetic syndromes are providing us with extremely valuable information about the role played by genetics in autism. This is the case of the following syndromes: Angelman syndrome, Prader-Willi syndrome, 15q11-q13 duplication, fragile X syndrome, fragile X premutation, deletion of chromosome 2q, XYY syndrome, Smith-Lemli-Opitz syndrome, Apert syndrome, mutations in the ARX gene, De Lange syndrome, Smith-Magenis syndrome, Williams syndrome, Rett syndrome, Noonan syndrome, Down syndrome, velo-cardio-facial syndrome, myotonic dystrophy, Steinert disease, tuberous sclerosis, Duchenne's disease, Timothy syndrome, 10p terminal deletion, Cowden syndrome, 45,X/46,XY mosaicism, Myhre syndrome, Sotos syndrome, Cohen syndrome, Goldenhar syndrome, Joubert syndrome, Lujan-Fryns syndrome, Moebius syndrome, hypomelanosis of Ito, neurofibromatosis type 1, CHARGE syndrome and HEADD syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15736079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "Seventeen children and young adults with Moebius syndrome were examined with a view to finding symptoms of autism. Some 40% of the group showed all or many of the symptoms typical of autistic disorder",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 283,
                    "text": "Fifty-nine cases with infantile autism/autistic disorder were subclassified according to associated medical condition (fragile-X, tuberous sclerosis, neurofibromatosis, hypo-melanosis of Ito, Moebius syndrome, Rett syndrome, and a 'new' syndrome associated with a marker chromosome).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Autism spectrum disorders in children and adolescents with Moebius sequence.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Moebius sequence and autism spectrum disorders--less frequently associated than formerly thought.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621443",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 427,
                    "text": "A strong association of Moebius sequence with autism spectrum disorders (ASDs) has been suggested in earlier studies with heterogenous age groups.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 39,
                    "text": "Autistic behaviour in Moebius syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 393,
                    "text": "The high frequency of autistic symptoms in Moebius syndrome might be a marked overrepresentation and could be suggestive of a common underlying neurobiological deficit at the brainstem level.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Autism spectrum disorders in children and adolescents with Moebius sequence.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Moebius sequence and autism spectrum disorders--less frequently associated than formerly thought.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621443",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 40,
                    "text": "Autistic behaviour in Moebius syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Can a peptide aptamer be used as protein inhibitor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20842131",
                "http://www.ncbi.nlm.nih.gov/pubmed/21296653",
                "http://www.ncbi.nlm.nih.gov/pubmed/20191379",
                "http://www.ncbi.nlm.nih.gov/pubmed/18186614",
                "http://www.ncbi.nlm.nih.gov/pubmed/22956136",
                "http://www.ncbi.nlm.nih.gov/pubmed/17917077",
                "http://www.ncbi.nlm.nih.gov/pubmed/16581027",
                "http://www.ncbi.nlm.nih.gov/pubmed/18195017",
                "http://www.ncbi.nlm.nih.gov/pubmed/19150354",
                "http://www.ncbi.nlm.nih.gov/pubmed/10439043",
                "http://www.ncbi.nlm.nih.gov/pubmed/19389625",
                "http://www.ncbi.nlm.nih.gov/pubmed/24130701",
                "http://www.ncbi.nlm.nih.gov/pubmed/22811618",
                "http://www.ncbi.nlm.nih.gov/pubmed/22714536",
                "http://www.ncbi.nlm.nih.gov/pubmed/12123800",
                "http://www.ncbi.nlm.nih.gov/pubmed/22533554",
                "http://www.ncbi.nlm.nih.gov/pubmed/16815302",
                "http://www.ncbi.nlm.nih.gov/pubmed/16139842",
                "http://www.ncbi.nlm.nih.gov/pubmed/24188027"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8405672",
                    "o": "D052158"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1567956",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17888724"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1567956",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17937093"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17888724",
                    "o": "Aptamers, Peptide [Chemical/Ingredient]"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8405672",
                    "o": "Aptamers, Peptide"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1567956",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8405672"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18057015",
                    "o": "Peptide Aptamers"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1567956",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18057015"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1567956",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8419254"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8419254",
                    "o": "D052158"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8405672",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8419254",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17888724",
                    "o": "N0000170367"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17937093",
                    "o": "N0000170367"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18057015",
                    "o": "N0000170367"
                }
            ],
            "ideal_answer": [
                "Yes, peptide aptamers can be used as inhibitors."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/INH_BPT4",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010455",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011500",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052158"
            ],
            "type": "yesno",
            "id": "53443b13aeec6fbd0700000e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Peptide aptamers of LIM-only protein 2 (Lmo2) were previously used to successfully treat Lmo2-induced tumours in a mouse model of leukaemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24188027",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10439043",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "text": "Accumulating work over the past decade has shown that peptide aptamer screening represents a valid strategy for inhibitor identification that can be applied to a variety of different targets. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956136",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 460,
                    "text": ". The target of one inhibitor peptide, Pep80, identified in this screen was determined to be Snapin, a protein associated with the soluble N-ethyl maleimide sensitive factor adaptor protein receptor (SNARE) complex that is critical for calcium-dependent exocytosis during neurotransmission. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24130701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1020,
                    "offsetInEndSection": 1174,
                    "text": "Use of the genetically selected intracellular aptamer inhibitors allowed us to define unique mechanisms important to HIV-1 replication and T cell biology.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24130701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1688,
                    "text": "This review will describe pre-clinical and clinical data of four major classes of TGF-\u03b2 inhibitor, namely i) ligand traps, ii) antisense oligonucleotides, iii) receptor kinase inhibitors and iv) peptide aptamers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811618",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 471,
                    "text": " A peptide aptamer (ID1/3-PA7) has been designed to prevent this interaction and thereby leading to the transcription of p16(INK4a).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22714536",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 530,
                    "text": "A peptide kinase inhibitor (IP(20)) was used as the aptameric peptide ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22533554",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Peptide aptamer mimicking RAD51-binding domain of BRCA2 inhibits DNA damage repair and survival in Trypanosoma brucei.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21296653",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 593,
                    "offsetInEndSection": 644,
                    "text": " peptide aptamer, Id1/3-PA7, targeting Id1 and Id3,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20842131",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20191379",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Aptamer-derived peptides as potent inhibitors of the oncogenic RhoGEF Tgat.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19389625",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 826,
                    "offsetInEndSection": 961,
                    "text": "Our approach thus demonstrates that peptide aptamers are potent inhibitors that can be used to interfere with RhoGEF functions in vivo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19389625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Development of systemic in vitro evolution and its application to generation of peptide-aptamer-based inhibitors of cathepsin E.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19150354",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 674,
                    "text": "he fusion peptide, TA aptamer, was observed within PC12 cytoplasm and maintained both Abeta-binding ability and antioxygenic property similar to TRX.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17917077",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "Stable expression of a novel fusion peptide of thioredoxin-1 and ABAD-inhibiting peptide protects PC12 cells from intracellular amyloid-beta.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17917077",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "In order to efficiently select aptamers that bind to and inhibit proteins,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815302",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Aptamer selection based on inhibitory activity using an evolution-mimicking algorithm.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815302",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 640,
                    "offsetInEndSection": 744,
                    "text": "This demonstrates the utility of this strategy for screening aptamers based on their inhibitory actions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815302",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 523,
                    "text": "Intracellular expression of the DRD-binding peptide aptamer specifically suppressed receptor-mediated extrinsic apoptosis but not intrinsic pathway, which was recapitulated by the antisense oligonucleotides for FLASH. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16581027",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Peptide aptamers are peptides constrained and presented by a scaffold protein that are used to study protein function in cells. They are able to disrupt protein-protein interactions ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16139842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 676,
                    "text": "Here we have used a genetic screen in yeast to select in vivo peptides coupled to thioredoxin, called aptamers, that could inhibit GEFD2 activity. One aptamer, TRIAPalpha (TRio Inhibitory APtamer), specifically blocks GEFD2-exchange activity on RhoA in vitro.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12123800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1375,
                    "text": "These results show that cell proliferation can be inhibited using genetically-selected synthetic peptides that specifically target protein-protein interaction motifs within cell cycle regulators.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10439043",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1590,
                    "offsetInEndSection": 1776,
                    "text": "These data highlight the utility of peptide aptamers to identify novel binding interfaces and highlight a role for MAP1B in DAPK-1-dependent signaling in autophagy and membrane blebbing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18195017",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the enzyme EPRS phosphorylated?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27729295",
                "http://www.ncbi.nlm.nih.gov/pubmed/21220307",
                "http://www.ncbi.nlm.nih.gov/pubmed/19647514",
                "http://www.ncbi.nlm.nih.gov/pubmed/23071094"
            ],
            "ideal_answer": [
                "Yes, EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999)"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "58cd522902b8c60953000038",
            "snippets": [
                {
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 560,
                    "text": "Phosphorylation of glutamyl-prolyl tRNA synthetase (EPRS) has been investigated extensively in our laboratory for more than a decade, and has served as an archetype for studies of other AARSs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729295",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 579,
                    "text": "EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999); ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071094",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 800,
                    "offsetInEndSection": 997,
                    "text": "Diphosphorylated EPRS is released from its residence in the tRNA multisynthetase complex for immediate binding to NS1-associated protein and subsequent binding to ribosomal protein L13a and GAPDH. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21220307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Two-site phosphorylation of EPRS coordinates multimodal regulation of noncanonical translational control activity.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19647514",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is lenvatinib effective for thyroid cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25974026",
                "http://www.ncbi.nlm.nih.gov/pubmed/26105190",
                "http://www.ncbi.nlm.nih.gov/pubmed/26316818",
                "http://www.ncbi.nlm.nih.gov/pubmed/25553081",
                "http://www.ncbi.nlm.nih.gov/pubmed/25671254",
                "http://www.ncbi.nlm.nih.gov/pubmed/25913680"
            ],
            "ideal_answer": [
                "Yes, lenvatinib is effective for thyroid cancer."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3963",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013964",
                "http://www.disease-ontology.org/api/metadata/DOID:1781"
            ],
            "type": "yesno",
            "id": "56c1f002ef6e394741000038",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25974026",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1130,
                    "offsetInEndSection": 1377,
                    "text": "However, even more impressive responses and progression-free survival benefits were seen in the phase III SELECT trial with lenvatinib, giving even higher hopes for the future management of what was considered just a decade ago an orphan disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25974026",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 514,
                    "offsetInEndSection": 741,
                    "text": "Sorafenib and lenvatinib, small-molecule multikinase inhibitors, were approved for the treatment of progressive, symptomatic, radioactive iodine refractory, advanced differentiated thyroid cancer in 2013 and 2015, respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26105190",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913680",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1811,
                    "offsetInEndSection": 2021,
                    "text": "CONCLUSIONS: In patients with and without prior exposure to VEGF therapy, the encouraging response rates, median time to response, and PFS for lenvatinib have prompted further investigation in a phase 3 trial. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 241,
                    "offsetInEndSection": 488,
                    "text": "Since 2011, four multikinase inhibitors (MKIs) have been approved by the US Food and Drug Administration for thyroid cancer - cabozantinib and vandetanib for medullary thyroid cancer and sorafenib and lenvatinib for differentiated thyroid cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316818",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 970,
                    "text": "Moreover, four of those investigational drugs, vandetanib, cabozantinib, sorafenib and lenvatinib, have reached a phase III clinical trial with favorable results in progression-free survival and overall survival in medullary thyroid carcinoma and differentiated thyroid carcinoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25553081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 241,
                    "offsetInEndSection": 486,
                    "text": "Since 2011, four multikinase inhibitors (MKIs) have been approved by the US Food and Drug Administration for thyroid cancer - cabozantinib and vandetanib for medullary thyroid cancer and sorafenib and lenvatinib for differentiated thyroid cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316818",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 654,
                    "text": "BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor \ufffd, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).METHODS: In our phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 patients to receive placebo. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25671254",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 803,
                    "text": "Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).METHODS: Fifty-eight patients with RR-DTC who had disease progression during the previous 12 months received lenvatinib 24 mg once daily in 28-day cycles until disease progression, unmanageable toxicity, withdrawal, or death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913680",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any HCV replication inhibitors available?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23791700",
                "http://www.ncbi.nlm.nih.gov/pubmed/23466233",
                "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
                "http://www.ncbi.nlm.nih.gov/pubmed/23629709",
                "http://www.ncbi.nlm.nih.gov/pubmed/24154738",
                "http://www.ncbi.nlm.nih.gov/pubmed/23453230",
                "http://www.ncbi.nlm.nih.gov/pubmed/21694902",
                "http://www.ncbi.nlm.nih.gov/pubmed/23896281",
                "http://www.ncbi.nlm.nih.gov/pubmed/24165192",
                "http://www.ncbi.nlm.nih.gov/pubmed/23745769",
                "http://www.ncbi.nlm.nih.gov/pubmed/23230455",
                "http://www.ncbi.nlm.nih.gov/pubmed/23431163",
                "http://www.ncbi.nlm.nih.gov/pubmed/23384816",
                "http://www.ncbi.nlm.nih.gov/pubmed/23454058",
                "http://www.ncbi.nlm.nih.gov/pubmed/23688081",
                "http://www.ncbi.nlm.nih.gov/pubmed/23896953",
                "http://www.ncbi.nlm.nih.gov/pubmed/21331152"
            ],
            "triples": [
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_type",
                    "s": "http://data.linkedct.org/resource/intervention/24334",
                    "o": "Drug"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://data.linkedct.org/resource/intervention/24334",
                    "o": "Intervention #24334 (Drug:HCV polymerase inhibitor pro-drug)"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_name",
                    "s": "http://data.linkedct.org/resource/intervention/24334",
                    "o": "HCV polymerase inhibitor pro-drug"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10759582",
                    "o": "Drug"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_type",
                    "s": "http://data.linkedct.org/resource/intervention/23449",
                    "o": "Drug"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://data.linkedct.org/resource/intervention/23449",
                    "o": "Intervention #23449 (Drug:HCV polymerase inhibitor pro-drug)"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_name",
                    "s": "http://data.linkedct.org/resource/intervention/23449",
                    "o": "HCV polymerase inhibitor pro-drug"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_type",
                    "s": "http://data.linkedct.org/resource/intervention/26936",
                    "o": "Drug"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_name",
                    "s": "http://data.linkedct.org/resource/intervention/26936",
                    "o": "HCV polymerase inhibitor pro-drug"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://data.linkedct.org/resource/intervention/26936",
                    "o": "Intervention #26936 (Drug:HCV polymerase inhibitor pro-drug)"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_type",
                    "s": "http://data.linkedct.org/resource/intervention/28754",
                    "o": "Drug"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://data.linkedct.org/resource/intervention/28754",
                    "o": "Intervention #28754 (Drug:HCV polymerase inhibitor pro-drug)"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_name",
                    "s": "http://data.linkedct.org/resource/intervention/28754",
                    "o": "HCV polymerase inhibitor pro-drug"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_type",
                    "s": "http://data.linkedct.org/resource/intervention/24333",
                    "o": "Drug"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://data.linkedct.org/resource/intervention/24333",
                    "o": "Intervention #24333 (Drug:HCV polymerase inhibitor pro-drug)"
                },
                {
                    "p": "http://data.linkedct.org/resource/linkedct/intervention_name",
                    "s": "http://data.linkedct.org/resource/intervention/24333",
                    "o": "HCV polymerase inhibitor pro-drug"
                }
            ],
            "ideal_answer": [
                "Chronic hepatitis C virus (HCV) infection is a worldwide health problem causing serious complications, such as liver cirrhosis and hepatoma. Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) have been reported to suppress gene expression significantly. HCV seems a suitable candidate for targets of siRNAs, as HCV is a positive single-strand RNA virus and replicates in the cytoplasm.  Based on results, nowadays there are few HCV replication inhibitors such as GS-563253, PSI-6130, NA-808, BMS-790052, GS-9132 and BMS-788329."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014779",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004364"
            ],
            "type": "yesno",
            "id": "53353927d6d3ac6a34000043",
            "snippets": [
                {
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 925,
                    "text": "We report here the discovery of the first small-molecule HCV infectivity inhibitor, GS-563253, also called HCV infectivity inhibitor 1 (HCV II-1). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 140,
                    "text": "Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24154738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 616,
                    "text": "We tested the ability of NA808 to inhibit SPT's enzymatic activity in FLR3-1 replicon cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23791700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1488,
                    "offsetInEndSection": 1631,
                    "text": "The SPT inhibitor NA808 prevents replication of HCV genotypes 1a, 1b, 2a, 3a, and 4a in cultured hepatocytes and in mice with humanized livers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23791700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 263,
                    "text": "Vaniprevir (phase III clinical trials) and MK-5172 (phase II clinical trials) are two potent antiviral compounds that target NS3/4A protease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23745769",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 200,
                    "text": "treatment for hepatitis C virus (HCV) infection has been significantly improved with the approval of the first two HCV NS3/4A protease inhibitors, telaprevir (Incivek) and boceprevir (Victrelis). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 1271,
                    "text": "Combination therapy with telaprevir and BMS-788329 (NS5A inhibitor) reduced serum HCV RNA to undetectable levels. The presence of an NS3-V36A telaprevir resistance mutation resulted in poor response to telaprevir monotherapy but showed significant HCV reduction when telaprevir was combined with BMS-788329. However, a BMS-788329-resistant strain emerged at low frequency. Infection with a BMS-788329-resistant NS5A-L31V mutation rapidly resulted in gain of an additional NS5A-Y93A mutation that conferred telaprevir resistance during combination therapy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23896953",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 240,
                    "text": "HCV NS5A replication complex inhibitors, exemplified by Daclatasvir (BMS-790052), represent a new class of DAA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23896281",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 265,
                    "text": "ACH-806 (or GS-9132) is a novel, small-molecule inhibitor specific for hepatitis C virus (HCV). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 329,
                    "text": "Telaprevir and boceprevir are the first two protease inhibitor (PI) DAAs to be approved for combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453230",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 130,
                    "text": "symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1040,
                    "offsetInEndSection": 1204,
                    "text": "In vitro, boceprevir is more active than telaprevir against the HCV G3 NS3/4A enzyme in cell-based and biochemical assays and against G3 isolates in replicon assays",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454058",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 351,
                    "offsetInEndSection": 577,
                    "text": "Alisporivir is the most advanced host-targeting antiviral in clinical development. Alisporivir blocks HCV replication by neutralizing the peptidyl-prolyl isomerase activity of the abundant host cytosolic protein, cyclophilin A",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 264,
                    "text": "Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23431163",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has saracatinib been tested in clinical trials?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                "http://www.ncbi.nlm.nih.gov/pubmed/26493492",
                "http://www.ncbi.nlm.nih.gov/pubmed/26062928",
                "http://www.ncbi.nlm.nih.gov/pubmed/26009269"
            ],
            "ideal_answer": [
                "Yes, saracatinib has been tested in multiple clinical trials."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e540db06d0a277941000053",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493492",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26009269",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 460,
                    "text": "Metastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 801,
                    "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1015,
                    "text": "The study was a 4-week Phase Ib multiple ascending dose, randomized, double-blind, placebo-controlled trial of AZD0530 in AD patients with Mini-Mental State Examination (MMSE) scores ranging from 16 to 26.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is rivaroxaban metabolized in kidneys?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23026665",
                "http://www.ncbi.nlm.nih.gov/pubmed/23631188",
                "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
                "http://www.ncbi.nlm.nih.gov/pubmed/22931521",
                "http://www.ncbi.nlm.nih.gov/pubmed/19712596",
                "http://www.ncbi.nlm.nih.gov/pubmed/19196845",
                "http://www.ncbi.nlm.nih.gov/pubmed/23652451",
                "http://www.ncbi.nlm.nih.gov/pubmed/22825670",
                "http://www.ncbi.nlm.nih.gov/pubmed/23790601"
            ],
            "ideal_answer": [
                "rivaroxaban undergoes renal metabolism"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007668",
                "http://www.biosemantics.org/jochem#4243836"
            ],
            "type": "yesno",
            "id": "532f09d2d6d3ac6a3400002b",
            "snippets": [
                {
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 636,
                    "text": "The novel oral anticoagulants (i.e., dabigatran, apixaban, rivaroxaban) all undergo renal metabolism to varying degrees, and hence dosing, efficacy, and safety require special consideration in CKD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23790601",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1473,
                    "offsetInEndSection": 1614,
                    "text": "The new oral anticoagulants have relatively little data in patients with severe renal impairment, and all have an element of renal excretion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 661,
                    "text": "Now new anticoagulant drugs(dabigatran and rivaroxaban) can become available. Therefore, we have to learn how to use those drugs. They have to carefully be used because they discharge from kidney and old aged patients have potential renal dysfunction. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23631188",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1115,
                    "offsetInEndSection": 1268,
                    "text": "In the everyday practice it will be necessary to be very cautious in patients with impaired renal function, as all these drugs are eliminated by kidneys.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026665",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1135,
                    "text": "Dabigatran etexilate and rivaroxaban carry the highest risk due to a high degree of renal excretion, whereas the risk for apixaban, edoxaban and betrixaban seems lower.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22931521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 800,
                    "text": "However, all these agents undergo renal clearance to varying degrees, and hence dosing, efficacy, and safety require special consideration in patients with CKD. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22825670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1665,
                    "offsetInEndSection": 1776,
                    "text": "Rivaroxaban being excreted via kidney and liver, some precautions should apply in case of liver insufficiency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1397,
                    "offsetInEndSection": 1496,
                    "text": "Rivaroxaban elimination is mainly renal, but also through faecal matter and by hepatic metabolism. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19712596",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do Conserved noncoding elements act as enhancers?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18047696",
                "http://www.ncbi.nlm.nih.gov/pubmed/21629789",
                "http://www.ncbi.nlm.nih.gov/pubmed/21081479",
                "http://www.ncbi.nlm.nih.gov/pubmed/19782672",
                "http://www.ncbi.nlm.nih.gov/pubmed/19805301",
                "http://www.ncbi.nlm.nih.gov/pubmed/18562680",
                "http://www.ncbi.nlm.nih.gov/pubmed/16533910",
                "http://www.ncbi.nlm.nih.gov/pubmed/21047394",
                "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                "http://www.ncbi.nlm.nih.gov/pubmed/17940009",
                "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                "http://www.ncbi.nlm.nih.gov/pubmed/17210927",
                "http://www.ncbi.nlm.nih.gov/pubmed/15859353",
                "http://www.ncbi.nlm.nih.gov/pubmed/20494938",
                "http://www.ncbi.nlm.nih.gov/pubmed/19704032",
                "http://www.ncbi.nlm.nih.gov/pubmed/19171877",
                "http://www.ncbi.nlm.nih.gov/pubmed/19073165"
            ],
            "ideal_answer": [
                "An important percentage of noncoding elements conserved across distant species shows enhancer activity and other forms of regulatory functionality."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024861",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0035326",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026801",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017124",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004742"
            ],
            "type": "yesno",
            "id": "5139ec51bee46bd34c000006",
            "snippets": [
                {
                    "offsetInBeginSection": 1169,
                    "offsetInEndSection": 1216,
                    "text": "The aCNEs are rich in tissue-specific enhancers",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081479",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1397,
                    "offsetInEndSection": 1483,
                    "text": "Transgenic zebrafish assay of some human CNE enhancers that have been lost in teleosts",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081479",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Conserved noncoding elements (CNEs) in vertebrate genomes often act as developmental enhancers,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20494938",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1433,
                    "offsetInEndSection": 1727,
                    "text": "In all four cases where the zebra fish and human CNE display a similar expression pattern in zebra fish, the human CNE also displays a similar expression pattern in mouse. This suggests that the endogenous enhancer activity of \u223c30% of human CNEs can be determined from experiments in zebra fish",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20494938",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1278,
                    "offsetInEndSection": 1530,
                    "text": "If these ancient CNEs are indeed enhancers directing tissue-specific expression of Hox genes, divergence of their sequences in vertebrate lineages might have led to altered expression patterns and presumably the functions of their associated Hox genes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 887,
                    "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "Animal genomes possess highly conserved cis-regulatory sequences that are often found near genes that regulate transcription and development.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704032",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 755,
                    "offsetInEndSection": 914,
                    "text": "We test 42 of our PCNEs in transgenic zebrafish assays--including examples from vertebrates and amphioxus--and find that the majority are functional enhancers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704032",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "The genomes of vertebrates, flies, and nematodes contain highly conserved noncoding elements (CNEs). CNEs cluster around genes that regulate development, and where tested, they can act as transcriptional enhancers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 1004,
                    "text": ", we identified 17 highly conserved noncoding elements, 9 of which revealed specific acetylation marks in chromatin-immunoprecipitation and microarray (ChIP-chip) assays performed across 250 kb of the Lmo2 locus in 11 cell types covering different stages of hematopoietic differentiation. All candidate regulatory regions were tested in transgenic mice. An extended LMO2 proximal promoter fragment displayed strong endothelial activity, while the distal promoter showed weak forebrain activity. Eight of the 15 distal candidate elements functioned as enhancers,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171877",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "Pan-vertebrate developmental cis-regulatory elements are discernible as highly conserved noncoding elements (HCNEs) and are often dispersed over large areas around the pleiotropic genes whose expression they control.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073165",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 677,
                    "text": "HCNEs of both human and zebrafish function as specific developmental enhancers in zebrafish.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073165",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1048,
                    "offsetInEndSection": 1165,
                    "text": "several transcriptional enhancers are conserved between amphioxus and vertebrates--a very wide phylogenetic distance.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18562680",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 463,
                    "text": "We recently described GRBs in vertebrates, where most HCNEs function as enhancers",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 762,
                    "text": "Besides developmental regulators that are likely targets of HCNE enhancers",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 734,
                    "text": "We identify and characterize highly conserved noncoding elements flanking the TNF gene, which undergo activation-dependent intrachromosomal interactions. These elements, hypersensitive site (HSS)-9 and HSS+3 (9 kb upstream and 3 kb downstream of the TNF gene, respectively), contain DNase I hypersensitive sites in naive, T helper 1, and T helper 2 primary T cells. Both HSS-9 and HSS+3 inducibly associate with acetylated histones, indicative of chromatin remodeling, bind the transcription factor nuclear factor of activated T cells (NFAT)p in vitro and in vivo, and function as enhancers",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17940009",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1032,
                    "offsetInEndSection": 1420,
                    "text": "We used the sequence signatures identified by this approach to successfully assign tissue-specific predictions to approximately 328,000 human-mouse conserved noncoding elements in the human genome. By overlapping these genome-wide predictions with a data set of enhancers validated in vivo, in transgenic mice, we were able to confirm our results with a 28% sensitivity and 50% precision.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210927",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 305,
                    "text": "Fish-mammal genomic comparisons have proved powerful in identifying conserved noncoding elements likely to be cis-regulatory in nature, and the majority of those tested in vivo have been shown to act as tissue-specific enhancers associated with genes involved in transcriptional regulation of development.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16533910",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 1016,
                    "text": "uncovered two anciently conserved noncoding sequences (CNS) upstream of COUP-TFII (CNS-62kb and CNS-66kb). Testing these two elements using reporter constructs in liver cells (HepG2) revealed that CNS-66kb, but not CNS-62kb, yielded robust in vitro enhancer activity.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15859353",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is there any software for automated analysis of FISH images?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21310746",
                "http://www.ncbi.nlm.nih.gov/pubmed/22665392",
                "http://www.ncbi.nlm.nih.gov/pubmed/21656271",
                "http://www.ncbi.nlm.nih.gov/pubmed/16749443",
                "http://www.ncbi.nlm.nih.gov/pubmed/17889539",
                "http://www.ncbi.nlm.nih.gov/pubmed/23903043",
                "http://www.ncbi.nlm.nih.gov/pubmed/15887538",
                "http://www.ncbi.nlm.nih.gov/pubmed/17674627",
                "http://www.ncbi.nlm.nih.gov/pubmed/22935778",
                "http://www.ncbi.nlm.nih.gov/pubmed/22163442",
                "http://www.ncbi.nlm.nih.gov/pubmed/20639591",
                "http://www.ncbi.nlm.nih.gov/pubmed/15351517",
                "http://www.ncbi.nlm.nih.gov/pubmed/11818019",
                "http://www.ncbi.nlm.nih.gov/pubmed/24240725",
                "http://www.ncbi.nlm.nih.gov/pubmed/20966547"
            ],
            "ideal_answer": [
                "FISH is a popular molecular cytogenetic method. The output of a single FISH analysis is a set of several tens or hundreds microscopic images \u2014 a single evaluated sample is of roughly 20mm diameter. The goal of an automated evaluation is to replace the subjective evaluation of images by the laboratory technician to achieve higher uniformity of results. Following explanation of the principle of the method and the typical contents of images, the processing flow of image segmentation is outlined and the results are presented on several example images. Based on results there are software for automated analysis of FISH images."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001331",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007091",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012984"
            ],
            "type": "yesno",
            "id": "5311cdcce3eabad021000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1622,
                    "offsetInEndSection": 1770,
                    "text": "he study demonstrated the feasibility of automated FISH signal analysis that applying a CAD scheme to the automated generated 2-D projection images.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 1485,
                    "text": "A color imaging technique, multiplex fluorescent in situ hybridization (M-FISH), has been developed to ease the analysis of the process. Using an M-FISH technique each chromosome class (1,2, \u2026,22,X,Y) is stained with a unique color. However, significant variations between images are observed due to a number of factors such as uneven hybridization and spectral overlap among channels. These types of variations influence the pixel classification accuracy of image classification methods which are supervised and require a set of annotated images for training. In this paper, we present a fully unsupervised M-FISH chromosome image classification methodology. Our main contributions are 1) the assumption that the intensity of a chromosome pixel is sampled from multiple Gaussian components [Gaussian mixture model (GMM)] such that each component corresponds to one chromosome class, and 2) the initialization of the GMM model using the emission information of each chromosome class. This is feasible since prior to the M-FISH image acquirement, we already know which chromosome class is emitting to each of the five M-FISH image channels. The method has been tested on a large number of M-FISH images and an overall accuracy of 89.85% is reported. Our method is unsupervised and presents higher classification accuracy even when it is compared with common supervised based methods.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240725",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 1620,
                    "text": "hybridization (FISH) tests provide promising molecular imaging biomarkers to more accurately and reliably detect and diagnose cancers and genetic disorders. Since current manual FISH signal analysis is low-efficient and inconsistent, which limits its clinical utility, developing automated FISH image scanning systems and computer-aided detection (CAD) schemes has been attracting research interests. To acquire high-resolution FISH images in a multi-spectral scanning mode, a huge amount of image data with the stack of the multiple three-dimensional (3-D) image slices is generated from a single specimen. Automated preprocessing these scanned images to eliminate the non-useful and redundant data is important to make the automated FISH tests acceptable in clinical applications. In this study, a dual-detector fluorescence image scanning system was applied to scan four specimen slides with FISH-probed chromosome X. A CAD scheme was developed to detect analyzable interphase cells and map the multiple imaging slices recorded FISH-probed signals into the 2-D projection images. CAD scheme was then applied to each projection image to detect analyzable interphase cells using an adaptive multiple-threshold algorithm, identify FISH-probed signals using a top-hat transform, and compute the ratios between the normal and abnormal cells. To assess CAD performance, the FISH-probed signals were also independently visually detected by an observer. The Kappa coefficients for agreement between CAD and observer ranged from 0.69 to 1.0 in detecting/counting FISH signal spots in four testing samples.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 1185,
                    "text": " In this paper we developed a sparse representation-based classification (SRC) algorithm based on L1-norm minimization for classifying chromosomes from multicolor fluorescence in situ hybridization (M-FISH) images. The algorithm has been tested on a comprehensive M-FISH database that we established, demonstrating improved performance in classification. When compared with other pixel-wise M-FISH image classifiers such as fuzzy c-means (FCM) clustering algorithms and adaptive fuzzy c-means (AFCM) clustering algorithms that we proposed earlier the current method gave the lowest classification error. In order to evaluate the performance of different SRC for M-FISH imaging analysis, three different sparse representation methods, namely, Homotopy method, Orthogonal Matching Pursuit (OMP), and Least Angle Regression (LARS), were tested and compared. Results from our statistical analysis have shown that Homotopy based method is significantly better than the other two methods. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665392",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1397,
                    "text": "Fluorescence in situ hybridization (FISH) is used to study the organization and the positioning of specific DNA sequences within the cell nucleus. Analyzing the data from FISH images is a tedious process that invokes an element of subjectivity. Automated FISH image analysis offers savings in time as well as gaining the benefit of objective data analysis. While several FISH image analysis software tools have been developed, they often use a threshold-based segmentation algorithm for nucleus segmentation. As fluorescence signal intensities can vary significantly from experiment to experiment, from cell to cell, and within a cell, threshold-based segmentation is inflexible and often insufficient for automatic image analysis, leading to additional manual segmentation and potential subjective bias. To overcome these problems, we developed a graphical software tool called FISH Finder to automatically analyze FISH images that vary significantly. By posing the nucleus segmentation as a classification problem, compound Bayesian classifier is employed so that contextual information is utilized, resulting in reliable classification and boundary extraction. This makes it possible to analyze FISH images efficiently and objectively without adjustment of input parameters. Additionally, FISH Finder was designed to analyze the distances between differentially stained FISH probes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1417,
                    "text": "The simultaneous detection of protein expression and gene copy number changes in patient samples, like paraffin-embedded tissue sections, is challenging since the procedures of immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) negatively influence each other which often results in suboptimal staining. Therefore, we developed a novel automated algorithm based on relocation which allows subsequent detection of protein content and gene copy number changes within the same cell. METHODS: Paraffin-embedded tissue sections of colorectal cancers were stained for CD133 expression. IHC images were acquired and image coordinates recorded. Slides were subsequently hybridized with fluorescently labeled DNA probes. FISH images were taken at the previously recorded positions allowing for direct comparison of protein expression and gene copy number signals within the same cells/tissue areas. Relocation, acquisition of the IHC and FISH images, and enumeration of FISH signals in the immunophenotyped tumour areas were done in an automated fashion. RESULTS: Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands. From the 13 cases four (31%) showed amplification for the MYC oncogene and seven of 13 (54%) cases were amplified for ZNF217.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21656271",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1516,
                    "text": "The simultaneous detection of protein expression and gene copy number changes in patient samples, like paraffin-embedded tissue sections, is challenging since the procedures of immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) negatively influence each other which often results in suboptimal staining.Therefore, we developed a novel automated algorithm based on relocation which allows subsequent detection of protein content and gene copy number changes within the same cell. METHODS: Paraffin-embedded tissue sections of colorectal cancers were stained for CD133 expression. IHC images were acquired and image coordinates recorded. Slides were subsequently hybridized with fluorescently labeled DNA probes. FISH images were taken at the previously recorded positions allowing for direct comparison of protein expression and gene copy number signals within the same cells/tissue areas. Relocation, acquisition of the IHC and FISH images, and enumeration of FISH signals in the immunophenotyped tumour areas were done in an automated fashion. RESULTS: Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands. From the 13 cases four (31%) showed amplification for the MYC oncogene and seven of 13 (54%) cases were amplified for ZNF217. There was no significant difference between CD133 positive tumour and CD133 negative tumour cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20966547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1513,
                    "text": "The simultaneous detection of protein expression and gene copy number changes in patient samples, like paraffin-embedded tissue sections, is challenging since the procedures of immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) negatively influence each other which often results in suboptimal staining.Therefore, we developed a novel automated algorithm based on relocation which allows subsequent detection of protein content and gene copy number changes within the same cell.Methods: Paraffin-embedded tissue sections of colorectal cancers were stained for CD133 expression. IHC images were acquired and image coordinates recorded. Slides were subsequently hybridized with fluorescently labeled DNA probes. FISH images were taken at the previously recorded positions allowing for direct comparison of protein expression and gene copy number signals within the same cells/tissue areas. Relocation, acquisition of the IHC and FISH images, and enumeration of FISH signals in the immunophenotyped tumour areas were done in an automated fashion.Results: Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands. From the 13 cases four (31%) showed amplification for the MYC oncogene and seven of 13 (54%) cases were amplified for ZNF217. There was no significant difference between CD133 positive tumour and CD133 negative tumour cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20639591",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can cardiospheres be produced from skin fibroblasts?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29999590"
            ],
            "ideal_answer": [
                "Yes, induced cardiospheres (iCS) can be produced by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c928afeecadf2e73f000018",
            "snippets": [
                {
                    "offsetInBeginSection": 331,
                    "offsetInEndSection": 461,
                    "text": "Therefore, there is an emerging interest in generating cardiosphere-like stem cells from somatic cells via somatic reprogramming. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29999590",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 805,
                    "text": "Here we provide the detailed protocol for generating induced cardiospheres (iCS) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29999590",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does Yersinia pestis causes a respiratory infection?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17041851",
                "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
                "http://www.ncbi.nlm.nih.gov/pubmed/16239527",
                "http://www.ncbi.nlm.nih.gov/pubmed/21859946",
                "http://www.ncbi.nlm.nih.gov/pubmed/26123398",
                "http://www.ncbi.nlm.nih.gov/pubmed/25928467",
                "http://www.ncbi.nlm.nih.gov/pubmed/25974210",
                "http://www.ncbi.nlm.nih.gov/pubmed/16714568",
                "http://www.ncbi.nlm.nih.gov/pubmed/19629028",
                "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
                "http://www.ncbi.nlm.nih.gov/pubmed/16964684",
                "http://www.ncbi.nlm.nih.gov/pubmed/24721571",
                "http://www.ncbi.nlm.nih.gov/pubmed/25691593"
            ],
            "ideal_answer": [
                "Inhalation of Yersinia pestis results in primary pneumonic plague."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015010",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015007",
                "http://www.disease-ontology.org/api/metadata/DOID:0050069",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015009"
            ],
            "type": "yesno",
            "id": "58caf86f02b8c60953000030",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 140,
                    "text": "Inhalation of Yersinia pestis results in primary pneumonic plague, a highly lethal and rapidly progressing necrotizing pneumonia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25691593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Yersinia pestis causes the fatal respiratory disease pneumonic plague.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123398",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Pulmonary infection by Yersinia pestis causes pneumonic plague, a rapidly progressing and often fatal disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16714568",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "Pulmonary infection with the bacterium Yersinia pestis causes pneumonic plague, an often-fatal disease for which no vaccine is presently available.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16239527",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 69,
                    "text": "Yersinia pestis causes the fatal respiratory disease pneumonic plague",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123398",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Pneumonic plague is a deadly respiratory disease caused by Yersinia pestis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24721571",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "On July 8, 2014, the Colorado Department of Public Health and Environment (CDPHE) laboratory identified Yersinia pestis, the bacterium that causes plague, in a blood specimen collected from a man (patient A) hospitalized with pneumonia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25928467",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 69,
                    "text": "Early emergence of Yersinia pestis as a severe respiratory pathogen.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123398",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "The aerosol form of the bacterium Yersinia pestis causes the pneumonic plague, a rapidly fatal disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17041851",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 17,
                    "offsetInEndSection": 331,
                    "text": " plague bacterium, Yersinia pestis, has historically been regarded as one of the deadliest pathogens known to mankind, having caused three major pandemics. After being transmitted by the bite of an infected flea arthropod vector, Y. pestis can cause three forms of human plague: bubonic, septicemic, and pneumonic,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21859946",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 561,
                    "text": "Plague is an infectious disease caused by the Yersinia pestis microorganism, which is transmitted to the human host from a natural reservoir (different rodent species) by a flea bite. Plague is still encountered in humans in the areas of its enzootic prevalence in local rodent populations. Infection by flea bite results in a bubonic or septicemic plague, possibly complicated by secondary pneumonia. The person with pneumonic symptoms may be a source of a droplet-borne inhalatory infection for other people who consequently develop primary pneumonic plague. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 166,
                    "text": "uring pneumonic plague, the bacterium Yersinia pestis elicits the development of inflammatory lung lesions that continue to expand throughout infection. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 582,
                    "text": "In November 2006, the Uganda Ministry of Health received reports of an increase in bubonic plague cases and a possible outbreak of pneumonic plague among residents in the Arua and Nebbi districts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19629028",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Pneumonic plague is a fatal disease caused by Yersinia pestis that is associated with a delayed immune response in the lungs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25974210",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there increased incidence of incontinence in athletes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19415493",
                "http://www.ncbi.nlm.nih.gov/pubmed/15385857",
                "http://www.ncbi.nlm.nih.gov/pubmed/16953954",
                "http://www.ncbi.nlm.nih.gov/pubmed/17390923",
                "http://www.ncbi.nlm.nih.gov/pubmed/15233598",
                "http://www.ncbi.nlm.nih.gov/pubmed/20390664",
                "http://www.ncbi.nlm.nih.gov/pubmed/20890872",
                "http://www.ncbi.nlm.nih.gov/pubmed/21571270",
                "http://www.ncbi.nlm.nih.gov/pubmed/23687004",
                "http://www.ncbi.nlm.nih.gov/pubmed/11689727",
                "http://www.ncbi.nlm.nih.gov/pubmed/23122895",
                "http://www.ncbi.nlm.nih.gov/pubmed/8684695",
                "http://www.ncbi.nlm.nih.gov/pubmed/23361854",
                "http://www.ncbi.nlm.nih.gov/pubmed/10932809",
                "http://www.ncbi.nlm.nih.gov/pubmed/18506324",
                "http://www.ncbi.nlm.nih.gov/pubmed/8041527",
                "http://www.ncbi.nlm.nih.gov/pubmed/11999199",
                "http://www.ncbi.nlm.nih.gov/pubmed/21501085"
            ],
            "ideal_answer": [
                "There is a very high prevalence of urinary incontinence in women athletes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014550",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056352",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014549"
            ],
            "type": "yesno",
            "id": "5361677c7d100faa09000008",
            "snippets": [
                {
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 482,
                    "text": "Urinary incontinence affects women of all ages, including top female athletes, but is often under-reported. The highest prevalence of urinary incontinence is reported in those participating in high impact sports.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23687004",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 29,
                    "offsetInEndSection": 196,
                    "text": "The prevalence of female stress urinary incontinence is high, and young adults are also affected, including athletes, especially those involved in \"high-impact\" sports",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23361854",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1841,
                    "offsetInEndSection": 2074,
                    "text": "Analysis of these data suggests that perineal pressure is decreased in female athletes compared with nonathlete women. A lower perineal pressure correlates with increased symptoms of urinary incontinence and pelvic floor dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23122895",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 943,
                    "offsetInEndSection": 1033,
                    "text": "Urinary incontinence is a prevalent condition among athletes that is not openly discussed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571270",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1464,
                    "offsetInEndSection": 1564,
                    "text": "High-level sport appears to be a significant independent risk factor for AI in healthy young women. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501085",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 671,
                    "text": "The prevalence of LUTS was 54.7%, and 30% for urinary incontinence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890872",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1528,
                    "offsetInEndSection": 1583,
                    "text": "LUTS and incontinence are prevalent in female athletes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890872",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "A relationship between sport or fitness activities and urinary incontinence (UI) previously has been described in women. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20390664",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 294,
                    "text": "studies have also shown a high prevalence of SUI in young, physically fit female athletes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19415493",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 830,
                    "text": "There was urinary incontinence in female long-distance runners and a correlation with eating disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506324",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 31,
                    "offsetInEndSection": 136,
                    "text": "young female athletes participating in high-impact sports may be at higher risk for urinary incontinence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17390923",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 631,
                    "text": "Results indicated that more than 25% of those completing surveys experienced incontinence and that more than 90% had never told anyone about their problem and had no knowledge of preventive measures; 16% reported incontinence negatively impacted their quality of life.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17390923",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1377,
                    "text": "There is a very high prevalence of urinary incontinence in women athletes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953954",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 832,
                    "text": "Women athletes should be counseled about the increased risk of urinary incontinence with ultra high-impact sports and eating disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15385857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 1036,
                    "text": "Stress urinary incontinence is a barrier to women's participation in sport and fitness activities and, therefore, it may be a threat to women's health, self-esteem and well-being. The prevalence during sports among young, nulliparous elite athletes varies between 0% (golf) and 80% (trampolinists). The highest prevalence is found in sports involving high impact activities such as gymnastics, track and field, and some ball games",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15233598",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1202,
                    "offsetInEndSection": 1330,
                    "text": "Urinary leakage is common among elite athletes and dancers, particularly during training, but also during daily life activities.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11999199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1850,
                    "offsetInEndSection": 2064,
                    "text": "There is a high prevalence of stress and urge incontinence in female elite athletes. The frequency of SUI and urge incontinence was significantly higher in eating disordered athletes compared with healthy athletes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11689727",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1419,
                    "text": "High impact sports activities may produce urinary incontinence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932809",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 906,
                    "text": "Urinary incontinence during physical stresses is common in young nulliparous wome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8684695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1307,
                    "offsetInEndSection": 1395,
                    "text": "Incontinence during physical stresses is common in young, highly fit, nulliparous women.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041527",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a mouse model for Fanconi anemia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10936049",
                "http://www.ncbi.nlm.nih.gov/pubmed/12135664",
                "http://www.ncbi.nlm.nih.gov/pubmed/12200363",
                "http://www.ncbi.nlm.nih.gov/pubmed/21240276",
                "http://www.ncbi.nlm.nih.gov/pubmed/9678061",
                "http://www.ncbi.nlm.nih.gov/pubmed/19561169",
                "http://www.ncbi.nlm.nih.gov/pubmed/11879775",
                "http://www.ncbi.nlm.nih.gov/pubmed/22660274",
                "http://www.ncbi.nlm.nih.gov/pubmed/8879267",
                "http://www.ncbi.nlm.nih.gov/pubmed/9531583",
                "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                "http://www.ncbi.nlm.nih.gov/pubmed/18812474",
                "http://www.ncbi.nlm.nih.gov/pubmed/19427003",
                "http://www.ncbi.nlm.nih.gov/pubmed/21915857"
            ],
            "ideal_answer": [
                "A number of mouse models have already been generated with a targeted disruption of several Fanconi anemia genes, such as FANCA, FANCF, FANCM, FANCD1, etc."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199",
                "http://www.disease-ontology.org/api/metadata/DOID:1062",
                "http://www.disease-ontology.org/api/metadata/DOID:13636"
            ],
            "type": "yesno",
            "id": "54edf05494afd6150400000e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22660274",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 702,
                    "text": "We compared Cy preconditioning with fludarabine (Flu) or cytarabine (AraC) or no conditioning as a control in fanca ( -/- ) mutant mice receiving gene-modified bone marrow cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22660274",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1132,
                    "offsetInEndSection": 1307,
                    "text": "We conclude that Cy is an effective and superior preparative regimen with respect to engraftment of lentivirus-transduced cells and functional correction in fanca ( -/- ) mice",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22660274",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 485,
                    "text": "To study whether there is a causal relationship between FA pathway defects and tumour development, we have generated a mouse model with a targeted disruption of the FA core complex gene Fancf",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 752,
                    "text": "Fancf-deficient mouse embryonic fibroblasts displayed a phenotype typical for FA cells: they showed an aberrant response to DNA cross-linking agents as manifested by G(2) arrest, chromosomal aberrations, reduced survival, and an inability to monoubiquitinate FANCD2",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 1082,
                    "text": "Fancf homozygous mice were viable, born following a normal Mendelian distribution, and showed no growth retardation or developmental abnormalities. The gonads of Fancf mutant mice functioned abnormally, showing compromised follicle development and spermatogenesis as has been observed in other FA mouse models and in FA patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1084,
                    "offsetInEndSection": 1190,
                    "text": "In a cohort of Fancf-deficient mice, we observed decreased overall survival and increased tumour incidence",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 393,
                    "text": "To provide further experimental access to the FA-M complementation group we have generated Fancm-deficient mice by deleting exon 2",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561169",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 395,
                    "offsetInEndSection": 563,
                    "text": "FANCM deficiency caused hypogonadism in mice and hypersensitivity to cross-linking agents in mouse embryonic fibroblasts (MEFs), thus phenocopying other FA mouse models",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561169",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 761,
                    "text": "Fancm(Delta2/Delta2) mice also showed unique features atypical for FA mice, including underrepresentation of female Fancm(Delta2/Delta2) mice and decreased overall and tumor-free survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561169",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561169",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "Fancf-deficient mice are prone to develop ovarian tumours",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915857",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812474",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 874,
                    "text": "Using an FA mouse model with a marked hematopoietic phenotype, the FA-D1 (Brca2(Delta27/Delta27)) mice, we demonstrate that the lentivirus-mediated gene therapy of FA HSCs results in the progressive expansion of genetically corrected clones in mild-conditioned FA-D1 recipients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1038,
                    "text": "Consistent with these data, hematopoietic progenitors from FA recipients progressively became mitomycin C resistant and their chromosomal instability was reverted",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "We have investigated the hematopoietic phenotype of mice with a hypomorphic mutation in the Brca2/Fancd1 gene (Brca2(Delta27/Delta27) mutation)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 867,
                    "text": "Conventional BM competition experiments showed a marked repopulation defect in Brca2(Delta27/Delta27) hematopoietic stem cells (HSCs), compared to wild-type HSCs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1069,
                    "text": "Moreover, we have observed for the first time in a DNA repair disease model a very significant proliferation defect in Brca2(Delta27/Delta27) HSCs maintained in their natural physiological environment",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1291,
                    "offsetInEndSection": 1509,
                    "text": "The hematopoietic phenotype associated with the Brca2(Delta27/Delta27) mutation suggests that this FA-D1 mouse model will constitute an important tool for the development of new therapies for FA, including gene therapy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200363",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 463,
                    "text": "In this study we characterized the hematopoietic phenotype of a Fanca knockout mouse model and corrected the main phenotypic characteristics of the bone marrow (BM) progenitors using retroviral vectors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 630,
                    "text": "The hematopoiesis of these animals was characterized by a modest though significant thrombocytopenia, consistent with reduced numbers of BM megakaryocyte progenitors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 757,
                    "text": "As observed in other FA models, the hematopoietic progenitors from Fanca(-/-) mice were highly sensitive to mitomycin C (MMC)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1839,
                    "text": "Aiming to correct the phenotype of Fanca(-/-) progenitors, purified Lin(-)Sca-1(+) cells were transduced with retroviral vectors encoding the enhanced green fluorescent protein (EGFP) gene and human FANCA genes. Lin(-)Sca-1(+) cells from Fanca(-/-) mice were transduced with an efficiency similar to that of samples from wild-type mice. More significantly, transductions with FANCA vectors corrected both the MMC hypersensitivity as well as the impaired ex vivo expansion ability that characterized the BM progenitors of Fanca(-/-) mice",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 1092,
                    "text": " The Btbd12 knockout mouse therefore establishes a disease model for Fanconi anemia and genetically links a regulator of nuclease incision complexes to the Fanconi anemia DNA crosslink repair pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21240276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9531583",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812474",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Assessment of the flexed-tail mouse as a possible model for Fanconi anemia: analysis of mitomycin C-induced micronuclei.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8879267",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 1098,
                    "text": "The Btbd12 knockout mouse therefore establishes a disease model for Fanconi anemia and genetically links a regulator of nuclease incision complexes to the Fanconi anemia DNA crosslink repair pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21240276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22660274",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 31,
                    "text": "Mouse models of Fanconi anemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19427003",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 591,
                    "offsetInEndSection": 735,
                    "text": "Five of these genes have been deleted or mutated in the mouse, as well as a sixth key regulatory gene, to create mouse models of Fanconi anemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19427003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 1039,
                    "text": "This review summarizes the phenotype of each of the Fanconi anemia mouse models and highlights how genetic and interventional studies using the strains have yielded novel insight into therapeutic strategies for Fanconi anemia and into how the Fanconi anemia pathway protects against genomic instability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19427003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 277,
                    "text": "To study FA complementation group A using the mouse as a model system, we cloned and characterized the mouse homolog of the human FANCA cDNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10936049",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 419,
                    "text": "Here we describe the phenotype of the Btbd12 knockout mouse, the mouse ortholog of SLX4, which recapitulates many key features of the human genetic illness Fanconi anemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21240276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 591,
                    "offsetInEndSection": 734,
                    "text": "Five of these genes have been deleted or mutated in the mouse, as well as a sixth key regulatory gene, to create mouse models of Fanconi anemia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19427003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 342,
                    "text": "In contrast to observations made in other Fanconi anemia (FA) mouse models, low numbers of hematopoietic colony-forming cells (CFCs) were noted in Brca2(Delta27/Delta27) mice, either young or adult",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Fanconi anemia group A and C double-mutant mice: functional evidence for a multi-protein Fanconi anemia complex.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12135664",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 724,
                    "offsetInEndSection": 796,
                    "text": "In addition, mouse models are also useful for testing treatments for FA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11879775",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Development and characterization of immortalized fibroblastoid cell lines from an FA(C) mouse model.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9678061",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 411,
                    "text": "These mouse models display the characteristic FA feature of cellular hypersensitivity to DNA cross-linking agents",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11879775",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is NEMO a zinc finger protein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28814200",
                "http://www.ncbi.nlm.nih.gov/pubmed/21622571",
                "http://www.ncbi.nlm.nih.gov/pubmed/26224629",
                "http://www.ncbi.nlm.nih.gov/pubmed/25734227",
                "http://www.ncbi.nlm.nih.gov/pubmed/24100029",
                "http://www.ncbi.nlm.nih.gov/pubmed/28035815"
            ],
            "ideal_answer": [
                "NEMO function is mediated by two distal ubiquitin binding domains located in the regulatory C-terminal domain of the protein: the coiled-coil 2-leucine zipper (CC2-LZ) domain and the zinc finger (ZF) domain."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a8a9f18fcd1d6a10c00001a",
            "snippets": [
                {
                    "offsetInBeginSection": 394,
                    "offsetInEndSection": 501,
                    "text": "To better understand the thermodynamics and dynamics of the zinc finger of NEMO (NF-\u03baB essential modulator)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035815",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 183,
                    "offsetInEndSection": 239,
                    "text": "an alteration in the zinc finger domain of NEMO (K392R) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "CYLD and the NEMO Zinc Finger Regulate Tumor Necrosis Factor Signaling and Early Embryogenesis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 726,
                    "text": "our simulations of the zinc finger NEMO",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734227",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "An important regulatory domain of NF-[Formula: see text]B Essential Modulator (NEMO) is a ubiquitin-binding zinc finger, with a tetrahedral CYS3HIS1 zinc-coordinating binding site.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28814200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 344,
                    "text": "NEMO function is mediated by two distal ubiquitin binding domains located in the regulatory C-terminal domain of the protein: the coiled-coil 2-leucine zipper (CC2-LZ) domain and the zinc finger (ZF) domain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100029",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 459,
                    "text": " We show here that the NEMO C terminus, comprising the ubiquitin binding region and a zinc finger,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21622571",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does thyroid hormone regulate calcium transient in the myocardium? ",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19298522",
                "http://www.ncbi.nlm.nih.gov/pubmed/9773867",
                "http://www.ncbi.nlm.nih.gov/pubmed/2428004",
                "http://www.ncbi.nlm.nih.gov/pubmed/9875761"
            ],
            "ideal_answer": [
                "YES"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/THA_LITCT",
                "http://www.uniprot.org/uniprot/THB_SHEEP",
                "http://www.uniprot.org/uniprot/THA_MOUSE",
                "http://www.uniprot.org/uniprot/THAA_PAROL",
                "http://www.uniprot.org/uniprot/THA_PYGAD",
                "http://www.uniprot.org/uniprot/THA_CHICK",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.uniprot.org/uniprot/THA_APTPA",
                "http://www.uniprot.org/uniprot/THB_CAIMO",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206",
                "http://www.uniprot.org/uniprot/THA_CAIMO",
                "http://www.uniprot.org/uniprot/THA_PIG",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988",
                "http://www.uniprot.org/uniprot/THBA_XENLA",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327",
                "http://www.uniprot.org/uniprot/THB_PAROL",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021",
                "http://www.uniprot.org/uniprot/THA_HIPHI",
                "http://www.uniprot.org/uniprot/THB_DANRE",
                "http://www.uniprot.org/uniprot/THB_RAT",
                "http://www.uniprot.org/uniprot/THAA_DANRE",
                "http://www.uniprot.org/uniprot/THA_ELECQ",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861",
                "http://www.uniprot.org/uniprot/THA_ONCMY",
                "http://www.uniprot.org/uniprot/THA_SPAAU",
                "http://www.uniprot.org/uniprot/THB_HUMAN",
                "http://www.uniprot.org/uniprot/THA_HUMAN",
                "http://www.uniprot.org/uniprot/THB_LITCT",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042",
                "http://www.uniprot.org/uniprot/THAA_XENLA",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284",
                "http://www.uniprot.org/uniprot/THB_CHICK",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887",
                "http://www.uniprot.org/uniprot/THA_RAT",
                "http://www.uniprot.org/uniprot/THA_NECMA",
                "http://www.uniprot.org/uniprot/THA_SALSA",
                "http://www.uniprot.org/uniprot/THB_MOUSE"
            ],
            "type": "yesno",
            "id": "515ac533d24251bc050000a9",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "3-iodothyronamine (T(1)AM) is a novel endogenous relative of thyroid hormone, able to interact with trace amine-associated receptors, a class of plasma membrane G protein-coupled receptors, and to produce a negative inotropic and chronotropic effect",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19298522",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 455,
                    "offsetInEndSection": 580,
                    "text": "In adult rat cardiomyocytes acute exposure to 20 microM T(1)AM decreased the amplitude and duration of the calcium transient.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19298522",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1520,
                    "offsetInEndSection": 1869,
                    "text": "In normal porcine myocardium T3 had no effect on the extent of isometric force generation but accelerated the time course of force development (p < 0.05) and increased the calcium transient (p < 0.001). After induction of myocardial depression by epinephrine exposure T3 accelerated the intracellular calcium transients and reduced diastolic calcium",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9875761",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 2162,
                    "offsetInEndSection": 2428,
                    "text": "The experimental data showing increased force amplitudes at unaltered amplitudes of the intracellular calcium transient and an even-reduced calcium time integral provide strong evidence for a sensitization of the contractile apparatus for calcium by triiodothyronine",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773867",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1313,
                    "offsetInEndSection": 1525,
                    "text": "hese results indicate that the thyroid state influences the time course of the calcium transient and are consistent with the abbreviation in the duration of contraction that is observed in the hyperthyroid state.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2428004",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is transcapillary  albumin escape altered in diabetic patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2060321",
                "http://www.ncbi.nlm.nih.gov/pubmed/21219847",
                "http://www.ncbi.nlm.nih.gov/pubmed/15616033",
                "http://www.ncbi.nlm.nih.gov/pubmed/2951101",
                "http://www.ncbi.nlm.nih.gov/pubmed/2949917",
                "http://www.ncbi.nlm.nih.gov/pubmed/3522326",
                "http://www.ncbi.nlm.nih.gov/pubmed/10922975",
                "http://www.ncbi.nlm.nih.gov/pubmed/7579054",
                "http://www.ncbi.nlm.nih.gov/pubmed/22950063",
                "http://www.ncbi.nlm.nih.gov/pubmed/6642091",
                "http://www.ncbi.nlm.nih.gov/pubmed/1619500",
                "http://www.ncbi.nlm.nih.gov/pubmed/18347777",
                "http://www.ncbi.nlm.nih.gov/pubmed/10703889",
                "http://www.ncbi.nlm.nih.gov/pubmed/3569694",
                "http://www.ncbi.nlm.nih.gov/pubmed/10027580",
                "http://www.ncbi.nlm.nih.gov/pubmed/2210073",
                "http://www.ncbi.nlm.nih.gov/pubmed/11395874",
                "http://www.ncbi.nlm.nih.gov/pubmed/8712223",
                "http://www.ncbi.nlm.nih.gov/pubmed/10405209",
                "http://www.ncbi.nlm.nih.gov/pubmed/2970919",
                "http://www.ncbi.nlm.nih.gov/pubmed/378740",
                "http://www.ncbi.nlm.nih.gov/pubmed/1547928",
                "http://www.ncbi.nlm.nih.gov/pubmed/9536925",
                "http://www.ncbi.nlm.nih.gov/pubmed/8960847",
                "http://www.ncbi.nlm.nih.gov/pubmed/22516624",
                "http://www.ncbi.nlm.nih.gov/pubmed/7698029",
                "http://www.ncbi.nlm.nih.gov/pubmed/8187356",
                "http://www.ncbi.nlm.nih.gov/pubmed/18712042",
                "http://www.ncbi.nlm.nih.gov/pubmed/8436254",
                "http://www.ncbi.nlm.nih.gov/pubmed/15581746",
                "http://www.ncbi.nlm.nih.gov/pubmed/15019550"
            ],
            "ideal_answer": [
                "An altered TERalb is present in type 2 diabetic patients, both with normal and altered patterns of AER.\nTERalb is increased also in normo-albuminuric type 1 diabetic patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012709",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058065",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000418",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003929"
            ],
            "type": "yesno",
            "id": "5321b4959b2d7acc7e000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1646,
                    "offsetInEndSection": 1826,
                    "text": "On the contrary, altered TERalb and increased carotid artery intimal thickness are shown by all hypertensive type 2 diabetic patients, both with normal and altered patterns of AER.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15616033",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1686,
                    "offsetInEndSection": 1804,
                    "text": "Altered systemic capillary permeability characterizes insulin-resistant hypertensive patients with Metabolic Syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15019550",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1606,
                    "offsetInEndSection": 1673,
                    "text": "TERalb is increased in normo-albuminuric type 1 diabetic patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10703889",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do tumour-associated macrophages have a prognostic role in gliomas?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28767130"
            ],
            "ideal_answer": [
                "M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c92159becadf2e73f000012",
            "snippets": [
                {
                    "offsetInBeginSection": 67,
                    "offsetInEndSection": 340,
                    "text": "Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1659,
                    "offsetInEndSection": 1932,
                    "text": "This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 941,
                    "offsetInEndSection": 1330,
                    "text": "Our data revealed that the amount of especially CD204+ TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between bruxism and reflux",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                "http://www.ncbi.nlm.nih.gov/pubmed/23937680",
                "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                "http://www.ncbi.nlm.nih.gov/pubmed/19830044"
            ],
            "ideal_answer": [
                "There is an association between bruxism and reflux."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057045",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004942",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020186",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005764",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002012"
            ],
            "type": "yesno",
            "id": "52f8a7eb2059c6d71c000052",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 326,
                    "text": "Rhythmic masticatory muscle activity, including sleep bruxism (SB), can be induced in healthy individuals by experimental esophageal acidification, which plays an important role in the pathogenesis of gastroesophageal reflux disease (GERD). However, no robust evidence supports the association between SB and GERD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1564,
                    "offsetInEndSection": 1647,
                    "text": "Sleep bruxism is prevalent in GERD patients, and GERD is highly associated with SB.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1471,
                    "offsetInEndSection": 1670,
                    "text": "Our large-scale cross-sectional study found that problem behaviors in adolescents were associated with sleep problems, including sleep bruxism, as well as lifestyle and food habits and GERD symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23937680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 741,
                    "text": "The frequencies of EMG bursts, rhythmic masticatory muscle activity (RMMA) episodes, grinding noise, and the RMMA/microarousal ratio were significantly higher in the 20-minute period after acidic infusion than after saline infusion. RMMA episodes including SB were induced by esophageal acidification. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Direct restorative treatment of dental erosion caused by gastroesophageal reflux disease associated with bruxism:",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 480,
                    "text": "This article presents a case report of a 27-year-old male smoker with tooth wear and dentin sensitivity caused by GERD associated with bruxism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Dental wear caused by association between bruxism and gastroesophageal reflux disease:",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 699,
                    "offsetInEndSection": 909,
                    "text": "This paper presents a case report in which bruxism associated with acid feeding, smoking habit and episodes of gastric reflow caused severe tooth wear and great muscular discomfort with daily headache episodes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 988,
                    "text": "most jaw muscle activities, ie, RMMA, single short-burst, and clenching episodes, occur in relation to gastroesophageal reflux mainly in the supine position.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Association between nocturnal bruxism and gastroesophageal reflux.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2192,
                    "offsetInEndSection": 2328,
                    "text": "Nocturnal bruxism may be secondary to nocturnal gastroesophageal reflux, occurring via sleep arousal and often together with swallowing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Citrobacter rodentium pathogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28085133",
                "http://www.ncbi.nlm.nih.gov/pubmed/27624779",
                "http://www.ncbi.nlm.nih.gov/pubmed/27821583",
                "http://www.ncbi.nlm.nih.gov/pubmed/27633986"
            ],
            "ideal_answer": [
                "Yes, the mouse pathogen Citrobacter rodentium, colonize the gut mucosa via attaching and effacing lesion formation and cause diarrheal diseases."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5aa4faaed6d6b54f7900000b",
            "snippets": [
                {
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 855,
                    "text": "One day after colonization, mice were infected with the colonic pathogen, Citrobacter rodentium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27633986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "The human pathogen enteropathogenic Escherichia coli (EPEC), as well as the mouse pathogen Citrobacter rodentium, colonize the gut mucosa via attaching and effacing lesion formation and cause diarrheal diseases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27624779",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1578,
                    "offsetInEndSection": 1624,
                    "text": "EPEC-like mouse pathogen Citrobacter rodentium",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085133",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 581,
                    "text": "Here, we develop a model that provides that link for the investigation of Citrobacter rodentium infection, a mouse model for enteropathogenic Escherichia coli (EPEC). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821583",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is pimavanserin a typical antipsychotic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29047301"
            ],
            "ideal_answer": [
                "No, pimavanserin is an atypical antipsychotic."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e2dbd0afbd6abf43b000017",
            "snippets": [
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 193,
                    "text": "Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26746652",
                "http://www.ncbi.nlm.nih.gov/pubmed/27900502",
                "http://www.ncbi.nlm.nih.gov/pubmed/28370177",
                "http://www.ncbi.nlm.nih.gov/pubmed/21799568",
                "http://www.ncbi.nlm.nih.gov/pubmed/29278542",
                "http://www.ncbi.nlm.nih.gov/pubmed/27177804",
                "http://www.ncbi.nlm.nih.gov/pubmed/28657199",
                "http://www.ncbi.nlm.nih.gov/pubmed/23570850",
                "http://www.ncbi.nlm.nih.gov/pubmed/23972284",
                "http://www.ncbi.nlm.nih.gov/pubmed/25987851"
            ],
            "ideal_answer": [
                "Pre-exposure prophylaxis (PrEP) with the drug combination Truvada can substantially decrease HIV transmission in individuals at risk.",
                "The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c5f2cef1a4c55d80b000022",
            "snippets": [
                {
                    "offsetInBeginSection": 26,
                    "offsetInEndSection": 169,
                    "text": "pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657199",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 308,
                    "text": "The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 352,
                    "text": "Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals in the USA, there has been much controversy about the implementation of this PrEP regimen in other countries throughout the world, and in Europe in particular.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23972284",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative people to prevent HIV infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27900502",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 332,
                    "text": "HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987851",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1107,
                    "offsetInEndSection": 1254,
                    "text": "CONCLUSIONS Combined ART + PrEP is likely to prevent more HIV infections than either strategy alone, but with higher prevalence of drug resistance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "INTRODUCTION Use of pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) has been shown to be effective in preventing HIV transmission.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27177804",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "Pre-exposure prophylaxis (PrEP) is an experimental approach to HIV prevention and consists of antiretroviral drugs to be taken before potential HIV exposure in order to reduce the risk of HIV infection and continued during periods of risk.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21799568",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "HIV pre-exposure prophylaxis (PrEP) is the use of one or more antiretroviral medications (in combination) to prevent HIV infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28370177",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 183,
                    "text": "The most commonly used PrEP medication (Truvada<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28370177",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "The use of antiretrovirals as pre-exposure prophylaxis (PrEP) is highly efficacious in HIV prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26746652",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the JNK pathway activated during liver regeneration?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18671679",
                "http://www.ncbi.nlm.nih.gov/pubmed/21338344",
                "http://www.ncbi.nlm.nih.gov/pubmed/20207439",
                "http://www.ncbi.nlm.nih.gov/pubmed/21354444",
                "http://www.ncbi.nlm.nih.gov/pubmed/18382767",
                "http://www.ncbi.nlm.nih.gov/pubmed/16797887",
                "http://www.ncbi.nlm.nih.gov/pubmed/11709497",
                "http://www.ncbi.nlm.nih.gov/pubmed/15970430",
                "http://www.ncbi.nlm.nih.gov/pubmed/12668975",
                "http://www.ncbi.nlm.nih.gov/pubmed/23035542",
                "http://www.ncbi.nlm.nih.gov/pubmed/17762881",
                "http://www.ncbi.nlm.nih.gov/pubmed/20578144",
                "http://www.ncbi.nlm.nih.gov/pubmed/16242670"
            ],
            "ideal_answer": [
                "Yes, the Jun-N-terminal kinase (JNK) pathway is strongly activated after partial hepatectomy."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020935",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031099",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012038",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007254",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031098",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048670",
                "http://www.uniprot.org/uniprot/JNK_DROME",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004705",
                "http://www.uniprot.org/uniprot/JNK_SUBDO",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008115"
            ],
            "type": "yesno",
            "id": "53455e0caeec6fbd0700000f",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 130,
                    "text": "analysis of the role of JNK signaling pathway in regulating cell proliferation and apoptosis of rat liver regeneration",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23035542",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1336,
                    "offsetInEndSection": 1419,
                    "text": "paths of JNK signaling pathway regulate cell proliferation and apoptosis in both LR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23035542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 72,
                    "text": "c-jun is not mandatory for mouse hepatocyte proliferation ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354444",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 111,
                    "text": "Mice lacking c-jun in the liver display impaired regeneration after partial hepatectomy (PH)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354444",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1002,
                    "text": "initial activity of the JNK pathway",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338344",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 606,
                    "text": "use of Drosophila for the study of regeneration ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338344",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 950,
                    "text": "Loss of macroautophagy led to overactivation of the c-Jun N-terminal kinase (JNK)/c-Jun signaling pathway that induced cell death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20578144",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 120,
                    "text": "stress induced during intermittent selective clamping accelerates rat liver regeneration through JNK pathway",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207439",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1186,
                    "text": "JNK2 promotes injury after mouse LT via the MPT",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18671679",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2,
                    "offsetInEndSection": 127,
                    "text": "Jun N-terminal kinase 2 promotes graft injury via the mitochondrial permeability transition after mouse liver transplantation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18671679",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 101,
                    "text": "add45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18382767",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1354,
                    "offsetInEndSection": 1481,
                    "text": "basis for JNK suppression during liver regeneration and identify Gadd45beta as a potential therapeutic target in liver diseases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18382767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 869,
                    "text": " genetic inactivation of the JNK pathway results in impaired proliferation of fetal hepatoblasts in vitro and defective adult liver regeneration in vivo",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17762881",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 53,
                    "offsetInEndSection": 178,
                    "text": "enhancement of the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase caused by partial hepatectomy",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16797887",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1268,
                    "offsetInEndSection": 1415,
                    "text": " arsenite induced apoptosis in the hepatocytes in vivo, through the enhancement of the activation of JNK and p38 MAPK caused by partial hepatectomy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16797887",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 586,
                    "offsetInEndSection": 647,
                    "text": "Jun N-terminal kinase and p38 MAPK, but not Akt, was altered.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16242670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 352,
                    "text": "Although mechanical stress has been implicated in hepatic cirrhosis and liver regeneration following hepatectomy, the signaling pathway(s) that may be activated in hepatocytes in response to mechanical stress have not been determined",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16242670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1471,
                    "text": " JNK, ERK and JAK2 inhibitors partially abrogated apoptosis and when used in combination reduced it to basal levels",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15970430",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1488,
                    "offsetInEndSection": 1633,
                    "text": "induction of CD40-mediated cholangiocyte apoptosis requires JAK2-mediated phosphorylation of STAT3 as well as sustained JNK1/2, ERK1/2 activation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15970430",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2,
                    "offsetInEndSection": 95,
                    "text": "Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12668975",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 94,
                    "text": "c-Jun-N-terminal kinase (JNK) pathway is strongly activated after partial hepatectomy (PH)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12668975",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 5,
                    "offsetInEndSection": 68,
                    "text": "growth factors and cytokines are involved in liver regeneration",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11709497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 644,
                    "text": "JAB1 (Jun activation domain-binding protein 1), a co-activator of AP-1, which is essential for liver regeneration, specifically interacts with intracellular HPO",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11709497",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is thrombophilia related to increased risk of miscarriage?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11583310",
                "http://www.ncbi.nlm.nih.gov/pubmed/18845284",
                "http://www.ncbi.nlm.nih.gov/pubmed/16962918",
                "http://www.ncbi.nlm.nih.gov/pubmed/19135285",
                "http://www.ncbi.nlm.nih.gov/pubmed/22543699",
                "http://www.ncbi.nlm.nih.gov/pubmed/15027582",
                "http://www.ncbi.nlm.nih.gov/pubmed/7986734",
                "http://www.ncbi.nlm.nih.gov/pubmed/20860491",
                "http://www.ncbi.nlm.nih.gov/pubmed/22164918",
                "http://www.ncbi.nlm.nih.gov/pubmed/15713144",
                "http://www.ncbi.nlm.nih.gov/pubmed/19165673",
                "http://www.ncbi.nlm.nih.gov/pubmed/19031171",
                "http://www.ncbi.nlm.nih.gov/pubmed/21380983"
            ],
            "ideal_answer": [
                "Thrombophilia has been found to be considerably more common in women with pregnancy-associated complications in comparison with the general population, and most frequently in conjunction with venous thromboembolism during pregnancy and the postpartum period. In particular there is an increased risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. When counseling white women with a history of preeclampsia, screening for thrombophilia can be useful for preconceptional counseling and pregnancy management."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0007565",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018566",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011248",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019851",
                "http://www.disease-ontology.org/api/metadata/DOID:10591",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011255",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011256"
            ],
            "type": "yesno",
            "id": "513cdc38bee46bd34c000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1159,
                    "text": "Thrombophilia does hardly increase the risk of IUGR/PMPC or if so, it can be prevented by LMWH",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22543699",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 796,
                    "text": "for illustrative purposes, a patient presenting with combined thrombophilia--both genetic and acquired--will be discussed. This patient had suffered severe gestational complications that led to devastating obstetrical outcome",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164918",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "text": "Thrombophilias have been implicated in complications related to ischemic placental disease including recurrent pregnancy loss, intrauterine fetal demise, preeclampsia, fetal growth restriction, placental abruption, and preterm delivery",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21380983",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1061,
                    "text": "Further information about the combined risk of aPC resistance and pregnancy is needed before guidance on the management of affected women can be formulated.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7986734",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 263,
                    "text": "Thrombotic risk during pregnancy and the puerperium is higher in asymptomatic women with than without thrombophilia",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027582",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 870,
                    "text": "Further studies are required to assess the thrombotic risk in women with preeclampsia as well as early or late recurrent pregnancy loss.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027582",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583310",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1265,
                    "offsetInEndSection": 1532,
                    "text": "In conclusion, homozygous carriers of factor V Leiden and, to a lesser extent, double heterozygous carriers of factor V Leiden and of the prothrombin mutation have an increased risk of venous thrombosis during pregnancy, particularly high during the postpartum period",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583310",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 767,
                    "offsetInEndSection": 873,
                    "text": "Careful diagnosis, observation and monitoring can add significant benefit to LMWH therapy during pregnancy",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19135285",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Pregnancy in healthy women is accompanied by hypercoagulable changes that may interact with thrombophilia risk factors and threaten pregnancy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1239,
                    "offsetInEndSection": 1444,
                    "text": "Fifty-three (13 %) women had antiphospholipid antibodies (lupus anticoagulant and/or anti-beta2-glycoprotein 1 antibodies) mainly associated with the risk of spontaneous abortion during the first trimester",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1461,
                    "offsetInEndSection": 1713,
                    "text": "thrombophilia was found to be considerably more common in women with pregnancy-associated complications in comparison with the general population, and most frequently in conjunction with venous thromboembolism during pregnancy and the postpartum period",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1104,
                    "offsetInEndSection": 1262,
                    "text": "When counseling white women with a history of preeclampsia, screening for thrombophilia can be useful for preconceptional counseling and pregnancy management.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18845284",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 779,
                    "text": "knowledge combined with the appropriate use of thromboprophylaxis and treatment in women who have objectively confirmed VTE continue to improve maternal and perinatal outcomes",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962918",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1508,
                    "offsetInEndSection": 1666,
                    "text": "The risk of having thrombophilia is doubled in men who have fathered pregnancies which ended in perinatal death as well as in the mothers of such pregnancies.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15713144",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 560,
                    "offsetInEndSection": 707,
                    "text": "The prevalence of thrombophilic variants is of possible public health significance for other morbidity; but perhaps not in relation to preeclampsia",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19165673",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 694,
                    "offsetInEndSection": 826,
                    "text": "This study suggests that thrombophilia \"mediates\" in lowering of cardiovascular risk factors in women with a history of preeclampsia",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20860491",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Can RG7112 inhibit MDM2?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23400593",
                "http://www.ncbi.nlm.nih.gov/pubmed/23808545",
                "http://www.ncbi.nlm.nih.gov/pubmed/24900694",
                "http://www.ncbi.nlm.nih.gov/pubmed/22753001",
                "http://www.ncbi.nlm.nih.gov/pubmed/23084521",
                "http://www.ncbi.nlm.nih.gov/pubmed/24869939",
                "http://www.ncbi.nlm.nih.gov/pubmed/24309210",
                "http://www.ncbi.nlm.nih.gov/pubmed/21391905",
                "http://www.ncbi.nlm.nih.gov/pubmed/25082860",
                "http://www.ncbi.nlm.nih.gov/pubmed/24812409"
            ],
            "ideal_answer": [
                "Yes, RG7112 is a small molecule MDM2 antagonist."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/MDM2_DANRE",
                "http://www.uniprot.org/uniprot/MDM2_MOUSE",
                "http://www.uniprot.org/uniprot/MDM2_MESAU",
                "http://www.uniprot.org/uniprot/MDM2_CANLF",
                "http://www.uniprot.org/uniprot/MDM2_HUMAN",
                "http://www.uniprot.org/uniprot/MDM2_FELCA",
                "http://www.uniprot.org/uniprot/MDM2_XENLA"
            ],
            "type": "yesno",
            "id": "56ed08062ac5ed1459000005",
            "snippets": [
                {
                    "offsetInBeginSection": 86,
                    "offsetInEndSection": 330,
                    "text": "To assess the influence of the p53 regulatory pathway further, we studied the effect of RG7112, a small molecule MDM2 antagonist that activates p53 by preventing its interaction with MDM2, on normal megakaryocytopoiesis and platelet production.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309210",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 723,
                    "text": "RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23084521",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "text": "We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23084521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 573,
                    "text": "To assess the influence of the p53 regulatory pathway further, we studied the effect of RG7112, a small molecule MDM2 antagonist that activates p53 by preventing its interaction with MDM2, on normal megakaryocytopoiesis and platelet production.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309210",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 398,
                    "offsetInEndSection": 477,
                    "text": "RG7112 was the first small-molecule p53-MDM2 inhibitor in clinical development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808545",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 467,
                    "offsetInEndSection": 568,
                    "text": "RG7112 binds MDM2 with high affinity (K(D) ~ 11 nmol/L), blocking its interactions with p53 in vitro.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 676,
                    "offsetInEndSection": 864,
                    "text": "The effects of RG7112 and Peg-IFN\u03b1 2a on MPN progenitor cells were dependent on blocking p53-MDM2 interactions and activating the p53 pathway, thereby increasing MPN CD34(+) cell apoptosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869939",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 243,
                    "text": "In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon \u03b1 (Peg-IFN\u03b1 2a) to target JAK2V617F hematopoietic progenitors and stem cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25082860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309210",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869939",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 802,
                    "text": "The primary endpoint was to assess markers of RG7112-dependent MDM2 inhibition and P53 pathway activation (P53, P21, MDM2, Ki-67, macrophage inhibitory cytokine-1 [MIC-1], and apoptosis). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23084521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 372,
                    "text": "RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 401,
                    "text": "However, the hydrophobic protein-protein interaction surface represents a significant challenge for the development of small-molecule inhibitors with desirable pharmacological profiles. RG7112 was the first small-molecule p53-MDM2 inhibitor in clinical development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808545",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 866,
                    "text": "Treatment with low doses of RG7112, an orally available small-molecule inhibitor of p53-MDM2, both alone and combined with pegylated interferon \u03b1 2a (Peg-IFN\u03b1 2a), significantly decreased MPN colony-forming unit-granulocyte macrophage and burst-forming unit-erythroid numbers and preferentially eliminated the total number of JAKV617F(+) MPN hematopoietic progenitor cells. The effects of RG7112 and Peg-IFN\u03b1 2a on MPN progenitor cells were dependent on blocking p53-MDM2 interactions and activating the p53 pathway, thereby increasing MPN CD34(+) cell apoptosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 807,
                    "text": "RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does melanoma  occur in people of African origin ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1920508",
                "http://www.ncbi.nlm.nih.gov/pubmed/20415670",
                "http://www.ncbi.nlm.nih.gov/pubmed/8260178",
                "http://www.ncbi.nlm.nih.gov/pubmed/19538377",
                "http://www.ncbi.nlm.nih.gov/pubmed/19450404",
                "http://www.ncbi.nlm.nih.gov/pubmed/475965",
                "http://www.ncbi.nlm.nih.gov/pubmed/15540891",
                "http://www.ncbi.nlm.nih.gov/pubmed/12883369",
                "http://www.ncbi.nlm.nih.gov/pubmed/1135705",
                "http://www.ncbi.nlm.nih.gov/pubmed/876685",
                "http://www.ncbi.nlm.nih.gov/pubmed/8000657",
                "http://www.ncbi.nlm.nih.gov/pubmed/8402099",
                "http://www.ncbi.nlm.nih.gov/pubmed/1138394",
                "http://www.ncbi.nlm.nih.gov/pubmed/5776549",
                "http://www.ncbi.nlm.nih.gov/pubmed/1156726",
                "http://www.ncbi.nlm.nih.gov/pubmed/18227705",
                "http://www.ncbi.nlm.nih.gov/pubmed/10461463",
                "http://www.ncbi.nlm.nih.gov/pubmed/97949",
                "http://www.ncbi.nlm.nih.gov/pubmed/11205232"
            ],
            "ideal_answer": [
                "Yes. Africans with dark skin have a reduced risk of getting all types of skin cancer as compared with Caucasians. The incidence of malignant melanoma in Johannesburg Black was 1,2 per 100 000 and accounted for 2% of all cancers. The largest number of cases occurred in the 50- 70-year age group and there was a female preponderance. As in previous studies, the sites predominantly affected were the foot and the hand, mainly on the plantar and palmar surfaces."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018326",
                "http://www.disease-ontology.org/api/metadata/DOID:1909",
                "http://www.disease-ontology.org/api/metadata/DOID:4159",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008545"
            ],
            "type": "yesno",
            "id": "515df6f2298dcd4e5100002d",
            "snippets": [
                {
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 174,
                    "text": "ALM is the most common type of melanoma amongst Asians, Africans,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20415670",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 442,
                    "text": "ALM develops on palmar, plantar, and subungual skin, and its biology is different from that of other cutaneous melanomas, where sunlight is the major known environmental determinant",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20415670",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 259,
                    "text": "We present four albinos with histologic diagnoses of skin cancer",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538377",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 633,
                    "text": "Four Nigerian albinos (two men and two women) with skin cancer",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538377",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 768,
                    "offsetInEndSection": 933,
                    "text": "The sites of the lesions included the head [squamous cell carcinoma (SCC) in two patients and basal cell carcinoma (BCC) in one patient] and the upper limb (melanoma",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538377",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 386,
                    "offsetInEndSection": 464,
                    "text": "wenty-nine patients (18 males and 11 females) with skin cancer were identified",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19450404",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 634,
                    "offsetInEndSection": 785,
                    "text": "Kaposi sarcoma associated with HIV represented 81.8 percent of KS cases found. Squamous cell carcinoma (SCC) ranked second and malignant melanoma third",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19450404",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "Earlier studies have shown frequent mutations in the BRAF and NRAS genes in cutaneous melanoma, but these alterations have not been examined in the rare category of melanoma from black Africans.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18227705",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1193,
                    "offsetInEndSection": 1666,
                    "text": "In a series of melanomas from black Africans (n=26), only two BRAF mutations (8%) were found, both being different from the common T1799A substitution. Moreover, melanomas from black Africans exhibited mutations in NRAS exon 1 only (12%), whereas NRAS exon 2 mutations were predominant in melanomas from Caucasians. Thus, the frequencies of BRAF and NRAS mutations were particularly low in melanomas from black Africans, supporting a different pathogenesis of these tumors.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18227705",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 324,
                    "text": "Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans. To the best of our knowledge, the current report of MM in a two-and-a-half-year-old Nigerian who had a pre-existing congenital giant hairy nevus is probably the first (in an accessible literature) in a black African child.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15540891",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Malignant melanomas in black Africans are predominantly located on the lower extremities",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11205232",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 994,
                    "offsetInEndSection": 1335,
                    "text": "Thus, our findings indicate that melanomas located on the lower extremities in black Africans show several features of aggressiveness; in particular, the proliferative activity was high, and p16 alterations was frequent as evidenced by loss of protein staining. Our findings also indicated that the diagnosis is delayed among black Africans.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11205232",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 724,
                    "text": "Africans with dark skin have a reduced risk of getting all types of skin cancer as compared with Caucasians, but the ratio of their incidence rates of cutaneous malignant melanoma to that of squamous cell carcinoma is larger than the corresponding ratio for Caucasians. (",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10461463",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 966,
                    "text": "Albino Africans, as compared with normally pigmented Africans, seem to have a relatively small risk of getting cutaneous malignant melanomas compared to nonmelanomas. This is probably also true for albino and normally pigmented Caucasians.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10461463",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 63,
                    "text": "Scant data exists on melanoma in blacks from Africa",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8000657",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 907,
                    "text": "The mean age at presentation of the 39 women and 24 men was 60.5 years (range of 30 to 85 years), with a peak incidence in the sixth decade. The foot was the most common site of disease (45 patients). Seven patients had subungual melanoma, seven had primary mucosal lesions, and in six, the primary lesion could not be found.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8000657",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1663,
                    "offsetInEndSection": 1801,
                    "text": "The poor prognosis in black patients in South Africa is the result of delayed presentation with thick primary lesions and advanced disease",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8000657",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "The outcome of treatment in 40 black patients (27 women, 13 men; mean age 62.9 years) with plantar melanoma over a 13-year period was analysed",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8402099",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1089,
                    "text": "Delay in presentation and locally advanced disease may explain the poor prognosis of plantar melanoma in black South Africans.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8402099",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 537,
                    "text": "Eighteen cases of malignant skin tumors seen at the University of Port Harcourt Teaching Hospital over 3 years (1984 to 1987) were analyzed for diagnoses, site of tumors, sex, and age. Seven patients (39%) had malignant melanomas affecting only the soles of the feet, while the same number had squamous cell carcinomas widely distributed in various parts of the body",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1920508",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 454,
                    "text": "Non-white populations experienced in general a much lower incidence of melanoma although there was some overlap of white and non-white rates.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/475965",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 729,
                    "text": "Populations of African descent were found to have a higher incidence than those of Asiatic origin, but it was concluded that this was due largely to the high frequency of tumours among Africans on the sole of the foot.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/475965",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 340,
                    "text": "Pathological features of twenty-one cases of malignant melanoma studied in the University of Nigeria Teaching Hospital, Enugu during the period January, 1974 to December, 1975 are presented. Malignant melanoma accounted for 2.4% of all tumours and 4.5% of all malignant tumours, greatest age incidence being in the fifth to seventh decades.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/97949",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 563,
                    "text": "81% melanomas occurred on the sole of feet validating the hypothesis that the pigmented skin in Africans is resistant to malignant melanoma.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/97949",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 319,
                    "text": "This paper reports the incidence of this lesion in association with invasive malignant melanomas of the feet and hands of Black Africans.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/876685",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Follow-up data (over a 3-year period) and the histological appearances of primary lesion were studied and related in 40 Black patients with malignant melanoma.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1138394",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Malignant melanoma of the skin in Blacks in formidable and sinister tumour.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1135705",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 932,
                    "offsetInEndSection": 1278,
                    "text": "The incidence of malignant melanoma in Johannesburg Black was 1,2 per 100 000 and accounted for 2% of all cancers. The largest number of cases occurred in the 50- 70-year age group and there was a female preponderance. As in previous studies, the sites predominantly affected were the foot and the hand, mainly on the plantar and palmar surfaces.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1135705",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 244,
                    "text": "Twenty-one cases of malignant melanoma occurring in the Igbos of Nigeria have been analysed. The site of predilection is the sole of the foot. This result supports the conclusion that Negroes tend to have the disease in the non-pigmented parts.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1156726",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "A case of leptomeningeal melanoma in an African child of 7 years is presented together with a survey of pigmentation in the normal African brain.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/5776549",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is miR-126 involved in heart failure?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21157109",
                "http://www.ncbi.nlm.nih.gov/pubmed/23465244"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11659990",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1537773",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11659990"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17697100",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17400039",
                    "o": "mmu-mir-126"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2741955",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17400039"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2825936",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17697100"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2351954",
                    "o": "http://linkedlifedata.com/resource/umls/label/A15584100"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15584100",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17399048",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2934296",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18459725"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18459725",
                    "o": "miR-126, zebrafish"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16480760",
                    "o": "hsa-mir-126 microRNA"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0018801",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0418144"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0418144",
                    "o": "HEART FAILURE"
                }
            ],
            "ideal_answer": [
                "Yes, miR-126 is associated with heart failure."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003015",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006333",
                "http://www.disease-ontology.org/api/metadata/DOID:114"
            ],
            "type": "yesno",
            "id": "51485008d24251bc05000028",
            "snippets": [
                {
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1714,
                    "text": "he miRNAs miR-126 and miR-508-5p are associated with the outcome of ICM and NICM patients with CHF. These two miRNAs could be useful in the diagnosis of CHF patients, and might provide novel targets for prevention and treatment of CHF.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23465244",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1099,
                    "offsetInEndSection": 1236,
                    "text": "The plasma concentration of miR-126 was negatively correlated with age and NYHA class, and could be a useful biomarker for heart failure.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157109",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 949,
                    "offsetInEndSection": 1085,
                    "text": "In 10 patients with heart failure, plasma concentrations of miR-126 were up-regulated with improvement of the NYHA class from IV to III.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157109",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is there an association between c-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients? ",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22392113",
                "http://www.ncbi.nlm.nih.gov/pubmed/21757662",
                "http://www.ncbi.nlm.nih.gov/pubmed/19682408",
                "http://www.ncbi.nlm.nih.gov/pubmed/18486699",
                "http://www.ncbi.nlm.nih.gov/pubmed/22952245",
                "http://www.ncbi.nlm.nih.gov/pubmed/23208059",
                "http://www.ncbi.nlm.nih.gov/pubmed/22732721",
                "http://www.ncbi.nlm.nih.gov/pubmed/20725805",
                "http://www.ncbi.nlm.nih.gov/pubmed/19409001",
                "http://www.ncbi.nlm.nih.gov/pubmed/16369143",
                "http://www.ncbi.nlm.nih.gov/pubmed/11680512",
                "http://www.ncbi.nlm.nih.gov/pubmed/22134501",
                "http://www.ncbi.nlm.nih.gov/pubmed/20375501"
            ],
            "ideal_answer": [
                "Yes. Higher concentrations of C-reactive protein are associated with worse outcomes of subarachnoid hemorrhage patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/CRP_RAT",
                "http://www.uniprot.org/uniprot/CRP_MESAU",
                "http://www.uniprot.org/uniprot/CRP_HUMAN",
                "http://www.uniprot.org/uniprot/CRP_CAVPO",
                "http://www.uniprot.org/uniprot/CRP_XENLA",
                "http://www.uniprot.org/uniprot/CRP_PIG",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017063",
                "http://www.uniprot.org/uniprot/CRP_MOUSE",
                "http://www.uniprot.org/uniprot/CRP_RABIT",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013345"
            ],
            "type": "yesno",
            "id": "514cbbf9d24251bc05000065",
            "snippets": [
                {
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 1003,
                    "text": "Besides the baseline characteristics, daily interleukin-6 (IL-6), procalcitonin, C-reactive protein levels, and leukocyte counts were prospectively measured until day 14 after subarachnoid hemorrhage. Occurrence of infectious complications and application of therapeutic hypothermia were assessed as confounding factors. The primary end point was outcome after 3 months, assessed by Glasgow Outcome Scale; the secondary end point was the occurrence of DINDs. RESULTS: : During a 3-year period, a total of 138 patients were included. All inflammatory parameters measured were higher in patients with unfavorable outcome (Glasgow Outcome Scale score, 1-3).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23208059",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 995,
                    "text": "Twenty-three and 28 patients showed poor outcome and symptomatic vasospasm after SAH, respectively. Both preoperative and postoperative CRP levels were significantly higher in patients with a poor outcome compared with patients with a good outcome (P<0.05).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22732721",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1248,
                    "text": "e area under the receiver operating characteristic curve of CRP measured on postoperative day 1 or 2 (CRP POD1-2) for predicting a poor clinical outcome was 0.870, and its cutoff point of 4 mg/dL had a sensitivity of 0.826 and a specificity of 0.843.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22732721",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1249,
                    "offsetInEndSection": 1442,
                    "text": "A high CRP level after aneurysm treatment was associated with severe neurological deterioration on admission, cerebral infarction, intracerebral hemorrhage, and surgical decompression (P<0.05).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22732721",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1443,
                    "offsetInEndSection": 1707,
                    "text": "CRP POD1-2, and not the preoperative CRP, was an independent factor in predicting symptomatic vasospasm (P<0.05). In patients with symptomatic vasospasm, an increase in the postoperative CRP was associated with the time profile of developing symptomatic vasospasm.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22732721",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1721,
                    "offsetInEndSection": 1877,
                    "text": "Postoperative CRP, especially CRP POD1-2, can be a useful prognostic factor for both poor outcome and symptomatic vasospasm in patients with aneurysmal SAH.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22732721",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 674,
                    "offsetInEndSection": 929,
                    "text": "Serum CRP levels were related to severity of aSAH. Patients with lower GCS scores and higher Hunt and Hess and Fisher grades presented statistically significant higher serum CRP levels. Patients with higher serum CRP levels had a less favorable prognosis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392113",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 943,
                    "offsetInEndSection": 1039,
                    "text": "Increased serum CRP levels were strongly associated with worse clinical prognosis in this study.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392113",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 288,
                    "text": "After SAH, the value of C-reactive protein (CRP)--an acute phase sensitive inflammatory marker--as a prognostic factor has been poorly studied, with conflicting results.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134501",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1193,
                    "offsetInEndSection": 1473,
                    "text": "Admission (18.0\u2009\u00b1\u200935.7 vs 8.5\u2009\u00b1\u20098.4 mg/l) and postoperative (41.0\u2009\u00b1\u200940.2 vs 21.1\u2009\u00b1\u200924.1 mg/l) CRP levels were higher (p\u2009<\u20090.001) in those with a poor outcome than in those with a favourable outcome, but CRP values did not predict delayed cerebral ischaemia or cerebral infarction.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134501",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1625,
                    "offsetInEndSection": 1757,
                    "text": "Higher increase in CRP level between admission and postoperative morning, however, independently predicted poor outcome (p\u2009=\u20090.004).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134501",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1875,
                    "offsetInEndSection": 1987,
                    "text": "CRP levels correlate with outcome but do not seem to predict delayed cerebral ischaemia or infarction after SAH.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134501",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1487,
                    "offsetInEndSection": 1617,
                    "text": "Systemic oxygen consumption is associated with hsCRP levels in the first 14 days after SAH and is an independent predictor of DCI.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21757662",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 1135,
                    "text": "Intracranial hypertension was associated with an inflammatory response, indicating activation of the inflammatory cascade in the brain (ECF) and systemic circulation with high IL-6 and C-reactive protein (CRP) plasma levels after SAH, the latter associated with unfavourable outcome.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19682408",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1529,
                    "offsetInEndSection": 1770,
                    "text": "Patients with angiographic vasospasm had higher CRP measurements in serum and CSF, in a statistically significant fashion (p < 0.0001). Additionally, patients with higher CRP levels in serum and CSF had less favorable outcome in this cohort.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19409001",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1918,
                    "offsetInEndSection": 2148,
                    "text": "Furthermore, patients developing angiographically proven vasospasm demonstrated significantly elevated CRP levels in serum and CSF, and increased CRP measurements were strongly associated with poor clinical outcome in this cohort.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19409001",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 844,
                    "offsetInEndSection": 1211,
                    "text": "Finally, serum concentrations of ICAM-1, VCAM-1, and hsCRP during the early (P = .0055, P = .0266, and P = .0266) and late (P = .0423, P = .0041, and P = .0004) period were significantly higher in patients with DIND than in patients without DIND. CONCLUSIONS: Serum levels of ICAM-1, VCAM-1 and hsCRP during the early and late period following SAH correlate with DIND",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18486699",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 809,
                    "text": "CRP levels on days 5, 6, 7, and 8 were statistically significantly higher in the group of patients developing a DIND (P < 0.025, P < 0.016, P < 0.011, P < 0.0002).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16369143",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1130,
                    "text": "Overall CRP values were higher with increasing severity of the initial ictus according to the Hunt and Hess Scale and to the outcome according to the Glasgow Outcome Scale from day 3 on.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16369143",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1220,
                    "offsetInEndSection": 1494,
                    "text": "The presented data do not prove that WBCs and CRP values have a direct contribution to the pathogenesis of ischemic complications following SAH, but it supports the assertion that inflammation may present a common pathogenic pathway in the development of such complications.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16369143",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1822,
                    "offsetInEndSection": 1924,
                    "text": "The CRP and TGF-beta1 levels in CSF are strongly concerned with communicating hydrocephalus after SAH.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11680512",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is there any link between ERCC1-XPF and cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28368372"
            ],
            "ideal_answer": [
                "Yes. ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0061774",
                "http://amigo.geneontology.org/amigo/term/GO:0008278",
                "http://amigo.geneontology.org/amigo/term/GO:0071921",
                "http://amigo.geneontology.org/amigo/term/GO:1905339",
                "http://amigo.geneontology.org/amigo/term/GO:0070522",
                "http://amigo.geneontology.org/amigo/term/GO:1905338",
                "http://www.disease-ontology.org/api/metadata/DOID:0110848",
                "http://amigo.geneontology.org/amigo/term/GO:0070312"
            ],
            "type": "yesno",
            "id": "5a6e4b72b750ff445500004c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "ERCC1-XPF cooperates with CTCF and cohesin to\u00a0facilitate the developmental silencing of imprinted\u00a0genes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 1050,
                    "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development. Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation. We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 521,
                    "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 805,
                    "offsetInEndSection": 1050,
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1051,
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 805,
                    "offsetInEndSection": 1054,
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "ERCC1-XPF cooperates with CTCF and cohesin to\u00a0facilitate the developmental silencing of imprinted\u00a0genes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 805,
                    "offsetInEndSection": 1051,
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does thyroid hormone affect cardiac remodeling?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18455802",
                "http://www.ncbi.nlm.nih.gov/pubmed/20926779",
                "http://www.ncbi.nlm.nih.gov/pubmed/23820669",
                "http://www.ncbi.nlm.nih.gov/pubmed/23532677",
                "http://www.ncbi.nlm.nih.gov/pubmed/17560116",
                "http://www.ncbi.nlm.nih.gov/pubmed/22039709",
                "http://www.ncbi.nlm.nih.gov/pubmed/22134702",
                "http://www.ncbi.nlm.nih.gov/pubmed/18430565",
                "http://www.ncbi.nlm.nih.gov/pubmed/18622044",
                "http://www.ncbi.nlm.nih.gov/pubmed/20730619",
                "http://www.ncbi.nlm.nih.gov/pubmed/16499159",
                "http://www.ncbi.nlm.nih.gov/pubmed/20668933",
                "http://www.ncbi.nlm.nih.gov/pubmed/17389455",
                "http://www.ncbi.nlm.nih.gov/pubmed/18274800",
                "http://www.ncbi.nlm.nih.gov/pubmed/17024559",
                "http://www.ncbi.nlm.nih.gov/pubmed/21568669",
                "http://www.ncbi.nlm.nih.gov/pubmed/23555069",
                "http://www.ncbi.nlm.nih.gov/pubmed/20560106",
                "http://www.ncbi.nlm.nih.gov/pubmed/18773293",
                "http://www.ncbi.nlm.nih.gov/pubmed/22403173",
                "http://www.ncbi.nlm.nih.gov/pubmed/19951746",
                "http://www.ncbi.nlm.nih.gov/pubmed/21159857",
                "http://www.ncbi.nlm.nih.gov/pubmed/19826181"
            ],
            "ideal_answer": [
                "TH affects cardiac remodeling"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963"
            ],
            "type": "yesno",
            "id": "52efc041c8da89891000001b",
            "snippets": [
                {
                    "offsetInBeginSection": 1161,
                    "offsetInEndSection": 1356,
                    "text": "The aim of this brief paper is to highlight new developments in understanding the cardioprotective role of thyroid hormone in reverting regulatory networks involved in adverse cardiac remodeling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23555069",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 270,
                    "text": "Thyroid hormone receptor \u03b11 (TR\u03b11) is shown to be critical for the maturation of cardiomyocytes and for the cellular response to stress. TR\u03b11 is altered during post ischemic cardiac remodeling but the physiological significance of this response is not fully understood. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532677",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1437,
                    "offsetInEndSection": 1581,
                    "text": "AMI induces downregulation of thyroid hormone signaling and pharmacological inhibition of TR\u03b11 further depresses post-ischemic cardiac function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532677",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1058,
                    "offsetInEndSection": 1219,
                    "text": "These findings reveal crucial roles for Dio3 in heart function and remodeling, which may have pathophysiologic implications for human restrictive cardiomyopathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403173",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1309,
                    "offsetInEndSection": 1661,
                    "text": "TH administration after AMI prevented tissue hypothyroidism and resulted in decreased beta-MHC expression, increased wall thickening and normalized wallstress, while stretch-induced p38 MAPK activation was increased. We conclude that diabetes exacerbates post-ischemic cardiac remodeling and that tissue hypothyroidism may be involved in this response.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22039709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730619",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1768,
                    "offsetInEndSection": 1965,
                    "text": "Acute myocardial infarction in diabetic rats results in TH receptor down-regulation with important physiological consequences. TH treatment prevents this response and improves cardiac hemodynamics.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 567,
                    "text": "TH affects cardiac remodeling by limiting reperfusion injury, and, at later states, by inducing distinct changes in cardiac chamber geometry in a time-dependent manner.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20668933",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 715,
                    "text": "Furthermore, administration of TH can convert pathologic to physiologic hypertrophy. These effects are the result of favorable cellular remodeling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20668933",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 276,
                    "text": "Thyroid hormone (TH) is critical in cardiac cell differentiation (regulating contractile proteins and cell geometry) and this effect could be potentially exploited therapeutically in reversing the process of de-differentiation which underlies postischemic cardiac remodeling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1549,
                    "text": "TH treatment partially reverses cardiac dysfunction in rats with old myocardial infarction by favorably changing cardiac chamber geometry and expression of myosin isoforms. Thyroid hormone, unlike current treatments, appears to be a paradigm of therapeutic intervention which aims at restoring cardiac geometry and may prove new effective treatment for heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 636,
                    "text": "Changes in thyroid hormone (TH)-TH receptors (TRs) axis occur in the course of post-infarction cardiac remodeling and seem to contribute to cardiac fetal phenotype. TH can \"rebuild\" the post-infarcted heart by preventing the fetal-like pattern of contractile proteins expression, normalizing wall tension, and optimizing cardiac chamber geometry. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773293",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 342,
                    "text": "TH, apart from its \"classical\" actions on cardiac contractility and heart rhythm, appears to regulate various intracellular signaling pathways related to stress responses and cardiac remodelling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18455802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 883,
                    "text": "More importantly, experimental and clinical studies demonstrate that TH can limit ischaemic injury, attenuate cardiac remodeling and improve cardiac hemodynamics. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18455802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560116",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1987,
                    "offsetInEndSection": 2121,
                    "text": "Thyroid hormone administration early after infarction attenuates cardiac remodeling and significantly improves myocardial performance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560116",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "It has previously been shown that thyroid hormone can reverse cardiac remodeling in failing hearts by reducing myocardial wall stress due to the unique changes induced in cardiac myocyte shape. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17024559",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can Daptacel be used instead of IPOL?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19117896"
            ],
            "ideal_answer": [
                "No,  Daptacel is a diphtheria, tetanus, 5-component acellular pertussis vaccine, while IPOL is an inactivated poliovirus vaccine."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e7f6090835f4e477700001a",
            "snippets": [
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 582,
                    "text": "Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2153,
                    "offsetInEndSection": 2251,
                    "text": "DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 603,
                    "offsetInEndSection": 825,
                    "text": " In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1102,
                    "offsetInEndSection": 1284,
                    "text": "DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117896",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are cyclophilins ubiquitously expressed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19403925",
                "http://www.ncbi.nlm.nih.gov/pubmed/15869639",
                "http://www.ncbi.nlm.nih.gov/pubmed/25259854",
                "http://www.ncbi.nlm.nih.gov/pubmed/23849880",
                "http://www.ncbi.nlm.nih.gov/pubmed/14568539",
                "http://www.ncbi.nlm.nih.gov/pubmed/24887548",
                "http://www.ncbi.nlm.nih.gov/pubmed/16928193",
                "http://www.ncbi.nlm.nih.gov/pubmed/23123451",
                "http://www.ncbi.nlm.nih.gov/pubmed/15735342",
                "http://www.ncbi.nlm.nih.gov/pubmed/21087465",
                "http://www.ncbi.nlm.nih.gov/pubmed/19923714",
                "http://www.ncbi.nlm.nih.gov/pubmed/17103061",
                "http://www.ncbi.nlm.nih.gov/pubmed/15935056"
            ],
            "ideal_answer": [
                "Yes, \tcyps (cyclophilins) are ubiquitous proteins of the immunophilin superfamily."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56f6ab7009dd18d46b00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Cyclophilin from Leishmania donovani (LdCyp) is a ubiquitous peptidyl-prolyl cis-trans isomerase",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24887548",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 269,
                    "offsetInEndSection": 417,
                    "text": "Cyclophilins (CYPs) and FK506-binding proteins (FKBPs) are ubiquitous proteins belonging to the peptidyl-prolyl cis/trans isomerase (PPIase) family.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25259854",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1440,
                    "offsetInEndSection": 1553,
                    "text": " However, their wide distribution and ubiquitous nature signifies their fundamental importance in plant survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23123451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Cyclophilins (Cyps) are ubiquitous proteins that effect the cis-trans isomerization of Pro amide bonds, and are thus crucial to protein folding.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23849880",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 296,
                    "text": "FK506 binding proteins (FKBPs) and cyclophilins (CYPs) are abundant and ubiquitous proteins belonging to the peptidyl-prolyl cis/trans isomerase (PPIase) superfamily, which regulate much of metabolism through a chaperone or an isomerization of proline residues during protein folding.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21087465",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Cyclophilin is a ubiquitous peptidyl prolyl cis/trans isomerase that plays critical roles in many biological processes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19403925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 448,
                    "text": "The receptor for cyclosporin is the protein cyclophilin, which is a ubiquitous peptidylprolyl isomerase. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923714",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Cyps (cyclophilins) are ubiquitous proteins of the immunophilin superfamily with proposed functions in protein folding, protein degradation, stress response and signal transduction. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16928193",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 322,
                    "text": "Cyclophilins are folding helper enzymes belonging to the class of peptidyl-prolyl cis-trans isomerases (PPIases; EC 5.2.1.8) that catalyze the cis-trans isomerization of peptidyl-prolyl bonds in proteins. They are ubiquitous proteins present in almost all living organisms analyzed to date, with extremely rare exceptions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103061",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Immunophilins are ubiquitous enzymes responsible for proline isomerisation during protein synthesis and for the chaperoning of several membrane proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15935056",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Cyclophilins (CyPs) are a large class of highly conserved ubiquitous peptidyl-prolyl cis-trans isomerases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15735342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Cyclophilins belong to the family of peptidyl-prolyl cis/trans isomerases (PPIases), which are ubiquitous and highly conserved enzymes capable of cis/trans isomerizing Xaa-Pro peptide bonds. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14568539",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "Originally identified as the cellular targets of immunosuppressant drugs, the immunophilins encompass two ubiquitous protein families: the FK-506 binding proteins or FKBPs, and the cyclosporin-binding proteins or cyclophilins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15869639",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Sarcolipin a regulatory/inhibitory protein of the Calcium ATPase SERCA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                "http://www.ncbi.nlm.nih.gov/pubmed/17515962",
                "http://www.ncbi.nlm.nih.gov/pubmed/18081313",
                "http://www.ncbi.nlm.nih.gov/pubmed/12237298",
                "http://www.ncbi.nlm.nih.gov/pubmed/20833651",
                "http://www.ncbi.nlm.nih.gov/pubmed/12032137",
                "http://www.ncbi.nlm.nih.gov/pubmed/22561503",
                "http://www.ncbi.nlm.nih.gov/pubmed/22496245",
                "http://www.ncbi.nlm.nih.gov/pubmed/16036219",
                "http://www.ncbi.nlm.nih.gov/pubmed/16365042",
                "http://www.ncbi.nlm.nih.gov/pubmed/17971438",
                "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                "http://www.ncbi.nlm.nih.gov/pubmed/19631655",
                "http://www.ncbi.nlm.nih.gov/pubmed/15556994",
                "http://www.ncbi.nlm.nih.gov/pubmed/22961106",
                "http://www.ncbi.nlm.nih.gov/pubmed/23455424",
                "http://www.ncbi.nlm.nih.gov/pubmed/21697544",
                "http://www.ncbi.nlm.nih.gov/pubmed/23341466"
            ],
            "ideal_answer": [
                "Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR) and it is a newly identified regulator of the sarco/endoplasmic reticulum Ca(2+)-ATPase (Serca) pump.  SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure. Sarcolipin is a key regulator of SERCA2a in atria.",
                "Sarcolipin (SLN) has emerged as an important regulator of the atrial sarcoplasmic reticulum (SR) Ca2+ transport.Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR). It has 31 amino acid residues; SLN and phopholamban (PLB) are belong to the same protein family, so they have similar physiological functions. SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4264789",
                "http://www.uniprot.org/uniprot/SARCO_MOUSE",
                "http://www.uniprot.org/uniprot/SARCO_HUMAN",
                "http://www.uniprot.org/uniprot/SARCO_RAT",
                "http://www.uniprot.org/uniprot/SARCO_RABIT",
                "http://www.uniprot.org/uniprot/AT2A_CHIOP",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053498"
            ],
            "type": "yesno",
            "id": "55016397e9bde69634000006",
            "snippets": [
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 896,
                    "text": "The activity of SERCA is regulated by two small, homologous membrane proteins called phospholamban (PLB, also known as PLN) and sarcolipin (SLN). Detailed structural information explaining this regulatory mechanism has been lacking, and the structural features defining the pathway through which cytoplasmic Ca(2+) enters the intramembranous binding sites of SERCA have remained unknown.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23455424",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 265,
                    "text": "Sarco(endo)plasmic reticulum Ca(2+)ATPase (SERCA) pump activity is modulated by phospholamban (PLB) and sarcolipin (SLN) in cardiac and skeletal muscle. Recent data suggest that SLN could play a role in muscle thermogenesis by promoting uncoupling of the SERCA pump",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23341466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 88,
                    "offsetInEndSection": 260,
                    "text": "Here we show that sarcolipin (Sln), a newly identified regulator of the sarco/endoplasmic reticulum Ca(2+)-ATPase (Serca) pump, is necessary for muscle-based thermogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22961106",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 397,
                    "text": "Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR). It has 31 amino acid residues; SLN and phopholamban (PLB) are belong to the same protein family, so they have similar physiological functions. SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Sarcolipin (SLN) is a key regulator of sarco(endo)plasmic reticulum (SR) Ca(2+)-ATPase (SERCA), and its expression is altered in diseased atrial myocardium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1233,
                    "offsetInEndSection": 1433,
                    "text": "Together, these findings indicate that ablation of SLN results in increased SERCA activity and SR Ca(2+) load, which, in turn, could cause abnormal intracellular Ca(2+) handling and atrial remodeling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Sarcolipin (SLN) inhibits sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA) pumps.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697544",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1552,
                    "offsetInEndSection": 1909,
                    "text": "These results show that 1) SLN regulates Ca(2+)-ATPase activity thereby regulating contractile kinetics in at least some skeletal muscles, 2) the functional significance of SLN is graded to the endogenous SLN expression level, and 3) SLN inhibitory effects on SERCA function are relieved in response to repeated contractions thus enhancing relaxation rates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697544",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 684,
                    "text": "The SERCA pump was constitutively activated in both atrial and ventricular chambers of the mouse heart by ablating its key regulators, phospholamban (PLN) and sarcolipin (SLN). The double-knockout (dKO) mice for PLN and SLN showed increased SERCA pump activity, Ca(2+) transients and SR Ca(2+) load, and developed cardiac hypertrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833651",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1006,
                    "offsetInEndSection": 1194,
                    "text": "Our findings also emphasize the need for dynamic regulation of the SERCA pump by PLN and/or SLN to maintain cardiac contractility in normal conditions and during pathophysiological states.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833651",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Sarcolipin (SLN) has emerged as an important regulator of the atrial sarcoplasmic reticulum (SR) Ca2+ transport.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631655",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 281,
                    "text": "The inhibitory effect of SLN on cardiac SR Ca2+ ATPase (SERCA) pump can be relieved by beta-adrenergic stimulation, which indicates that SLN is a reversible inhibitor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631655",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Sarcolipin is a novel regulator of cardiac sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) and is expressed abundantly in atria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1054,
                    "offsetInEndSection": 1249,
                    "text": "Our study documented that sarcolipin is a key regulator of SERCA2a in atria. Importantly, our data demonstrate the existence of distinct modulators for the SERCA pump in the atria and ventricles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 494,
                    "text": "Sarcoplasmic reticulum (SR) Ca(2+) ATPase (SERCA) is a membrane protein that catalyzes the ATP-dependent transport of Ca(2+) from the cytosol to the SR. The activity of SERCA is inhibited by phospholamban (PLN) and sarcolipin (SLN), and all these proteins participate in maintaining the normal intracellular calcium handling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17515962",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "Sarcolipin (SLN) is an integral membrane protein that is expressed in both skeletal and cardiac muscle, where it inhibits SERCA (calcium ATPase) by lowering its apparent Ca2+ affinity in a manner similar to that of its homologue phospholamban (PLN).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1061,
                    "offsetInEndSection": 1271,
                    "text": "Remarkably, each domain of SLN behaves in a manner similar to that of the corresponding domains in PLN, supporting the hypothesis that both SLN and PLN bind SERCA in the same groove and with similar mechanisms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 516,
                    "text": "The role of sarcolipin (SLN) in cardiac physiology was critically evaluated by generating a transgenic (TG) mouse model in which the SLN to sarco(endoplasmic)reticulum (SR) Ca(2+) ATPase (SERCA) ratio was increased in the ventricle. Overexpression of SLN decreases SR calcium transport function and results in decreased calcium transient amplitude and rate of relaxation. SLN TG hearts exhibit a significant decrease in rates of contraction and relaxation when assessed by ex vivo work-performing heart preparations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16365042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1160,
                    "offsetInEndSection": 1296,
                    "text": "We conclude that SLN is a novel regulator of SERCA pump activity, and its inhibitory effect can be reversed by beta-adrenergic agonists.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16365042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Sarcolipin, a homologue of phospholamban, regulates Ca2+ uptake through the interaction with sarcoplasmic reticulum Ca2+ ATPase (SERCA) and is predominantly expressed in the atrial muscle.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16036219",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Sarcolipin (SLN) and phospholamban (PLN) are effective inhibitors of the sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15556994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1450,
                    "text": "These results show that NF-SLN expression impairs muscle contractile function by inhibiting SERCA function and diminishing sarcoplasmic reticulum Ca(2+) stores.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12237298",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 299,
                    "text": "Sarcolipin (SLN) is an inhibitor of sarco(endo)plasmic reticulum Ca(2+)-ATPases (SERCAs) in vitro, but its function in vivo has not been defined. NF-SLN cDNA (SLN tagged N-terminally with a FLAG epitope) was introduced into rat soleus muscle in one hindlimb by plasmid injection and electrotransfer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12237298",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "Sarcolipin (SLN), a regulator of the sarco(endo)plasmic reticulum Ca(2+)-ATPase of fast-twitch skeletal muscle (SERCA1a), is also expressed in cardiac and slow-twitch skeletal muscles where phospholamban (PLN) and SERCA2a are expressed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12032137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Sarco(endo)plasmic reticulum calcium ATPase (SERCA) inhibition by sarcolipin is encoded in its luminal tail.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "The sarco(endo)plasmic reticulum calcium ATPase (SERCA) is regulated in a tissue-dependent manner via interaction with the short integral membrane proteins phospholamban (PLN) and sarcolipin (SLN).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "Phospholamban (PLN) and sarcolipin (SLN) are two single-pass membrane proteins that regulate Ca2+-ATPase (SERCA), an ATP-driven pump that translocates calcium ions into the lumen of the sarcoplasmic reticulum, initiating muscle relaxation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18081313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "The sarco(endo)plasmic reticulum calcium ATPase (SERCA) is regulated in a tissue-dependent manner via interaction with the short integral membrane proteins phospholamban (PLN) and sarcolipin (SLN)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "[Research progress of sarcolipin-a new regulatory protein of sarcoplasmic reticulum Ca2+ ATPase].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561503",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 238,
                    "text": "Phospholamban (PLN) and sarcolipin (SLN) are two single-pass membrane proteins that regulate Ca2+-ATPase (SERCA), an ATP-driven pump that translocates calcium ions into the lumen of the sarcoplasmic reticulum, initiating muscle relaxation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18081313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "text": "Sarcolipin (SLN) is an integral membrane protein that is expressed in both skeletal and cardiac muscle, where it inhibits SERCA (calcium ATPase) by lowering its apparent Ca2+ affinity in a manner similar to that of its homologue phospholamban (PLN)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are astrocytes part of the blood brain barrier?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28883042",
                "http://www.ncbi.nlm.nih.gov/pubmed/28822114"
            ],
            "ideal_answer": [
                "Yes\nThe blood-brain barrier (BBB) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e6e35b07fc1ee872b000004",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "The blood-brain barrier (BBB) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822114",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "The blood-brain barrier (BBB) consists of endothelial cells, astrocytes, and pericytes embedded in basal lamina (BL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28883042",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has field-programmable gate array (FPGA) technology been used to solve sequence alignment problems?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21724593",
                "http://www.ncbi.nlm.nih.gov/pubmed/17555593",
                "http://www.ncbi.nlm.nih.gov/pubmed/18048180",
                "http://www.ncbi.nlm.nih.gov/pubmed/17946720",
                "http://www.ncbi.nlm.nih.gov/pubmed/22151470",
                "http://www.ncbi.nlm.nih.gov/pubmed/18798993",
                "http://www.ncbi.nlm.nih.gov/pubmed/16342039",
                "http://www.ncbi.nlm.nih.gov/pubmed/15919726",
                "http://www.ncbi.nlm.nih.gov/pubmed/18412963",
                "http://www.ncbi.nlm.nih.gov/pubmed/19273034",
                "http://www.ncbi.nlm.nih.gov/pubmed/19208138",
                "http://www.ncbi.nlm.nih.gov/pubmed/19492068",
                "http://www.ncbi.nlm.nih.gov/pubmed/8481828"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0021572",
                    "o": "Alignments, Sequence"
                }
            ],
            "ideal_answer": [
                "Yes. Field-Programmable Gate Arrays (FPGAs) are reconfigurable computing platforms that have found several applications in diverse domains, including  digital signal processing, medical imaging and bioinformatics. Specific applications of FPGAs for biological sequence alignment have been reported for dynamic programming-based pairwise (local or global) sequence alignment, progressive multiple sequence alignment, profile alignment, Burrows-Wheeler transform (BWT) based alignment, heuristic pairwise alignment."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017421",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017422",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017423",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017385",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012689",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017386",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003201",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016415",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020539"
            ],
            "type": "yesno",
            "id": "51be1750047fa84d1d000005",
            "snippets": [
                {
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 1262,
                    "text": "A linear error model for the raw intensity data and Burrows-Wheeler transform (BWT) based alignment are combined utilizing a Bayesian score function, which is then globally optimized over all possible genomic locations using an efficient branch-and-bound approach. The algorithm has been implemented in soft- and hardware [field-programmable gate array (FPGA)] to achieve real-time performance.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21724593",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 800,
                    "text": "we have designed and built a high-performance FPGA-accelerated version of BLASTP, Mercury BLASTP. In this paper, we describe the architecture of the portions of the application that are accelerated in the FPGA, and we also describe the integration of these FPGA-accelerated portions with the existing BLASTP software. We have implemented Mercury BLASTP on a commodity workstation with two Xilinx Virtex-II 6000 FPGAs.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492068",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 889,
                    "text": "This paper shows how reconfigurable architectures can be used to derive an efficient fine-grained parallelization of the dynamic programming calculation. We describe how this technique leads to significant runtime savings for HMM database scanning on a standard off-the-shelf field-programmable gate array (FPGA).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273034",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 650,
                    "text": "We have constructed a linear systolic array to perform pairwise sequence distance computations using dynamic programming. This results in an implementation with significant runtime savings on a standard FPGA.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18048180",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 459,
                    "text": "in this paper, we focused on accelerating the Smith-Waterman algorithm by modifying the computationally repeated portion of the algorithm by FPGA hardware custom instructions.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17946720",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 839,
                    "text": "We present a reconfigurable systolic architecture that can be applied for the efficient treatment of several dynamic programming methods for resolving well-known problems, such as global and local sequence alignment, approximate string matching and longest common subsequence. The dynamicity of the reconfigurability was found to be useful for practical applications in the construction of sequence alignments. A VHDL (VHSIC hardware description language) version of this new architecture was implemented on an APEX FPGA (Field programmable gate array).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16342039",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 368,
                    "text": "This results in an implementation of ClustalW with significant runtime savings on a standard off-the-shelf FPGA.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15919726",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 978,
                    "text": "The accelerator implements a version of the Needleman-Wunsch algorithm for nucleotide sequence alignment. Sequence lengths are constrained only by available memory; the product of sequence lengths in the current implementation can be up to 2(22). The machine is implemented as two NuBus boards connected to a Mac IIf/x, using a mixture of TTL and FPGA technology clocked at 10 MHz.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8481828",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is flibanserin effetive for Hypoactive Sexual Desire Disorder? ",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20646181",
                "http://www.ncbi.nlm.nih.gov/pubmed/23421417",
                "http://www.ncbi.nlm.nih.gov/pubmed/25659981",
                "http://www.ncbi.nlm.nih.gov/pubmed/25187905",
                "http://www.ncbi.nlm.nih.gov/pubmed/24281236",
                "http://www.ncbi.nlm.nih.gov/pubmed/22727480"
            ],
            "ideal_answer": [
                "Yes, flibanserin, a novel serotonin (5-HT)(1A) agonist and 5-HT(2A) antagonist, has been shown to increase sexual desire and reduce distress in women with Hypoactive Sexual Desire Disorder."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4266735",
                "http://www.biosemantics.org/jochem#4266735",
                "http://www.disease-ontology.org/api/metadata/DOID:13868"
            ],
            "type": "yesno",
            "id": "56bb6b0eac7ad1001900000e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659981",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Flibanserin is a novel multifunctional serotonin agonist and antagonist (MSAA) that improves sexual functioning in premenopausal women who suffer from reduced sexual interest and desire.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659981",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 518,
                    "text": "Flibanserin is a novel, non-hormonal drug for the treatment of HSDD in pre- and postmenopausal women, although the application submitted to the U.S. Food and Drug Administration by Sprout Pharmaceuticals is only for premenopausal women.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25187905",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1455,
                    "offsetInEndSection": 1717,
                    "text": "CONCLUSIONS: In naturally postmenopausal women with HSDD, flibanserin, compared with placebo, has been associated with improvement in sexual desire, improvement in the number of SSEs, and reduced distress associated with low sexual desire, and is well tolerated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24281236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "INTRODUCTION: Flibanserin is a mixed 5-HT1A agonist/5-HT2A antagonist that has been developed for the treatment of hypoactive sexual desire disorder in women",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421417",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "BACKGROUND: Flibanserin, a novel serotonin (5-HT)(1A) agonist and 5-HT(2A) antagonist, has been shown to increase sexual desire and reduce distress in women with Hypoactive Sexual Desire Disorder (HSDD). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727480",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 431,
                    "text": "Hypoactive sexual desire disorder (HSDD) is the most commonly described form of female sexual dysfunction. There is currently no pharmacological therapy approved to treat HSDD, and therefore, there is an unmet medical need for the development of efficacious treatment alternatives. Flibanserin is a novel, non-hormonal drug for the treatment of HSDD in pre- and postmenopausal women, although the application submitted to the U.S. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25187905",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1562,
                    "offsetInEndSection": 1982,
                    "text": "Sexual function adverse events across flibanserin groups were generally comparable to placebo.Although these studies were not designed or powered to compare sexual function outcomes, results suggested a potential benefit of flibanserin on sexual function, particularly on female sexual desire, and provided a rationale to evaluate the efficacy of flibanserin as a treatment for female hypoactive sexual desire disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20646181",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is TIM-3 a target for cancer immunotherapy in NSCLC?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27699239",
                "http://www.ncbi.nlm.nih.gov/pubmed/29440769",
                "http://www.ncbi.nlm.nih.gov/pubmed/27283895",
                "http://www.ncbi.nlm.nih.gov/pubmed/29721382",
                "http://www.ncbi.nlm.nih.gov/pubmed/26851185",
                "http://www.ncbi.nlm.nih.gov/pubmed/27846884"
            ],
            "ideal_answer": [
                "Yes. Furthermore, TIM-3 and CEACAM1 were strongly expressed simultaneously during long-term CIK culture and showed a significant and mutually positive correlation.",
                "Yes, TIM-3 has shown promising results in early phases of trials in NSCLC patients and can be a target for cancer immunotherapy.",
                "Yes, TIM-3 has emerged as an important target of cancer immunotherapy because of its preferential expression in NSCLC cell lines and its presence in 90% of tumors. (PMID: 21494614) We have developed a cancer vaccine in whichtim-3 is fused with dendritic cells resulting in the presentation of tumor antigens in the context of DC-mediated costimulation. This (CT)n element has been shown to induce poly(ADP-ribose) polymerase activation, and it has also been suggested thatTim-3 may act as a tumor suppressor gene, thus making it a potential therapeutic target of CDKN2A/PD-",
                " Our results imply that implementing combined treatment on CIK cells before transfusion via antibodies targeting PD-L1, LAG-3, TIM-3, and CEACAM-1 might improve the efficiency of CIK therapy for NSCLC patients. Furthermore, TIM-3 and CEACAM1 were strongly expressed simultaneously during long-term CIK culture and showed a significant and mutually positive correlation.",
                "Implementing combined treatment on CIK cells before transfusion via antibodies targeting PD-L1, LAG-3, TIM-3, and CEACAM-1 might improve the efficiency of CIK therapy for NSCLC patients.",
                " Our results imply that implementing combined treatment on CIK cells before transfusion via antibodies targeting PD-L1, LAG-3, TIM-3, and CEACAM-1 might improve the efficiency of CIK therapy for NSCLC patients. Cytometric profiling identified an immunologically \"hot\" cluster with abundant CD8+ T cells expressing high levels of PD-1 and TIM-3 and an immunologically \"cold\" cluster with lower relative abundance of CD8+ T cells and expression of inhibitory markers"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c7a4c35d774d04240000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1539,
                    "offsetInEndSection": 1749,
                    "text": " Our results imply that implementing combined treatment on CIK cells before transfusion via antibodies targeting PD-L1, LAG-3, TIM-3, and CEACAM-1 might improve the efficiency of CIK therapy for NSCLC patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27283895",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1018,
                    "offsetInEndSection": 1177,
                    "text": "Furthermore, TIM-3 and CEACAM1 were strongly expressed simultaneously during long-term CIK culture and showed a significant and mutually positive correlation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27283895",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 488,
                    "text": "In present study, we detected the dynamic expression of eight major checkpoint molecules (CTLA-4, PD-1, PD-L1, TIM- 3, CEACAM-1, LAG-3, TIGIT and BTLA) on CIK cells from NSCLC patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27283895",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2689,
                    "offsetInEndSection": 2906,
                    "text": "Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors on T cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1483,
                    "text": "We found immune activation coexistent with elevation of multiple targetable immune checkpoint molecules, including PD-L1, PD-L2, PD-1, TIM-3, B7-H3, BTLA, and CTLA-4, along with increases in tumor infiltration by CD4(+)Foxp3(+) regulatory T cells in lung adenocarcinomas that displayed an EMT phenotype",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26851185",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 853,
                    "text": "Cytometric profiling identified an immunologically \"hot\" cluster with abundant CD8+ T cells expressing high levels of PD-1 and TIM-3 and an immunologically \"cold\" cluster with lower relative abundance of CD8+ T cells and expression of inhibitory markers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1052,
                    "offsetInEndSection": 1249,
                    "text": " Interestingly, CD161+ CD4+ T cells highly express OX40 co-stimulatory receptor, less frequently 4-1BB, and display an activated but not completely exhausted PD-1-positive Tim-3-negative phenotype.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29721382",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1046,
                    "text": ". Furthermore, overexpression of targetable immune checkpoints, such as CTLA-4 and TIM-3 were associated with EMT in both NSCLCs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29440769",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Solanezumab effective for Alzheimer's Disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29067346",
                "http://www.ncbi.nlm.nih.gov/pubmed/26238576",
                "http://www.ncbi.nlm.nih.gov/pubmed/28593105",
                "http://www.ncbi.nlm.nih.gov/pubmed/28649604",
                "http://www.ncbi.nlm.nih.gov/pubmed/24450890",
                "http://www.ncbi.nlm.nih.gov/pubmed/26990863",
                "http://www.ncbi.nlm.nih.gov/pubmed/26815584",
                "http://www.ncbi.nlm.nih.gov/pubmed/27223100",
                "http://www.ncbi.nlm.nih.gov/pubmed/27239541"
            ],
            "ideal_answer": [
                "No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D000544",
                "http://www.disease-ontology.org/api/metadata/DOID:10652"
            ],
            "type": "yesno",
            "id": "5a70e1d999e2c3af26000007",
            "snippets": [
                {
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 704,
                    "text": "An analysis of publicly available data from the Phase II studies for bapineuzumab and solanezumab indicates that neither compound produced compelling evidence of drug-like behavior that would justify their progression into pivotal trials. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067346",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 783,
                    "text": "Notably, a recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkinson's disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649604",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 734,
                    "text": "For example, Eli Lilly announced a major change to its closely watched clinical trial for the Alzheimer's drug solanezumab which failed to reach statistical significance. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28593105",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 738,
                    "text": "Areas covered: This contradiction prompted us to review all study phases of Intravenous Immunoglobulin (IVIG), Bapineuzumab, Solanezumab, Avagacestat and Dimebolin to shed more light on these recent failures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27223100",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 441,
                    "text": " Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26815584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 869,
                    "text": "Secondary analyses of EXPEDITION studies suggested a smaller functional effect of solanezumab relative to cognition. An increasing effect of solanezumab over 18\u00a0months was shown for cognition and function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239541",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 862,
                    "text": "RESULTS: In the mild AD population, less cognitive and functional decline was observed with solanezumab (n\u00a0=\u00a0659) versus placebo (n\u00a0=\u00a0663), measured by Alzheimer's Disease Assessment Scale Cognitive subscale, Mini-Mental State Examination, and Alzheimer's Disease Cooperative Study-Activities of Daily Living functional scale Instrumental ADLs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238576",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "The promising results obtained with aducanumab and solanezumab against Alzheimer's disease (AD) strengthen the vaccine approach to prevent AD, despite of the many clinical setbacks. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26990863",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2247,
                    "offsetInEndSection": 2376,
                    "text": "CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24450890",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 298,
                    "text": "Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26815584",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does an interferon (IFN) signature exist for SLE patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29850618",
                "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
                "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
                "http://www.ncbi.nlm.nih.gov/pubmed/28830352"
            ],
            "ideal_answer": [
                "Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. An IFN-I score (positive or negative), as a measure of IFN-I activation, is assessed using the expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs)."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c7019557c78d6947100005f",
            "snippets": [
                {
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 167,
                    "text": "Interferon regulatory factor 7 activation correlates with the IFN signature and recurrent disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 941,
                    "text": "In SLE post-transplant, recurrent disease activity and induction of IRF7 protein expression correlated with activation of the IFN signature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830352",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1329,
                    "text": "We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830352",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 748,
                    "offsetInEndSection": 992,
                    "text": "We found that cDCs from prediseased TCSle male mice express the IFN signature as female TCSle cDCs do. Estrogens are necessary but not sufficient to express this IFN signature, but high doses of E2 can compensate for other steroidal components.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850618",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Conventional DCs from Male and Female Lupus-Prone B6.NZM Sle1/Sle2/Sle3 Mice Express an IFN Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850618",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "text": "Type I IFN signature in childhood-onset systemic lupus erythematosus",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 190,
                    "text": " Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 677,
                    "text": "The IFN-I score (positive or negative), as a measure of IFN-I activation, was assessed using real-time quantitative PCR (RT-PCR) expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                "http://www.ncbi.nlm.nih.gov/pubmed/24950205"
            ],
            "ideal_answer": [
                "Yes. Activation-induced miR-155 targets the chromatin protein Jarid2 to regulate proinflammatory cytokine production in T helper 17 cells."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/JARD2_CHICK",
                "http://www.uniprot.org/uniprot/JARD2_HUMAN",
                "http://amigo.geneontology.org/amigo/term/GO:2000317",
                "http://www.uniprot.org/uniprot/JARD2_MOUSE",
                "http://amigo.geneontology.org/amigo/term/GO:0072538",
                "http://amigo.geneontology.org/amigo/term/GO:2000318",
                "http://amigo.geneontology.org/amigo/term/GO:2000316",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058504",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018417"
            ],
            "type": "yesno",
            "id": "56b8f28a156496395c000006",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 50,
                    "text": "Jarid2 links MicroRNA and chromatin in Th17 cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950205",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "In this issue of Immunity, Escobar et\u00a0al. (2014) bring microRNAs and chromatin together by showing how activation-induced miR-155 targets the chromatin protein Jarid2 to regulate proinflammatory cytokine production in T helper 17 cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 1032,
                    "text": "Mir155 was bound by Th17 cell transcription factors and was highly expressed during Th17 cell differentiation. miR-155-deficient Th17 and T regulatory (Treg) cells expressed increased amounts of Jarid2, a DNA-binding protein that recruits the Polycomb Repressive Complex 2 (PRC2) to chromatin. PRC2 binding to chromatin and H3K27 histone methylation was increased in miR-155-deficient cells, coinciding with failure to express Il22, Il10, Il9, and Atf3. Defects in Th17 cell cytokine expression and Treg cell homeostasis in the absence of Mir155 could be partially suppressed by Jarid2 deletion. Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1122,
                    "text": "Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1032,
                    "text": "Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 1033,
                    "text": "Defects in Th17 cell cytokine expression and Treg cell homeostasis in the absence of Mir155 could be partially suppressed by Jarid2 deletion. Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1033,
                    "text": "Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26391045",
                "http://www.ncbi.nlm.nih.gov/pubmed/19636252",
                "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                "http://www.ncbi.nlm.nih.gov/pubmed/9800738",
                "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
                "http://www.ncbi.nlm.nih.gov/pubmed/2143053",
                "http://www.ncbi.nlm.nih.gov/pubmed/3036686",
                "http://www.ncbi.nlm.nih.gov/pubmed/9050924",
                "http://www.ncbi.nlm.nih.gov/pubmed/23394617",
                "http://www.ncbi.nlm.nih.gov/pubmed/18801168",
                "http://www.ncbi.nlm.nih.gov/pubmed/27931082",
                "http://www.ncbi.nlm.nih.gov/pubmed/11371509",
                "http://www.ncbi.nlm.nih.gov/pubmed/26300975",
                "http://www.ncbi.nlm.nih.gov/pubmed/18056702",
                "http://www.ncbi.nlm.nih.gov/pubmed/21081842",
                "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                "http://www.ncbi.nlm.nih.gov/pubmed/25862935",
                "http://www.ncbi.nlm.nih.gov/pubmed/24980541",
                "http://www.ncbi.nlm.nih.gov/pubmed/2880544",
                "http://www.ncbi.nlm.nih.gov/pubmed/15176487",
                "http://www.ncbi.nlm.nih.gov/pubmed/25706610",
                "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                "http://www.ncbi.nlm.nih.gov/pubmed/23686780",
                "http://www.ncbi.nlm.nih.gov/pubmed/28342823",
                "http://www.ncbi.nlm.nih.gov/pubmed/24210986",
                "http://www.ncbi.nlm.nih.gov/pubmed/7532356"
            ],
            "ideal_answer": [
                "Yes, Downs syndrome is caused by a duplication or all or part of chromosome 21.",
                "Down syndrome (DS), trisomy 21, is caused by increased dose of genes present on human chromosome 21 (HSA21). ",
                "Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D004314",
                "https://meshb.nlm.nih.gov/record/ui?ui=D056915",
                "https://meshb.nlm.nih.gov/record/ui?ui=D000076103",
                "https://meshb.nlm.nih.gov/record/ui?ui=D002891"
            ],
            "type": "yesno",
            "id": "5a76016683b0d9ea6600000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27931082",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Down syndrome (DS), trisomy 21, is caused by increased dose of genes present on human chromosome 21 (HSA21)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28342823",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 97,
                    "offsetInEndSection": 207,
                    "text": "Down syndrome, or Trisomy 21, is the most frequently occurring chromosomal abnormality in live-born children. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 55,
                    "text": "Down syndrome (DS), caused by trisomy of chromosome 21,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26391045",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Submicroscopic duplication of chromosome 21 and trisomy 21 phenotype (Down syndrome).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3036686",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Trisomy 21 or Down syndrome is a chromosomal disorder resulting from the presence of all or part of an extra Chromosome 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19636252",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Down syndrome is a genetic disorder, occurring when an individual has all or part of an extra copy of chromosome 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 769,
                    "text": "Aneuploidy refers to the presence of an extra copy of a specific chromosome, or trisomy, as seen in Down's syndrome (trisomy 21), or the absence of a single chromosome, or monosomy, as seen in Turner syndrome (a single X chromosome in females: 45, X).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980541",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "Down syndrome (DS) or Trisomy 21 (Ts21) is caused by the presence of an extra copy of all or part of human chromosome 21 (Hsa21) and is the most frequent survivable congenital chromosomal abnormality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "text": "Down syndrome (DS) is a major cause of mental retardation and heart disease. Although it is usually caused by the presence of an extra chromosome 21, a subset of the diagnostic features may be caused by the presence of only band 21q22.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2143053",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 55,
                    "text": "Down syndrome is usually caused by complete trisomy 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7532356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Down syndrome, the most frequent genetic disorder, is characterized by an extra copy of all or part of chromosome 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056702",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 190,
                    "text": "Down syndrome (DS), caused by an extra copy of chromosome 21, affects 1 in 750 live births and is characterized by cognitive impairment and a constellation of congenital defects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394617",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Down syndrome (DS) results from one extra copy of human chromosome 21 and leads to several alterations including intellectual disabilities and locomotor defects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25706610",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Down's syndrome results from the production of three copies of chromosome 21 within a cell. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9050924",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Trisomy 21 (Ts21) is the most common live-born human aneuploidy; it results in a constellation of features known as Down's syndrome (DS).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11371509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 98,
                    "text": "Down syndrome comprises multiple malformations and is due to trisomy of chromosome 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25862935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 292,
                    "text": "n 1959, J. Lejeune, M. Gautier, and R. Turpin demonstrated that the children with Down syndrome had an extra copy of chromosome 21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 112,
                    "text": "To develop a reliable and specific method for rapid prenatal diagnosis of Trisomy 21 (Down syndrome).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23686780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 126,
                    "text": "Trisomy 21 Down syndrome is the most common genetic cause for congenital malformations and intellectual disability",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26300975",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 154,
                    "text": "Down syndrome, characterized by an extra chromosome 21 is the most common genetic cause for congenital malformations and learning disability. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801168",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there focused databases from which you can retrieve gene expression data on renal disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20616184",
                "http://www.ncbi.nlm.nih.gov/pubmed/23593176",
                "http://www.ncbi.nlm.nih.gov/pubmed/21143788",
                "http://www.ncbi.nlm.nih.gov/pubmed/19604367",
                "http://www.ncbi.nlm.nih.gov/pubmed/21044771",
                "http://www.ncbi.nlm.nih.gov/pubmed/21930502",
                "http://www.ncbi.nlm.nih.gov/pubmed/19703314",
                "http://www.ncbi.nlm.nih.gov/pubmed/17877839"
            ],
            "ideal_answer": [
                "Biological databases are used to store and edit large amount of data, created from genomics data. In the most of the cases the data are stored according to their type but there are cases of focused databases that store database on a specific disease. In the case of renal disease there are plenty of databases, for example KUPKB a collection of omics datasets, Nephromine a renal genome-wide gene expression dataset based in transcriptomics, CDKD and Proteomics Database in Chronic Kidney Disease."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020869",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059467",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051436",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007674",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870"
            ],
            "type": "yesno",
            "id": "532c0946d6d3ac6a34000019",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 45,
                    "text": "Proteomics database in chronic kidney disease",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044771",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616184",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is avanafil indicated for treatment of erectile dysfunction?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23321580",
                "http://www.ncbi.nlm.nih.gov/pubmed/27121186",
                "http://www.ncbi.nlm.nih.gov/pubmed/25591992",
                "http://www.ncbi.nlm.nih.gov/pubmed/25684196",
                "http://www.ncbi.nlm.nih.gov/pubmed/22704456",
                "http://www.ncbi.nlm.nih.gov/pubmed/23521325",
                "http://www.ncbi.nlm.nih.gov/pubmed/23955441",
                "http://www.ncbi.nlm.nih.gov/pubmed/22448738",
                "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                "http://www.ncbi.nlm.nih.gov/pubmed/22248153",
                "http://www.ncbi.nlm.nih.gov/pubmed/23219537",
                "http://www.ncbi.nlm.nih.gov/pubmed/22788525",
                "http://www.ncbi.nlm.nih.gov/pubmed/25455484",
                "http://www.ncbi.nlm.nih.gov/pubmed/24589460",
                "http://www.ncbi.nlm.nih.gov/pubmed/26784833",
                "http://www.ncbi.nlm.nih.gov/pubmed/22759639",
                "http://www.ncbi.nlm.nih.gov/pubmed/27377089",
                "http://www.ncbi.nlm.nih.gov/pubmed/25801159",
                "http://www.ncbi.nlm.nih.gov/pubmed/25582903",
                "http://www.ncbi.nlm.nih.gov/pubmed/24259695",
                "http://www.ncbi.nlm.nih.gov/pubmed/24331245",
                "http://www.ncbi.nlm.nih.gov/pubmed/26316720",
                "http://www.ncbi.nlm.nih.gov/pubmed/24701971",
                "http://www.ncbi.nlm.nih.gov/pubmed/23590161"
            ],
            "ideal_answer": [
                "Yes, avanafil is indicated for treatment of erectile dysfunction."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.biosemantics.org/jochem#4243720",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007172"
            ],
            "type": "yesno",
            "id": "5895d0457d9090f35300000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "CONTEXT: Avanafil (AVA) is used in the treatment of erectile dysfunction, but is reported for its poor aqueous solubility. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26784833",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377089",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591992",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "PURPOSE: We examined the therapeutic effects of avanafil 15 minutes after dosing in men with mild to severe erectile dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 307,
                    "offsetInEndSection": 440,
                    "text": "Sildenafil, vardenafil, tadalafil and avanafil are FDA approved drugs in market as PDE5 inhibitors for treating erectile dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25801159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1428,
                    "offsetInEndSection": 1711,
                    "text": "CONCLUSION: Avanafil along with the other PDE5Is has shown to be a safe and effective oral treatment for ED, with avanafil's possible place in therapy for patients who want an on-demand option or as an alternative in patients who experience visual disturbances with the other agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316720",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Avanafil (STENDRA\u2122, SPEDRA\u2122, Zepeeed\u2122) is an oral phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 669,
                    "text": "In a 12-week, randomized, double-blind, placebo-controlled, multicentre trial in patients with erectile dysfunction, avanafil 50, 100 and 200 mg recipients had significantly greater improvements from baseline than placebo recipients in mean international index of erectile dysfunction-erectile function domain scores and in successful vaginal penetration and sexual intercourse attempts (coprimary endpoints).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Avanafil for the treatment of erectile dysfunction. An updated review.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582903",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759639",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22248153",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704456",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321580",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1809,
                    "offsetInEndSection": 1912,
                    "text": "Cumulative data suggest that avanafil has a promising pharmacological profile for erectile dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704456",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1630,
                    "text": "These findings suggest that intracavernosal administration of avanafil might be beneficial for the treatment of erectile dysfunction in patients with T2DM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23521325",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 246,
                    "text": "Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22448738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1259,
                    "offsetInEndSection": 1546,
                    "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Avanafil (STENDRA\u2122, SPEDRA\u2122, Zepeeed\u2122) is an oral phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 670,
                    "text": "Avanafil is rapidly absorbed after oral administration, with a median time to maximum plasma concentration of 30 to 45 min. In a 12-week, randomized, double-blind, placebo-controlled, multicentre trial in patients with erectile dysfunction, avanafil 50, 100 and 200 mg recipients had significantly greater improvements from baseline than placebo recipients in mean international index of erectile dysfunction-erectile function domain scores and in successful vaginal penetration and sexual intercourse attempts (coprimary endpoints)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22788525",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 375,
                    "text": "To evaluate the safety, efficacy and time course of three doses of avanafil (50 mg, 100 mg and 200 mg) compared with sildenafil 50 mg or placebo, given in conjunction with visual sexual stimulation (VSS) videos in men with mild to moderate erectile dysfunction (ED).Male patients, 35-70 years of age, with mild to moderate ED of \u22656 months duration, were included in the study",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22788525",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 33,
                    "text": "Avanafil for erectile dysfunction",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 472,
                    "text": "To review the pharmacology, pharmacokinetics, safety, and efficacy of avanafil and evaluate relevant clinical trial data.A MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches (1966 to July 2013) were conducted using the key words: avanafil, erectile dysfunction, and phosphodiesterase type 5 (PDE5) inhibitor.Articles evaluating avanafil for erectile dysfunction (ED) published in English and using human subjects were selected",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1305,
                    "text": "In trials in patients with erectile dysfunction in association with diabetes mellitus, and after nerve-sparing radical prostatectomy, avanafil 100 or 200 mg was significantly more efficacious than placebo for primary and most secondary endpoints",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1321,
                    "offsetInEndSection": 1864,
                    "text": "However, the potentiating effect of avanafil at 1 mg/kg was significantly weaker than that of sildenafil (p &lt;0.05).Data suggest that avanafil has a favorable safety profile for erectile dysfunction, which is attributable to its high inhibitory selectivity for phosphodiesterase type 5 against type 6 (retina) and 1 (vessels, etc), respectively, and its short acting pharmacodynamic property.<CopyrightInformation>Copyright \u00a9 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321580",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25455484",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22448738",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "The phosphodiesterese-5 (PDE5) inhibitors, including sildenafil (Viagra\u2122), vardenafil (Levitra\u2122), tadalafil (Cialis\u2122) and avanafil (Stendra\u2122) have been developed for the treatment of erectile dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23590161",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 299,
                    "text": "To compare the efficacy and safety between different dosages of avanafil for the treatment of erectile dysfunction (ED).PubMed, Cochrane Library, and Embase were searched to identify randomized controlled trials which compared avanafil with placebo, or compared different dosages of avanafil for ED.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 389,
                    "text": "We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.This was a double-blind, placebo controlled, parallel group, phase 3 study in males age 18 to 70 years with a history of erectile dysfunction of 6 months or more after bilateral nerve sparing radical prostatectomy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "text": "To determine the effect of avanafil, a novel phosphodiesterase-5 inhibitor, on the treatment of erectile dysfunction associated with type 2 diabetes mellitus (T2DM).In 2-day-old rats, T2DM was induced by single intraperitoneal injection of 90 mg/kg of streptozotocin (STZ; i.p.).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1434,
                    "offsetInEndSection": 1665,
                    "text": "These findings suggest that intracavernosal administration of avanafil might be beneficial for the treatment of erectile dysfunction in patients with T2DM.<CopyrightInformation>Copyright \u00a9 2014 Elsevier Inc. All rights reserved.</C",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysfunction (ED).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1260,
                    "offsetInEndSection": 1548,
                    "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 1150,
                    "text": "Coprimary end points assessed changes in the percentage of sexual attempts in which men were able to maintain an erection of sufficient duration to have successful intercourse (Sexual Encounter Profile [SEP] 3), percentage of sexual attempts in which men were able to insert the penis into the partner's vagina (SEP 2), and International Index of Erectile Function erectile function domain score.RESULTS: Compared with placebo, least-squares mean change from baseline to study end in SEP 3, SEP 2, and International Index of Erectile Function erectile function domain score were significantly improved with both avanafil, 100 mg (P?.002), and avanafil, 200 mg (P<.001).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1299,
                    "offsetInEndSection": 1599,
                    "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.CONCLUSION: Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Avanafil for the treatment of erectile dysfunction. An updated review.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582903",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 35,
                    "text": "Avanafil for erectile dysfunction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "To compare the efficacy and safety between different dosages of avanafil for the treatment of erectile dysfunction (ED).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759639",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is P. gingivalis bacteria found in brain?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28800332",
                "http://www.ncbi.nlm.nih.gov/pubmed/30281647"
            ],
            "ideal_answer": [
                "Yes"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c5f2b771a4c55d80b000020",
            "snippets": [
                {
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 439,
                    "text": "studies using animal model of periodontitis and human post-mortem brain tissues from subjects with AD strongly suggest that a gram-negative periodontal pathogen, Porphyromonas gingivalis (Pg) and/or its product gingipain is/are translocated to the brain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30281647",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "The polymicrobial dysbiotic subgingival biofilm microbes associated with periodontal disease appear to contribute to developing pathologies in distal body sites, including the brain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800332",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any specific antidotes for rivaroxaban?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12871541",
                "http://www.ncbi.nlm.nih.gov/pubmed/23117666",
                "http://www.ncbi.nlm.nih.gov/pubmed/23312927",
                "http://www.ncbi.nlm.nih.gov/pubmed/19351313",
                "http://www.ncbi.nlm.nih.gov/pubmed/23821689",
                "http://www.ncbi.nlm.nih.gov/pubmed/24170233",
                "http://www.ncbi.nlm.nih.gov/pubmed/24103671",
                "http://www.ncbi.nlm.nih.gov/pubmed/23810130",
                "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
                "http://www.ncbi.nlm.nih.gov/pubmed/20858186",
                "http://www.ncbi.nlm.nih.gov/pubmed/23628464",
                "http://www.ncbi.nlm.nih.gov/pubmed/23953907",
                "http://www.ncbi.nlm.nih.gov/pubmed/23866358",
                "http://www.ncbi.nlm.nih.gov/pubmed/23460104",
                "http://www.ncbi.nlm.nih.gov/pubmed/23657589",
                "http://www.ncbi.nlm.nih.gov/pubmed/22353706",
                "http://www.ncbi.nlm.nih.gov/pubmed/23790307",
                "http://www.ncbi.nlm.nih.gov/pubmed/23634925",
                "http://www.ncbi.nlm.nih.gov/pubmed/22308807"
            ],
            "ideal_answer": [
                "Currently, there is no specific antidote for rivaroxaban"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931",
                "http://www.biosemantics.org/jochem#4243836"
            ],
            "type": "yesno",
            "id": "532f08b8d6d3ac6a34000029",
            "snippets": [
                {
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 490,
                    "text": "Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24103671",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 414,
                    "text": "he new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821689",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 592,
                    "text": "Given the absence of a specific antidote, the action to be taken in these situations must be defined. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810130",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1018,
                    "offsetInEndSection": 1176,
                    "text": "The fact that there is no specific antidote to reverse the anticoagulant action of the new anticoagulants can impair management of hemorrhagic complications; ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23790307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 200,
                    "offsetInEndSection": 537,
                    "text": "Like any new therapy, the potential benefits must be weighed against the potential challenges and one of the most concerning aspects of the new target-specific oral anticoagulants is the lack of a proven method to reverse their effect. Unlike the vitamin K antagonist, i.e. warfarin, there is no specific antidote for these medications. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23657589",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1598,
                    "text": "Two major drawbacks are on the one hand the risk of drug accumulation in kidney and/or liver disease and, on the other hand, the lack of specific antidotes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460104",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1741,
                    "text": "NOA also have other unresolved problems: drug interactions are still possible, specific coagulation test to assess them must be developed, and no specific antidote is currently available in case of hemorrhagic complication.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23312927",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1191,
                    "offsetInEndSection": 1333,
                    "text": "But they have disadvantages also, they depend on renal clearance, they can interact with other medicaments and they lack a specific antidote. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117666",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 957,
                    "text": "While these trial data are extremely encouraging, several practical issues (e.g., lack of specific antidote, safety of long-term treatment or cost-effectiveness in \"real-life\" clinical practice) still need to be elucidated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22353706",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 661,
                    "text": "In case of massive bleeding, management is unclear and none of these newer agents has a specific antidote that completely reverses its anticoagulant effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308807",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1935,
                    "offsetInEndSection": 2044,
                    "text": "The short half-life of these new agents compensates for the lack of any specific antidote in many instances. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 750,
                    "text": "Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20858186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 865,
                    "text": "Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 731,
                    "text": "Increased use of dabigatran, rivaroxaban, and apixaban as oral anticoagulants for the treatment of atrial fibrillation and acute deep venous thrombosis has increased despite the lack of known antidotes to these medications.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23634925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 812,
                    "text": "There is no antidote for reversal and no reliable laboratory monitoring of the anticoagulant effect for emergency situations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628464",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1259,
                    "offsetInEndSection": 1570,
                    "text": "Further concerns about the use of NOAC in the elderly are the high prevalence of renal insufficiency in AF patients >75 years of age, the largely unknown risk of drug-drug and drug-food interactions, the lack of easily available laboratory monitoring tests of anticoagulant activity and the lack of an antidote.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 576,
                    "text": "Specific antidotes for the reversal of the anticoagulant effect of these drugs, such as monoclonal antibodies against the direct thrombin inhibitor dabigatran or recombinant Xa-analog in the case of factor Xa inhibitors, are still being investigated in early clinical trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23953907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1429,
                    "offsetInEndSection": 1596,
                    "text": "In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23866358",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the protein lefty an inhibitor of nodal?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26506307",
                "http://www.ncbi.nlm.nih.gov/pubmed/25669884",
                "http://www.ncbi.nlm.nih.gov/pubmed/25672326",
                "http://www.ncbi.nlm.nih.gov/pubmed/25684355",
                "http://www.ncbi.nlm.nih.gov/pubmed/26377939"
            ],
            "ideal_answer": [
                "Yes, lefty is an inhibitor of nodal."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "58a93877ee23e0236b000001",
            "snippets": [
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 178,
                    "text": "The expression of lefty, an inhibitor of nodal is often reduced in tumor cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25672326",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 416,
                    "text": " Nodal, and an inhibitor, Lefty.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684355",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1029,
                    "offsetInEndSection": 1097,
                    "text": "as well as the expression of Lefty, an inhibitor of nodal signaling,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26377939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 648,
                    "text": "he Nodal inhibitor lefty",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 367,
                    "text": "The morphogen Nodal was proposed to form a long-range signaling gradient via a reaction-diffusion system, on the basis of differential diffusion rates of Nodal and its antagonist Lefty.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26506307",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is CHEK2 involved in cell cycle control?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17517688",
                "http://www.ncbi.nlm.nih.gov/pubmed/16596250",
                "http://www.ncbi.nlm.nih.gov/pubmed/21956126",
                "http://www.ncbi.nlm.nih.gov/pubmed/11751432",
                "http://www.ncbi.nlm.nih.gov/pubmed/23030661",
                "http://www.ncbi.nlm.nih.gov/pubmed/18024013",
                "http://www.ncbi.nlm.nih.gov/pubmed/17577921"
            ],
            "ideal_answer": [
                "CHEK2 is a key cell cycle control gene encoding a pluripotent kinase that can cause arrest or apoptosis in response to unrepaired DNA damage."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000075",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071850",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064447",
                "http://www.uniprot.org/uniprot/CHK2_HUMAN",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059565",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031575",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0022402",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051726",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010564",
                "http://www.uniprot.org/uniprot/CHK2_MOUSE",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007050",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071780",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007049",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002453",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031569",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007346",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059447"
            ],
            "type": "yesno",
            "id": "53175e25b166e2b806000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1904,
                    "offsetInEndSection": 2184,
                    "text": "Moreover, cell-cycle progression genes [i.e. E2F transcription factor (E2F) family and histone deacetylase ( HDAC )] and DNA-repair genes [i.e. growth arrest and DNA-damage-inducible, gamma ( GADD45G ) family and serine/threonine-protein kinase Chk2 ( CHEK2)] were also increased.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030661",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 333,
                    "text": "As CHEK2 is a cell-cycle master controller, we tested the hypothesis that heterozygosity for the frameshift alteration CHEK2*1100delC is associated with increased risk of malignant melanoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956126",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "In the current study, we evaluated the possible associations of seven common variants of the DNA repair and cell cycle control genes BRCA2 and CHEK2 with malignant melanoma (MM).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18024013",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 717,
                    "text": "Promotor methylation analysis of key regulatory genes involved in cell cycle control (p14, p15, p16, CHK2), DNA repair (hMLH1), apoptosis (p73, survivin, DAPK), and differentiation (RARb, WT1) was performed by methylation-specific polymerase chain reaction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17577921",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "CHEK2 is a key cell cycle control gene encoding a pluripotent kinase that can cause arrest or apoptosis in response to unrepaired DNA damage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17517688",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 387,
                    "text": "High-fidelity maintenance of genomic integrity in eukaryotes is ensured by cell cycle checkpoints and DNA repair. The checkpoint kinase, Chk2, has been implicated in both of these responses. In response to DNA damage, Chk2 is initially phosphorylated at Thr-68, which leads to its full activation. The fully activated Chk2 then phosphorylates downstream substrates of cell cycle control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16596250",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Checkpoint kinase 2 (hCHK2/hCds1) is a tumor suppressor gene involved in cell-cycle control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11751432",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does Groucho related gene 5 (GRG5) have a role only in late development?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30214018"
            ],
            "ideal_answer": [
                "Groucho related gene 5 (GRG5) has been described as a multifunctional protein that has been implicated in late embryonic and postnatal mouse development. By both loss and gain of function approaches ablation of GRG5 has been shown to deregulate the Embryonic Stem Cell (ESC) pluripotent state whereas its overexpression leads to enhanced self-renewal and acquisition of cancer cell-like properties. The malignant characteristics of teratomas generated by ESCs that overexpress GRG5 reveal its pro-oncogenic potential."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c629fffe842deac67000009",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 638,
                    "text": "Groucho related gene 5 (GRG5) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development. Here, we describe a previously unknown role of GRG5 in early developmental stages by analyzing its function in stem cell fate decisions. By both loss and gain of function approaches we demonstrate that ablation of GRG5 deregulates the Embryonic Stem Cell (ESC) pluripotent state whereas its overexpression leads to enhanced self-renewal and acquisition of cancer cell-like properties. The malignant characteristics of teratomas generated by ESCs that overexpress GRG5 reveal its pro-oncogenic potential.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30214018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 271,
                    "text": "Here, we describe a previously unknown role of GRG5 in early developmental stages by analyzing its function in stem cell fate decisions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30214018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "Groucho related gene 5 (GRG5) is involved in embryonic and neural stem cell state decisions.Groucho related gene 5 (GRG5) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30214018",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is K-63 linked protein ubiquitination related to proteasomal degradation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18042044",
                "http://www.ncbi.nlm.nih.gov/pubmed/21737094",
                "http://www.ncbi.nlm.nih.gov/pubmed/19091944",
                "http://www.ncbi.nlm.nih.gov/pubmed/21071436",
                "http://www.ncbi.nlm.nih.gov/pubmed/15728425",
                "http://www.ncbi.nlm.nih.gov/pubmed/20663875"
            ],
            "ideal_answer": [
                "Ubiquitination is best known for its role in targeting proteins for degradation by the proteasome, but evidence of the nonproteolytic functions of ubiquitin is also rapidly accumulating. One example of the regulatory, rather than proteolytic, function of ubiquitin is provided by study of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins, which function as ubiquitin ligases to synthesize lysine 63 (K(63))-linked polyubiquitin chains to mediate protein kinase activation through a proteasome-independent mechanism. Some TRAF proteins, such as TRAF2 and TRAF3, have recently been shown to have a positive role in the canonical pathway that activates nuclear factor kappaB (NF-kappaB) through IkappaB kinase beta (IKKbeta), but a negative role in the noncanonical pathway that activates NF-kappaB through IKKalpha. These opposing roles of TRAF proteins may be linked to their ability to synthesize distinct forms of polyubiquitin chains. Indeed, the TRAF2-interacting protein RIP can mediate IKK activation when it is modified by K(63) polyubiquitin chains, but is targeted to degradation by the proteasome when it is K(48)-polyubiquitinted by the NF-kappaB inhibitor A20. Thus, ubiquitin chains are dynamic switches that can influence signaling outputs in dramatically different ways.In contrast to K48-linked polyubiquitin chains, K63-linked polyubiquitin chains function in nonproteasomal biological processes.",
                "In contrast to K48-linked polyubiquitin chains, K63-linked polyubiquitin chains function in nonproteasomal biological processes. Modification of proteins by the addition of lysine (K)-63-linked polyubiquitin (polyUb) chains is suggested to play important roles in a variety of cellular events, including DNA repair, signal transduction, and receptor endocytosis. One example of the regulatory, rather than proteolytic, function of ubiquitin is provided by study of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins, which function as ubiquitin ligases to synthesize lysine 63 (K(63))-linked polyubiquitin chains to mediate protein kinase activation through a proteasome-independent mechanism.",
                "One example of the regulatory, rather than proteolytic, function of ubiquitin is provided by study of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins, which function as ubiquitin ligases to synthesize lysine 63 (K(63))-linked polyubiquitin chains to mediate protein kinase activation through a proteasome-independent mechanism",
                "Modification of proteins by the addition of lysine (K)-63-linked polyubiquitin (polyUb) chains is suggested to play important roles in a variety of cellular events, including DNA repair, signal transduction, and receptor endocytosis. In contrast to K48-linked polyubiquitin chains, K63-linked polyubiquitin chains function in nonproteasomal biological processes."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0061136",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016567",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010498"
            ],
            "type": "yesno",
            "id": "550899c92e93f0133a000003",
            "snippets": [
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 364,
                    "text": "In contrast to K48-linked polyubiquitin chains, K63-linked polyubiquitin chains function in nonproteasomal biological processes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663875",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "Modification of proteins by the addition of lysine (K)-63-linked polyubiquitin (polyUb) chains is suggested to play important roles in a variety of cellular events, including DNA repair, signal transduction, and receptor endocytosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19091944",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1310,
                    "text": "Ubiquitination is best known for its role in targeting proteins for degradation by the proteasome, but evidence of the nonproteolytic functions of ubiquitin is also rapidly accumulating. One example of the regulatory, rather than proteolytic, function of ubiquitin is provided by study of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins, which function as ubiquitin ligases to synthesize lysine 63 (K(63))-linked polyubiquitin chains to mediate protein kinase activation through a proteasome-independent mechanism. Some TRAF proteins, such as TRAF2 and TRAF3, have recently been shown to have a positive role in the canonical pathway that activates nuclear factor kappaB (NF-kappaB) through IkappaB kinase beta (IKKbeta), but a negative role in the noncanonical pathway that activates NF-kappaB through IKKalpha. These opposing roles of TRAF proteins may be linked to their ability to synthesize distinct forms of polyubiquitin chains. Indeed, the TRAF2-interacting protein RIP can mediate IKK activation when it is modified by K(63) polyubiquitin chains, but is targeted to degradation by the proteasome when it is K(48)-polyubiquitinted by the NF-kappaB inhibitor A20. Thus, ubiquitin chains are dynamic switches that can influence signaling outputs in dramatically different ways.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15728425",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1709,
                    "offsetInEndSection": 1961,
                    "text": "Importantly, although Lys-48-linked ubiquitin chains appear to trigger proteasomal degradation, the presence of Lys-63-linked ubiquitin chains suggests that ubiquitination of IP(3)Rs may have physiological consequences beyond signaling for degradation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21071436",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 263,
                    "text": "Chains of ubiquitin linked via lysine 48 (K48) are associated with protein degradation while chains linked via lysine 63 (K63) are associated with intracellular signaling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737094",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 481,
                    "text": "Lys(48)-linked chains target proteins for proteasomal degradation, and Lys(63)-linked chains function in signal transduction, endocytosis and DNA repair",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18042044",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1302,
                    "offsetInEndSection": 1535,
                    "text": "Remarkably, the attached Lys-48- and Lys-63-linked ubiquitin chains are homogeneous and are segregated to separate IP(3)R subunits, and Lys-48-linked ubiquitin chains, but not Lys-63-linked chains, are required for IP(3)R degradation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21071436",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Activated inositol 1,4,5-trisphosphate receptors are modified by homogeneous Lys-48- and Lys-63-linked ubiquitin chains, but only Lys-48-linked chains are required for degradation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21071436",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is Tofacitinib effective for Ulcerative Colitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                "http://www.ncbi.nlm.nih.gov/pubmed/27663846",
                "http://www.ncbi.nlm.nih.gov/pubmed/28503977",
                "http://www.ncbi.nlm.nih.gov/pubmed/28164724",
                "http://www.ncbi.nlm.nih.gov/pubmed/28158411",
                "http://www.ncbi.nlm.nih.gov/pubmed/27140405",
                "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
                "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
                "http://www.ncbi.nlm.nih.gov/pubmed/28790099",
                "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
                "http://www.ncbi.nlm.nih.gov/pubmed/28475384",
                "http://www.ncbi.nlm.nih.gov/pubmed/26608188"
            ],
            "ideal_answer": [
                "Yes. Tofacitinib, an oral small-molecule Janus kinase inhibitor, is effective in the treatment of moderate-severe ulcerative colitis. It is also effective treatment of rheumatoid arthritis and autoimmune encephalomyelitis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:8577",
                "https://meshb.nlm.nih.gov/record/ui?ui=D016896",
                "https://meshb.nlm.nih.gov/record/ui?ui=D003093"
            ],
            "type": "yesno",
            "id": "5a723edd2dc08e987e00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 1027,
                    "text": "Tofacitinib, inhibiting signalling via all Janus kinase family members, was effective in phase 2 and 3 trials in moderate-severe ulcerative colitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158411",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 564,
                    "text": "Among them, Janus kinase (JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF na\u00efve and anti-TNF experienced patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28164724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1116,
                    "text": "Near future conventional drug options include oral agents such as tofacitinib and mongersen. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28475384",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 781,
                    "text": "Tofacitinib showed dose related efficacy for induction therapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503977",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2243,
                    "offsetInEndSection": 2404,
                    "text": "CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 96,
                    "offsetInEndSection": 295,
                    "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "<b>BACKGROUND</b>: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1932,
                    "offsetInEndSection": 2444,
                    "text": "Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was associated with increased lipid levels.<br><b>CONCLUSIONS</b>: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 96,
                    "offsetInEndSection": 294,
                    "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790099",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2249,
                    "offsetInEndSection": 2409,
                    "text": "CONCLUSIONS In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 409,
                    "text": "Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn's disease according to phase 2 trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27663846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2066,
                    "offsetInEndSection": 2252,
                    "text": "CONCLUSIONS Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1996,
                    "offsetInEndSection": 2285,
                    "text": "Three patients treated with tofacitinib had an absolute neutrophil count of less than 1500.<br><b>CONCLUSIONS</b>: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 2467,
                    "text": "tofacitinib an oral small molecule janus kinase inhibitor was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial we further evaluated the efficacy of tofacitinib as induction and maintenance therapy we conducted three phase 3 randomized double blind placebo controlled trials of tofacitinib therapy in adults with ulcerative colitis in the octave induction 1 and 2 trials 598 and 541 patients respectively who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib 10 mg twice daily or placebo for 8 weeks the primary end point was remission at 8 weeks in the octave sustain trial 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib either 5 mg or 10 mg twice daily or placebo for 52 weeks the primary end point was remission at 52 weeks in the octave induction 1 trial remission at 8 weeks occurred in 18 5 of the patients in the tofacitinib group versus 8 2 in the placebo group p 0 007 in the octave induction 2 trial remission occurred in 16 6 versus 3 6 p 0 001 in the octave sustain trial remission at 52 weeks occurred in 34 3 of the patients in the 5 mg tofacitinib group and 40 6 in the 10 mg tofacitinib group versus 11 1 in the placebo group p 0 001 for both comparisons with placebo in the octave induction 1 and 2 trials the rates of overall infection and serious infection were higher with tofacitinib than with placebo in the octave sustain trial the rate of serious infection was similar across the three treatment groups and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo across all three trials adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo as compared with placebo tofacitinib was associated with increased lipid levels in patients with moderately to severely active ulcerative colitis tofacitinib was more effective as induction and maintenance therapy than placebo funded by pfizer octave induction 1 octave induction 2 and octave sustain clinicaltrials gov numbers nct01465763 nct01458951 and nct01458574 respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 2176,
                    "text": "ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective one additional treatment may be tofacitinib cp 690 550 an oral inhibitor of janus kinases 1 2 and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2 which is expected to block signaling involving gamma chain containing cytokines including interleukins 2 4 7 9 15 and 21 these cytokines are integral to lymphocyte activation function and proliferation in a double blind placebo controlled phase 2 trial we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis patients were randomly assigned to receive tofacitinib at a dose of 0 5 mg 3 mg 10 mg or 15 mg or placebo twice daily for 8 weeks the primary outcome was a clinical response at 8 weeks defined as an absolute decrease from baseline in the score on the mayo scoring system for assessment of ulcerative colitis activity possible score 0 to 12 with higher scores indicating more severe disease of 3 or more and a relative decrease from baseline of 30 or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an absolute rectal bleeding subscore of 0 or 1 the primary outcome clinical response at 8 weeks occurred in 32 48 61 and 78 of patients receiving tofacitinib at a dose of 0 5 mg p 0 39 3 mg p 0 55 10 mg p 0 10 and 15 mg p 0 001 respectively as compared with 42 of patients receiving placebo clinical remission defined as a mayo score 2 with no subscore 1 at 8 weeks occurred in 13 33 48 and 41 of patients receiving tofacitinib at a dose of 0 5 mg p 0 76 3 mg p 0 01 10 mg p 0 001 and 15 mg p 0 001 respectively as compared with 10 of patients receiving placebo there was a dose dependent increase in both low density and high density lipoprotein cholesterol three patients treated with tofacitinib had an absolute neutrophil count of less than 1500 patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo funded by pfizer clinicaltrials gov number nct00787202.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 851,
                    "text": "recently several medical treatments for ulcerative colitis uc have been developed including 5 aminosalicylic acids 5 asas corticosteroids thiopurine calcineurin inhibitors and anti tumor necrosis factor tnf \u03b1 treatments treatment options including calcineurin inhibitors and anti tnf treatment for refractory uc are discussed in this article furthermore upcoming treatments are introduced such as golimumab vedolizumab ajm300 tofacitinib budesonide foamwill be used as one treatment option in patients with distal colitis herbal medicine such as qing dai is also effective for active uc and may be useful for patients who are refractory to anti tnf\u03b1 treatments in the near future physicians will able to use many different treatments for uc patients however we should not forget 5 asa and corticosteroids as the fundamental treatments for uc patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1420,
                    "text": "the inflammatory diseases ulcerative colitis and crohn s disease constitute the two main forms of inflammatory bowel disease ibd they are characterized by chronic relapsing inflammation of the gastrointestinal tract significantly impacting on patient quality of life and often requiring prolonged treatment existing therapies for ibd are not effective for all patients and an unmet need exists for additional therapies to induce and maintain remission here we describe the mechanism of action of the janus kinase jak inhibitor tofacitinib for the treatment of ibd and the effect of jak inhibition on the chronic cycle of inflammation that is characteristic of the disease the pathogenesis of ibd involves a dysfunctional response from the innate and adaptive immune system resulting in overexpression of multiple inflammatory cytokines many of which signal through jaks thus jak inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in ibd thereby interrupting the cycle of inflammation tofacitinib is an oral small molecule jak inhibitor that is being investigated as a targeted immunomodulator for ibd clinical development of tofacitinib and other jak inhibitors is ongoing with the aspiration of providing new treatment options for ibd that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608188",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is CTCF bound at nucleosome free regions?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30188887",
                "http://www.ncbi.nlm.nih.gov/pubmed/21249180",
                "http://www.ncbi.nlm.nih.gov/pubmed/16877759",
                "http://www.ncbi.nlm.nih.gov/pubmed/30414923",
                "http://www.ncbi.nlm.nih.gov/pubmed/25348714"
            ],
            "ideal_answer": [
                "yes, robust inter-nucleosomal interactions exist around transcription start site (TSS), transcription termination sites (TTS) or around CTCF binding sites",
                "nucleosome occupancy at nucleosome-free regions (NFRs), many of which are located at sites occupied by the multivalent factors Ctcf and cohesin.",
                "Nucleosome occupancy is reduced at nucleosome-free regions (NFRs), many of which are located at sites occupied by the multivalent factors CTCF and cohesin.  Robust inter-nucleosomal interactions exist around transcription start site (TSS), transcription termination sites (TTS) or around CTCF binding sites",
                "Nucleosome occupancy at nucleosome-free regions (nfrs), many of which are located at sites occupied by the multivalent factors ctcf and cohesin. This general architectural change correlate with enhanced binding of ct cf and more pronounced insulation across chromatin boundaries in lineage-committed cells.",
                "robust inter-nucleosomal interactions exist around transcription start site (TSS), transcription termination sites (TTS) or around CTCF binding sites"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d371ec97bc3fee31f00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 928,
                    "offsetInEndSection": 1081,
                    "text": "Nucleosome depletion at 5'-HS4 was dependent on interaction of the insulator protein CCCTC-binding factor (CTCF) and was required for enhancer blocking. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16877759",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 553,
                    "offsetInEndSection": 946,
                    "text": "Here, we show that promoter classes are significantly differentiated by nucleosome organization and chromatin structure. Dispersed promoters display higher associations with well-positioned nucleosomes downstream of the TSS and a more clearly defined nucleosome free region upstream, while focused promoters have a less organized nucleosome structure, yet higher presence of RNA polymerase II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 948,
                    "offsetInEndSection": 1130,
                    "text": "hese differences extend to histone variants (H2A.Z) and marks (H3K4 methylation), as well as insulator binding (such as CTCF), independent of the expression levels of affected genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 649,
                    "text": "nucleosome occupancy at nucleosome-free regions (NFRs), many of which are located at sites occupied by the multivalent factors Ctcf and cohesin. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348714",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 772,
                    "text": "This general architectural change correlates with enhanced binding of CTCF and cohesins and more pronounced insulation of contacts across chromatin boundaries in lineage-committed cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30414923",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 837,
                    "text": "robust inter-nucleosomal interactions exist around transcription start site (TSS), transcription termination sites (TTS) or around CTCF binding sites",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30188887",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a disease or condition called Exploding Head Syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                "http://www.ncbi.nlm.nih.gov/pubmed/24703829",
                "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                "http://www.ncbi.nlm.nih.gov/pubmed/20726288",
                "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                "http://www.ncbi.nlm.nih.gov/pubmed/11309216",
                "http://www.ncbi.nlm.nih.gov/pubmed/28385085",
                "http://www.ncbi.nlm.nih.gov/pubmed/2030791",
                "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                "http://www.ncbi.nlm.nih.gov/pubmed/23467433"
            ],
            "ideal_answer": [
                "Exploding head syndrome (EHS) is characterized by loud noises or a sense of explosion in the head during sleep transitions."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a8ee9d1fcd1d6a10c000027",
            "snippets": [
                {
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 293,
                    "text": "This case report describes the first-ever diagnosis of exploding head syndrome in a patient with longstanding epilepsy and novel nocturnal events. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 134,
                    "text": "Exploding head syndrome (EHS) is characterized by loud noises or a sense of explosion in the head during sleep transitions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385085",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 206,
                    "text": "Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Exploding head syndrome is characterized by the perception of abrupt, loud noises when going to sleep or waking up.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24703829",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 15,
                    "offsetInEndSection": 148,
                    "text": "xploding head syndrome (EHS) is a rare parasomnia in which affected individuals awaken from sleep with the sensation of a loud bang. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1141,
                    "offsetInEndSection": 1272,
                    "text": "Contrary to some earlier theorizing, exploding head syndrome was found to be a relatively common experience in younger individuals.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Fifty patients suffering from the \"exploding head syndrome\" are described.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 375,
                    "text": "In spite of the fact that its characteristic symptomatology was first described approximately 150 y ago, exploding head syndrome has received relatively little empirical and clinical attention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24703829",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 693,
                    "text": "After first discussing the history, prevalence, and associated features, the available polysomnography data and five main etiological theories for exploding head syndrome are summarized.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24703829",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "text": "Exploding head syndrome: six new cases and review of the literature.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Exploding Head Syndrome in the Epilepsy Monitoring Unit: Case Report and Literature Review.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 39,
                    "text": "Exploding head syndrome: a case report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 54,
                    "text": "Exploding head syndrome is common in college students.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1141,
                    "text": "Exploding head syndrome episodes were accompanied by clinically significant levels of fear, and a minority (2.80%) experienced it to such a degree that it was associated with clinically significant distress and/or impairment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "text": "Attention has recently been drawn to a condition termed the exploding head syndrome, which is characterized by unpleasant, even terrifying sensations of flashing lights and/or sounds during reported sleep.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Exploding head syndrome is a rare phenomenon but can be a significant disruption to quality of life.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726288",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 610,
                    "offsetInEndSection": 704,
                    "text": "The rare headache disorder hypnic headache and the exploding head syndrome are also discussed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 292,
                    "text": "This case report describes the first-ever diagnosis of exploding head syndrome in a patient with longstanding epilepsy and novel nocturnal events.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "text": "BACKGROUND Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "INTRODUCTION Exploding head syndrome (EHS) is a rare parasomnia in which affected individuals awaken from sleep with the sensation of a loud bang.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1273,
                    "text": "Contrary to some earlier theorizing, exploding head syndrome was found to be a relatively common experience in younger individuals.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 210,
                    "text": "This hitherto unreported syndrome is characterised by a sense of an explosive noise in the head usually in the twilight stage of sleep.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1011,
                    "offsetInEndSection": 1070,
                    "text": "EHS is a well-defined disease entity with a benign nature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 40,
                    "text": "Exploding head syndrome: a case report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 50,
                    "text": "Clinical features of the exploding head syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 55,
                    "text": "Exploding head syndrome is common in college students.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "The exploding head syndrome: polysomnographic recordings and therapeutic suggestions.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "This article reviews the features of an uncommon malady termed \"the exploding head syndrome.\" Sufferers describe terrorizing attacks of a painless explosion within their head",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11309216",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "The case is reported of a 47-year old female suffering from the exploding head syndrome. This syndrome consists of a sudden awakening due to a loud noise shortly after falling asleep, sometimes accompanied by a flash of light.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2030791",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is gastro esophageal reflux related to burning mouth syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8725589",
                "http://www.ncbi.nlm.nih.gov/pubmed/17849966",
                "http://www.ncbi.nlm.nih.gov/pubmed/3244997",
                "http://www.ncbi.nlm.nih.gov/pubmed/23201368",
                "http://www.ncbi.nlm.nih.gov/pubmed/10546306",
                "http://www.ncbi.nlm.nih.gov/pubmed/21359587",
                "http://www.ncbi.nlm.nih.gov/pubmed/10431669",
                "http://www.ncbi.nlm.nih.gov/pubmed/12617256",
                "http://www.ncbi.nlm.nih.gov/pubmed/14969159",
                "http://www.ncbi.nlm.nih.gov/pubmed/11871678",
                "http://www.ncbi.nlm.nih.gov/pubmed/18343329",
                "http://www.ncbi.nlm.nih.gov/pubmed/23050296",
                "http://www.ncbi.nlm.nih.gov/pubmed/24096230",
                "http://www.ncbi.nlm.nih.gov/pubmed/23589947",
                "http://www.ncbi.nlm.nih.gov/pubmed/8543701",
                "http://www.ncbi.nlm.nih.gov/pubmed/9237148",
                "http://www.ncbi.nlm.nih.gov/pubmed/18284539",
                "http://www.ncbi.nlm.nih.gov/pubmed/19938882",
                "http://www.ncbi.nlm.nih.gov/pubmed/23809306",
                "http://www.ncbi.nlm.nih.gov/pubmed/19658340",
                "http://www.ncbi.nlm.nih.gov/pubmed/1873324",
                "http://www.ncbi.nlm.nih.gov/pubmed/15773524",
                "http://www.ncbi.nlm.nih.gov/pubmed/18625105",
                "http://www.ncbi.nlm.nih.gov/pubmed/16637799",
                "http://www.ncbi.nlm.nih.gov/pubmed/18313197"
            ],
            "ideal_answer": [
                "No data indicate causal connection between gastro esophageal/laryngopharyngeal(LPR)  reflux disease and the occurrence of intraoral burning sensations"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002054",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005764",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004941",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004935",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004942",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009059",
                "http://www.disease-ontology.org/api/metadata/DOID:8534",
                "http://www.disease-ontology.org/api/metadata/DOID:4331"
            ],
            "type": "yesno",
            "id": "5321ae889b2d7acc7e000006",
            "snippets": [
                {
                    "offsetInBeginSection": 1082,
                    "offsetInEndSection": 1234,
                    "text": "Our results suggest that there is no causal connection between LPR episodes and the occurrence of intraoral burning sensations in the examined patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21359587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 555,
                    "offsetInEndSection": 803,
                    "text": "As reported below, although this symptom may well be diagnostically misleading, careful diagnosis based on clinical signs may distinguish patients with BMS from those with reflux disease, and successful management of burning mouth is often enables.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15773524",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Lennox-Gastaut Syndrome usually diagnosed in older adults?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22576075",
                "http://www.ncbi.nlm.nih.gov/pubmed/8029151",
                "http://www.ncbi.nlm.nih.gov/pubmed/19588340",
                "http://www.ncbi.nlm.nih.gov/pubmed/26166587",
                "http://www.ncbi.nlm.nih.gov/pubmed/24659735",
                "http://www.ncbi.nlm.nih.gov/pubmed/20542434",
                "http://www.ncbi.nlm.nih.gov/pubmed/26945476",
                "http://www.ncbi.nlm.nih.gov/pubmed/9400037",
                "http://www.ncbi.nlm.nih.gov/pubmed/20518600"
            ],
            "ideal_answer": [
                "Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography.",
                "lennox-gastaut syndrome (lgs) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 hz) spike wave discharges on electroencephalography.",
                " children with Lennox-Gastaut syndrome Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:0050561",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065768"
            ],
            "type": "yesno",
            "id": "58dbb4f08acda3452900001a",
            "snippets": [
                {
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 729,
                    "text": "We studied 15 LGS patients (mean age \u00b1 1 standard deviation [SD] = 28.7 \u00b1 10.6 years) and 17 healthy controls (mean age \u00b1 1 SD = 27.6 \u00b1 6.6 years)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26945476",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 129,
                    "text": " children with Lennox-Gastaut syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659735",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "Clinical course and results of therapy were analysed in the group of 92 children, aged between 3 and 9 years, with diagnosed Lennox-Gastaut syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8029151",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 659,
                    "text": "We report the case of a 27-year-old man with a neurodevelopmental syndrome due to a 15q duplication, with intellectual disability, psychiatric disturbances, and an epileptic phenotype diagnosed as late-onset Lennox-Gastaut syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22576075",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "Lennox-Gastaut Syndrome is a severe childhood epilepsy syndrome characterised by the diagnostic triad of a slow spike and wave pattern on electroencephalogram, multiple seizure types and developmental delay",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20542434",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 660,
                    "text": "We report the case of a 27-year-old man with a neurodevelopmental syndrome due to a 15q duplication, with intellectual disability, psychiatric disturbances, and an epileptic phenotype diagnosed as late-onset Lennox-Gastaut syndrome..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22576075",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "The Lennox-Gastaut syndrome, a severe form of epilepsy that usually begins in early childhood, is difficult to treat.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9400037",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "text": "Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 400,
                    "text": "The Lennox-Gastaut syndrome is an age-specific disorder, characterised by epileptic seizures, a characteristic electroencephalogram (EEG), psychomotor delay and behaviour disorders. It occurs more frequently in males and onset is usually before the age of eight, with a peak between three and five years. Late cases occurring in adolescence and early adulthood have rarely been reported. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19588340",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are messenger RNA molecules epigenetically methylated?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26121403",
                "http://www.ncbi.nlm.nih.gov/pubmed/24768686",
                "http://www.ncbi.nlm.nih.gov/pubmed/25469751",
                "http://www.ncbi.nlm.nih.gov/pubmed/24480744",
                "http://www.ncbi.nlm.nih.gov/pubmed/25378335",
                "http://www.ncbi.nlm.nih.gov/pubmed/26458103",
                "http://www.ncbi.nlm.nih.gov/pubmed/25430002"
            ],
            "ideal_answer": [
                "Yes, methyltranscriptome is an exciting new area that studies the mechanisms and functions of methylation in transcripts."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012333",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0080188",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0032259",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008745",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0036265",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001510"
            ],
            "type": "yesno",
            "id": "56d2ee61f22319765a000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "The most abundant mRNA post-transcriptional modification is N(6)-methyladenosine (m(6)A), which has broad roles in RNA biology.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26458103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "N(6)-methyladenosine (m6A) is the most abundant modified base in eukaryotic mRNA and has been linked to diverse effects on mRNA fate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26121403",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 489,
                    "offsetInEndSection": 742,
                    "text": " Recently, methylation patterns have also been revealed in mRNA. Surprisingly, the two most commonly studied methylation states in mRNA (m6A and m5C) are found to be enriched in 3'-UTRs (untranslated regions), the target site for the majority of miRNAs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25469751",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "MeT-DB: a database of transcriptome methylation in mammalian cells",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378335",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "text": "Methyltranscriptome is an exciting new area that studies the mechanisms and functions of methylation in transcripts. The MethylTranscriptome DataBase (MeT-DB, http://compgenomics.utsa.edu/methylation/) is the first comprehensive resource for N6-methyladenosine (m(6)A) in mammalian transcriptome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378335",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 266,
                    "text": "Mammalian messenger RNA (mRNA) and long noncoding RNA (lncRNA) contain tens of thousands of posttranscriptional chemical modifications. Among these, the N(6)-methyl-adenosine (m(6)A) modification is the most abundant and can be removed by specific mammalian enzymes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24768686",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 221,
                    "text": "Recent discoveries of reversible N(6)-methyladenosine (m(6)A) methylation on messenger RNA (mRNA) and mapping of m(6)A methylomes in mammals and yeast have revealed potential regulatory functions of this RNA modification.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430002",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 543,
                    "text": "There are several identified methylation modifications in eukaryotic messenger RNA (mRNA), such as N(7)-methylguanosine (m(7)G) at the cap, N(6)-methyl-2'-O-methyladenosine (m(6)Am), 2'-O-methylation (Nm) within the cap and the internal positions, and internal N(6)-methyladenosine (m(6)A) and 5-methylcytosine (m(5)C).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24480744",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is TNF-\u03b1 an activator of pancreatic stellate cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24089530",
                "http://www.ncbi.nlm.nih.gov/pubmed/20689058"
            ],
            "ideal_answer": [
                "Yes,\nTNF-\u03b1  is the prime factor responsible for the activation of pancreatic stellate cells."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c9f0dabecadf2e73f00003b",
            "snippets": [
                {
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 910,
                    "text": "TNF-\u03b1 is the prime factor responsible for the activation of pancreatic stellate cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24089530",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 735,
                    "text": "Activated PSCs expressed IL-33 in the nucleus, and the expression was increased by IL-1\u03b2, TNF-\u03b1, PDGF-BB, and IFN-\u03b3, but not TGF-\u03b21. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689058",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is a mutation of the  ZIKV's membrane protein prM responsible for the microcephaly in new-born infants?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28971967"
            ],
            "ideal_answer": [
                "Yes, a single mutation in the prM protein of Zika virus contributes to fetal microcephaly."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ac0aee419833b0d7b000004",
            "snippets": [
                {
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 557,
                    "text": "Here we show that a single serine-to-asparagine substitution [Ser139\u2192Asn139(S139N)] in the viral polyprotein substantially increased ZIKV infectivity in both human and mouse neural progenitor cells (NPCs) and led to more severe microcephaly in the mouse fetus, as well as higher mortality rates in neonatal mice.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971967",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "A single mutation in the prM protein of Zika virus contributes to fetal microcephaly.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971967",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does the hERG gene code for a protein which is part of a sodium channel?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26363003",
                "http://www.ncbi.nlm.nih.gov/pubmed/24475291",
                "http://www.ncbi.nlm.nih.gov/pubmed/18250496",
                "http://www.ncbi.nlm.nih.gov/pubmed/14975928",
                "http://www.ncbi.nlm.nih.gov/pubmed/25498859",
                "http://www.ncbi.nlm.nih.gov/pubmed/8521555",
                "http://www.ncbi.nlm.nih.gov/pubmed/25247487",
                "http://www.ncbi.nlm.nih.gov/pubmed/17882949",
                "http://www.ncbi.nlm.nih.gov/pubmed/16244363",
                "http://www.ncbi.nlm.nih.gov/pubmed/9556090",
                "http://www.ncbi.nlm.nih.gov/pubmed/19139152",
                "http://www.ncbi.nlm.nih.gov/pubmed/25218469",
                "http://www.ncbi.nlm.nih.gov/pubmed/24154981",
                "http://www.ncbi.nlm.nih.gov/pubmed/8873679",
                "http://www.ncbi.nlm.nih.gov/pubmed/10613047",
                "http://www.ncbi.nlm.nih.gov/pubmed/23103450",
                "http://www.ncbi.nlm.nih.gov/pubmed/12142119",
                "http://www.ncbi.nlm.nih.gov/pubmed/8995352",
                "http://www.ncbi.nlm.nih.gov/pubmed/24642409",
                "http://www.ncbi.nlm.nih.gov/pubmed/16472284",
                "http://www.ncbi.nlm.nih.gov/pubmed/16967046",
                "http://www.ncbi.nlm.nih.gov/pubmed/12063277",
                "http://www.ncbi.nlm.nih.gov/pubmed/17311278",
                "http://www.ncbi.nlm.nih.gov/pubmed/10816797",
                "http://www.ncbi.nlm.nih.gov/pubmed/26775140",
                "http://www.ncbi.nlm.nih.gov/pubmed/24045971",
                "http://www.ncbi.nlm.nih.gov/pubmed/26659724",
                "http://www.ncbi.nlm.nih.gov/pubmed/26519040",
                "http://www.ncbi.nlm.nih.gov/pubmed/8587608",
                "http://www.ncbi.nlm.nih.gov/pubmed/23792956",
                "http://www.ncbi.nlm.nih.gov/pubmed/9272507",
                "http://www.ncbi.nlm.nih.gov/pubmed/10531299",
                "http://www.ncbi.nlm.nih.gov/pubmed/9570196",
                "http://www.ncbi.nlm.nih.gov/pubmed/18617000",
                "http://www.ncbi.nlm.nih.gov/pubmed/9272155",
                "http://www.ncbi.nlm.nih.gov/pubmed/10483966"
            ],
            "ideal_answer": [
                "The hERG AKA Human ether-a-go-go-related gene coded for a protein subunit of a potassium channel that conducts delayed rectifier K(+) current"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "58bdc76102b8c60953000013",
            "snippets": [
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 115,
                    "text": " The human ether-\u00e0-go-go-related gene (hERG 1a) potassium channel is critical for cardiac repolarization",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775140",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Human ether-a-go-go-related gene (hERG) channels conduct delayed rectifier K(+) current. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26659724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 939,
                    "offsetInEndSection": 1187,
                    "text": "The KvLQT1 and minK genes code the slowly activating, delayed rectifier (Iks) potassium channel, the HERG gene code the rapidly activating, delayed rectifier (Ikr) potassium channel of the heart, while the SCN5A gene codes a cardiac sodium channel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 432,
                    "offsetInEndSection": 705,
                    "text": "The molecular basis of inherited disorders caused by a mutation in either the gene coding for a particular potassium channel called HERG-or another gene, SCN5A, which codes for the sodium channel and disruption of which results in a loss of inactivation of the Na+ current.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "The aim of this study was to test whether a recently reported polymorphism in the HERG gene coding for the rapidly activating delayed rectifier K+ channel has influence on myocardial repolarization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12142119",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1426,
                    "text": "Mutations in KvLQT1, minK and HERG genes affects repolarising, rectifier potassium currents, while SCN5A mutations cause delayed inactivation and reopening of the cardiac sodium channel, which initiates the depolarisation of cardiac cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8587608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1433,
                    "offsetInEndSection": 1612,
                    "text": "Therefore, matrine and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing hERG channel expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103450",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "The human delta1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8995352",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "HERG (human eag-related gene) encodes an inward-rectifier potassium channel formed by the assembly of four subunits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8995352",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "The human ether-?-go-go-related gene (HERG) encodes the pore-forming subunit of the rapidly activating delayed rectifier potassium channel in the heart.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063277",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "The human ether-a-go-go-related gene (hERG) encodes the rapidly activating, delayed rectifier potassium channel (IKr) important for cardiac repolarization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103450",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Role of glycosylation in cell surface expression and stability of HERG potassium channels.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063277",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "text": "The human ERG protein (HERG or Kv 11.1) encoded by the human ether-a-go-go-related gene (herg) is the pore-forming subunit of the cardiac delayed rectifier potassium current (IKr) responsible for action potential (AP) repolarization",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24154981",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Human ether-a-go-go related gene (herg) encoding HERG K(+) channel has been demonstrated in many previous studies with its association to cell cycle progression and growth in tumor cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25247487",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8587608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16967046",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "OBJECTIVES: The aim of this study was to test whether a recently reported polymorphism in the HERG gene coding for the rapidly activating delayed rectifier K+ channel has influence on myocardial repolarization. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12142119",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 477,
                    "text": "The aim of this study was to test whether the K897T polymorphism of the KCNH2 (HERG) gene coding for the rapidly activating delayed rectifier K+ channel influences cardiac repolarization assessed by principal component analysis (PCA) of T-wave morphology. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472284",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1192,
                    "text": "The KvLQT1 and minK genes code the slowly activating, delayed rectifier (Iks) potassium channel, the HERG gene code the rapidly activating, delayed rectifier (Ikr) potassium channel of the heart, while the SCN5A gene codes a cardiac sodium channel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 953,
                    "offsetInEndSection": 1264,
                    "text": "All code for subunits of sodium or potassium channels: two a subunits of the potassium channels (QVLQT1 for LQT1, HERG for LQT2), the a subunit of the sodium channel INa (SCN5A for LQT3), and two regulatory subunits of potassium channels (KCNE1 for LQT5 regulating the KvLQT1 channel and MiRP1 regulating HERG).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10816797",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 563,
                    "text": "The corresponding genes code for potassium channels KVLQT1 (LQT1) and HERG (LQT2) and the sodium channel SCN5A (LQT3).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272155",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 709,
                    "text": "The molecular basis of inherited disorders caused by a mutation in either the gene coding for a particular potassium channel called HERG-or another gene, SCN5A, which codes for the sodium channel and disruption of which results in a loss of inactivation of the Na+ current.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1449,
                    "text": "There may also be correlation between the strength of binding of the medicinal substance to the potassium channel coded by the HERG gene and prolongation of the QT interval.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 723,
                    "text": "We demonstrate that the mRNA 3'UTR of ppk29 affects neuronal firing rates and associated heat-induced seizures by acting as a natural antisense transcript (NAT) that regulates the neuronal mRNA levels of seizure (sei), the Drosophila homolog of the human Ether-\u00e0-go-go Related Gene (hERG) potassium channel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642409",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1193,
                    "offsetInEndSection": 1432,
                    "text": "Mutations in KvLQT1, minK and HERG genes affects repolarising, rectifier potassium currents, while SCN5A mutations cause delayed inactivation and reopening of the cardiac sodium channel, which initiates the depolarisation of cardiac cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 710,
                    "offsetInEndSection": 903,
                    "text": "Among the congenital forms, particularly interest is focused on the potassium channel coded by the HERG gene located on chromosome 7 and with a key role in the normal electric cardiac activity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 531,
                    "text": "By employing heterologous expression and making comparisons to cells expressing wild-type human-ether-a-go-go-related protein (HERG), a potassium channel that contributes to I(Kr) current in ventricular cardiomyocytes, we demonstrate activation of an elevated endoplasmic reticulum (ER) stress response by the mutant I593R HERG potassium channel implicated in long QT syndrome type 2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531299",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 493,
                    "offsetInEndSection": 603,
                    "text": "Mutations in the human ether-\u00e0-go-go-related gene (HERG), which encodes a delayed-rectifier potassium channel,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8873679",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 413,
                    "text": "s HERG and KvLQT1 potassium channel genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272507",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 722,
                    "offsetInEndSection": 771,
                    "text": "HERG encodes the cardiac I(Kr) potassium channel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9556090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 239,
                    "text": "block of the cardiac potassium channel human ether-\u00e0-go-go-related gene (hERG) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139152",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "text": "The human ether-a-go-go-related gene (hERG) encodes the pore-forming \u03b1-subunit of the rapidly activating delayed rectifier K(+) channel in the heart, which plays a critical role in cardiac action potential repolarization. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23792956",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 48,
                    "text": "Effects of donepezil on hERG potassium channels.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25498859",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Human ether-a-go-go related-gene K\u207a channels (hERG) participate in the regulation of tumor cell proliferation and apoptosis. HERG channel activity is up-regulated by growth factors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24475291",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 45,
                    "text": " hERG potassium channels",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045971",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 185,
                    "text": "HERG, a K+ channel gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8521555",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can LB-100 sensitize ovarian carcinoma to cisplatin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25376608"
            ],
            "ideal_answer": [
                "Yes, LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e29f959aa19d74431000004",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376608",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 892,
                    "text": "LB100 sensitized ovarian carcinoma lines to cisplatin-mediated cell death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1666,
                    "text": "Our results suggest that LB100 sensitizes ovarian cancer cells to cisplatin in vitro and in vivo by modulation of the DDR pathway and cell-cycle checkpoint abrogation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376608",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can the yeast protein Abf1 act as insulator?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12200417"
            ],
            "ideal_answer": [
                "Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity",
                "yes",
                "Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a857bfffaa1ab7d2e000030",
            "snippets": [
                {
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 187,
                    "text": "Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 424,
                    "text": "Insulating domains in Rap1p coincide with previously described transcription activation domains, whereas four adjacent subdomains spanning the whole of the Abf1p C terminus (440-731) were found to display autonomous insulating capacity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 658,
                    "text": "That both Rap1p and Abf1p silencing domains either contain or largely overlap with an insulating domain suggests that insulation conveys some undefined chromosome organization capacity that also contributes a function in silencing. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is apixaban effective for treatment of acute venous thromboembolism?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18393142",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084658",
                "http://www.ncbi.nlm.nih.gov/pubmed/22153026",
                "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
                "http://www.ncbi.nlm.nih.gov/pubmed/23808982",
                "http://www.ncbi.nlm.nih.gov/pubmed/24554904",
                "http://www.ncbi.nlm.nih.gov/pubmed/19014462",
                "http://www.ncbi.nlm.nih.gov/pubmed/22795419",
                "http://www.ncbi.nlm.nih.gov/pubmed/23233582",
                "http://www.ncbi.nlm.nih.gov/pubmed/19308891",
                "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
                "http://www.ncbi.nlm.nih.gov/pubmed/24278706",
                "http://www.ncbi.nlm.nih.gov/pubmed/23822763",
                "http://www.ncbi.nlm.nih.gov/pubmed/23117646"
            ],
            "ideal_answer": [
                "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.",
                "Yes, apixaban is effective for treatment of acute venous thromboembolismis. Apixiban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013923",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020246",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054556",
                "http://www.biosemantics.org/jochem#4243936"
            ],
            "type": "yesno",
            "id": "52fc94572059c6d71c000070",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1132,
                    "text": "These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1718,
                    "offsetInEndSection": 1898,
                    "text": "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 186,
                    "text": "To critically review the effectiveness of the novel oral anticoagulants (rivaroxaban, dabigatran, ximelagatran, and apixaban) in the treatment of acute venous thromboembolism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2087,
                    "offsetInEndSection": 2308,
                    "text": "ompared with vitamin K antagonists, the novel oral anticoagulants had a similar risk of recurrence of acute venous thromboembolism and all cause mortality, though rivaroxaban was associated with a reduced risk of bleeding",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 329,
                    "text": "Nowadays, the new anticoagulants, such as dabigatran, rivaroxaban and apixaban, show potential advantages over classical treatments. These agents inhibit specific coagulation factors and are administered orally at fixed doses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117646",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1192,
                    "offsetInEndSection": 1308,
                    "text": "In a recently completed phase III trial, apixaban also demonstrated promising efficacy and safety in that indication",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795419",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 419,
                    "text": "the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18393142",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does physical activity influence gut hormones?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2888163",
                "http://www.ncbi.nlm.nih.gov/pubmed/23402716",
                "http://www.ncbi.nlm.nih.gov/pubmed/18987287",
                "http://www.ncbi.nlm.nih.gov/pubmed/11321513",
                "http://www.ncbi.nlm.nih.gov/pubmed/21554896",
                "http://www.ncbi.nlm.nih.gov/pubmed/22619704",
                "http://www.ncbi.nlm.nih.gov/pubmed/19158129",
                "http://www.ncbi.nlm.nih.gov/pubmed/16942616",
                "http://www.ncbi.nlm.nih.gov/pubmed/15795476",
                "http://www.ncbi.nlm.nih.gov/pubmed/20690071",
                "http://www.ncbi.nlm.nih.gov/pubmed/23111564",
                "http://www.ncbi.nlm.nih.gov/pubmed/19737911",
                "http://www.ncbi.nlm.nih.gov/pubmed/21615652",
                "http://www.ncbi.nlm.nih.gov/pubmed/17470516",
                "http://www.ncbi.nlm.nih.gov/pubmed/21927572",
                "http://www.ncbi.nlm.nih.gov/pubmed/20061436"
            ],
            "ideal_answer": [
                "Yes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015444"
            ],
            "type": "yesno",
            "id": "5158644cd24251bc0500008e",
            "snippets": [
                {
                    "offsetInBeginSection": 1052,
                    "offsetInEndSection": 1259,
                    "text": "Increases in blood PYY(3-36) levels were dependent on the exercise intensity (effect of session: P<0.001 by two-way ANOVA), whereas those in GLP-1 levels were similar between two different exercise sessions.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737911",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1289,
                    "offsetInEndSection": 1430,
                    "text": "A decrease in serum leptin levels (-48.4%, p < 0.001) was observed after intervention without changes in total peptide YY and insulin levels.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615652",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1576,
                    "offsetInEndSection": 1765,
                    "text": "ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554896",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1102,
                    "offsetInEndSection": 1165,
                    "text": "Hunger and gut hormones remained unchanged during the bed rest.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20061436",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1309,
                    "text": "weight-bearing exercise has a greater exercise-induced appetite suppressive effect compared with non-weight-bearing exercise, and both forms of exercise lowered acylated ghrelin and increased total PYY, but the changes did not differ significantly between exercise modes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23402716",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1211,
                    "text": "Appetite (P\u00a0<\u00a00.0005) and acylated ghrelin (P\u00a0<\u00a00.002) were suppressed during exercise but more so during SIE. Peptide YY increased during exercise but most consistently during END (P\u00a0<\u00a00.05). Acylated ghrelin was lowest in the afternoon of SIE (P\u00a0=\u00a00.018) despite elevated appetite",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23111564",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1298,
                    "offsetInEndSection": 1791,
                    "text": "Following the pre-exercise meal, ghrelin was suppressed ~17% and insulin and PYY were elevated ~157 and ~40%, respectively, relative to fasting (day 7). Following exercise, PYY, ghrelin, and GH were significantly (p < 0.0001) increased by ~11, ~16 and ~813%, respectively. The noted disruption in the typical inverse relationship between ghrelin and PYY following exercise suggests that interaction of these peptides may be at least partially responsible for post-exercise appetite suppression",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21927572",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 926,
                    "text": "Plasma levels of PYY and GLP-1 were increased by exercise, whereas plasma ghrelin levels were unaffected by exercise",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158129",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1370,
                    "offsetInEndSection": 1457,
                    "text": "These findings suggest ghrelin and PYY may regulate appetite during and after exercise,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18987287",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 913,
                    "offsetInEndSection": 1125,
                    "text": "significant (P < 0.05) interaction effects for hunger, acylated ghrelin, and PYY, indicating suppressed hunger and acylated ghrelin during aerobic and resistance exercise and increased PYY during aerobic exercise",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18987287",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1682,
                    "offsetInEndSection": 1774,
                    "text": "'exercise-induced anorexia' may potentially be linked to increased PYY, GLP-1 and PP levels.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470516",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1271,
                    "offsetInEndSection": 1393,
                    "text": "Hunger scores and PYY, GLP-1 and PP levels showed an inverse temporal pattern during the 1-h exercise/control intervention",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470516",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 969,
                    "text": "Exercise significantly increased mean PYY, GLP-1 and PP levels, and this effect was maintained during the post-exercise period for GLP-1 and PP. No significant effect of exercise was observed on postprandial levels of ghrelin",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470516",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 2370,
                    "offsetInEndSection": 2469,
                    "text": "following blood donation the strenuous exercise resulted in a marked reduction in the plasma leptin",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11321513",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1977,
                    "offsetInEndSection": 2362,
                    "text": "We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11321513",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 811,
                    "text": "the unrestricted exercise group has a significantly elevated SRIF-LI concentration",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2888163",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 360,
                    "offsetInEndSection": 440,
                    "text": "Exercise has recently been reported to influence ghrelin and PYY concentrations.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20690071",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is pesticide exposure associated with polyneuropathy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2158793",
                "http://www.ncbi.nlm.nih.gov/pubmed/23251840",
                "http://www.ncbi.nlm.nih.gov/pubmed/23251841",
                "http://www.ncbi.nlm.nih.gov/pubmed/16140621",
                "http://www.ncbi.nlm.nih.gov/pubmed/21432383",
                "http://www.ncbi.nlm.nih.gov/pubmed/19079407",
                "http://www.ncbi.nlm.nih.gov/pubmed/22728724",
                "http://www.ncbi.nlm.nih.gov/pubmed/23185328",
                "http://www.ncbi.nlm.nih.gov/pubmed/21787602",
                "http://www.ncbi.nlm.nih.gov/pubmed/12718377",
                "http://www.ncbi.nlm.nih.gov/pubmed/7998771",
                "http://www.ncbi.nlm.nih.gov/pubmed/15116371",
                "http://www.ncbi.nlm.nih.gov/pubmed/17107865",
                "http://www.ncbi.nlm.nih.gov/pubmed/11600725",
                "http://www.ncbi.nlm.nih.gov/pubmed/7194975",
                "http://www.ncbi.nlm.nih.gov/pubmed/10528323",
                "http://www.ncbi.nlm.nih.gov/pubmed/21258583",
                "http://www.ncbi.nlm.nih.gov/pubmed/9311548",
                "http://www.ncbi.nlm.nih.gov/pubmed/14691285",
                "http://www.ncbi.nlm.nih.gov/pubmed/16856766",
                "http://www.ncbi.nlm.nih.gov/pubmed/16042503",
                "http://www.ncbi.nlm.nih.gov/pubmed/16702122",
                "http://www.ncbi.nlm.nih.gov/pubmed/19922373",
                "http://www.ncbi.nlm.nih.gov/pubmed/7787373",
                "http://www.ncbi.nlm.nih.gov/pubmed/11843436",
                "http://www.ncbi.nlm.nih.gov/pubmed/21601587",
                "http://www.ncbi.nlm.nih.gov/pubmed/22399093",
                "http://www.ncbi.nlm.nih.gov/pubmed/23703814",
                "http://www.ncbi.nlm.nih.gov/pubmed/22262687",
                "http://www.ncbi.nlm.nih.gov/pubmed/1481520",
                "http://www.ncbi.nlm.nih.gov/pubmed/8160653",
                "http://www.ncbi.nlm.nih.gov/pubmed/11146591",
                "http://www.ncbi.nlm.nih.gov/pubmed/6179111",
                "http://www.ncbi.nlm.nih.gov/pubmed/9592856",
                "http://www.ncbi.nlm.nih.gov/pubmed/11045057",
                "http://www.ncbi.nlm.nih.gov/pubmed/22655091",
                "http://www.ncbi.nlm.nih.gov/pubmed/2707289",
                "http://www.ncbi.nlm.nih.gov/pubmed/2462700",
                "http://www.ncbi.nlm.nih.gov/pubmed/18780003",
                "http://www.ncbi.nlm.nih.gov/pubmed/21120082",
                "http://www.ncbi.nlm.nih.gov/pubmed/1665780"
            ],
            "ideal_answer": [
                "Yes, it is associated with peripheral neuropathy.",
                "Yes, pesticide exposure is associated with delayed polyneuropathy. Electrophysiological studies have revealed three characteristic phenomena: (i) repetitive firing following a single stimulus; (ii) gradual reduction in twitch height or compound muscle action potential followed by an increase with repetitive stimulation (the 'decrement-increment response'); and (iii) continued reduction in twitch height or compound muscle action potential with repetitive simulation ('decrementing response'). Pesticide exposure was also implicated in Alzheimer's disease, suicide attempts and affective disorders."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:1389",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011115",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004781",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016273",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010575"
            ],
            "type": "yesno",
            "id": "530cefaaad0bf1360c000010",
            "snippets": [
                {
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 431,
                    "text": "As the syndrome occurred after the acute cholinergic syndrome but before organophosphate-induced delayed polyneuropathy, the syndrome was called 'intermediate syndrome'.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 1204,
                    "text": "The characteristic features of the IMS are weakness of the muscles of respiration (diaphragm, intercostal muscles and accessory muscles including neck muscles) and of proximal limb muscles. Accompanying features often include weakness of muscles innervated by some cranial nerves. It is now emerging that the degree and extent of muscle weakness may vary following the onset of the IMS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3353,
                    "offsetInEndSection": 3805,
                    "text": "Electrophysiological studies following OP poisoning have revealed three characteristic phenomena: (i) repetitive firing following a single stimulus; (ii) gradual reduction in twitch height or compound muscle action potential followed by an increase with repetitive stimulation (the 'decrement-increment response'); and (iii) continued reduction in twitch height or compound muscle action potential with repetitive simulation ('decrementing response'). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 387,
                    "text": "Organophosphate-induced delayed polyneuropathy is a sensory-motor distal axonopathy which usually occurs after exposure of certain OP insecticides. Neuropathies due to ingestion of OPs have rarely been reported in the literature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 830,
                    "text": "We report a patient with serious organophosphorus-induced delayed neuropathy due to malathion injection. The patient was a 32-year-old female who self-injected undetermined amounts of malathion over the median nerve trace on the forearm crease in a suicide attempt which resulted in peripheral neuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 845,
                    "text": " Acutely, these patients present with cholinergic crisis; intermediate syndrome and delayed polyneuropathy are other sequel of this form of poisoning.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19079407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1667,
                    "offsetInEndSection": 1803,
                    "text": "There was no strong evidence of irreversible peripheral nerve damage following acute OP poisoning, however further studies are required.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1345,
                    "offsetInEndSection": 1613,
                    "text": "Particular interactions are also addressed, such as those of pesticides acting as endocrine disruptors, the cumulative toxicity of organophosphates and organochlorines resulting in estrogenic effects and the promotion of organophosphate-induced delayed polyneuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22728724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1453,
                    "text": "The multivariate analyses showed that the population living in areas with high pesticide use had an increased risk for Alzheimer's disease and suicide attempts and that males living in these areas had increased risks for polyneuropathies, affective disorders and suicide attempts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21601587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 357,
                    "text": "These compounds cause four important neurotoxic effects in humans: the cholinergic syndrome, the intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP) and chronic organophosphate-induced neuropsychiatric disorder (COPIND). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21787602",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 819,
                    "text": "An 18-year-old woman and a 22-year-old man were admitted to the hospital with weakness, paresthesia, and gait disturbances at 35 and 22 days, respectively, after ingesting dimethyl-2,2-dichloro vinyl phosphate (DDVP). Neurological examination revealed weakness, vibration sense loss, bilateral dropped foot, brisk deep tendon reflexes, and bilaterally positive Babinski sign. Electroneurography demonstrated distal motor polyneuropathy with segmental demyelination associated with axonal degeneration prominent in the distal parts of both lower extremities.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19922373",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 741,
                    "offsetInEndSection": 912,
                    "text": "Sensory complaints and electrodiagnostic findings consistent with polyneuropathy were found in a minority (3/7) of subjects 28 years after an acute toxic arsenic exposure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702122",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Organophosphate-induced delayed polyneuropathy (OPIDP) is a rare toxicity resulting from exposure to certain organophosphorus (OP) esters. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16042503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1800,
                    "offsetInEndSection": 1914,
                    "text": "Therefore, OPIDP may develop only after very large exposures to insecticides, causing severe cholinergic toxicity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16042503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Several studies have reported the occurrence of sensory neuropathy with exposure to chlorpyrifos and other organophosphorus insecticides, at levels not associated with overt toxicity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15116371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1478,
                    "text": "We found no evidence of sensory neuropathy or isolated peripheral abnormalities among subjects with long-term chlorpyrifos exposure at levels known to be associated with the manufacturing process.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15116371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1790,
                    "text": "Persistent, mainly motor, impairment of the peripheral nervous system was found in men two years after OP poisoning, in particular in severe occupational and intentional poisonings with neuropathic OPs. This finding is possibly due to remaining organophosphate induced delayed polyneuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14691285",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 284,
                    "text": "Besides the well known acute cholinergic toxicity, these compounds may cause late-onset distal polyneuropathy occurring two to three weeks after the acute exposure. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12718377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 730,
                    "text": "Electromyography demonstrated motor weighed sensory-motor polyneuropathy with axonal degeneration significant in the distal parts of bilateral lower extremities. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12718377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1055,
                    "text": "The two cases are presented here since organophosphate poisonings are common in our country, and since late-onset polyneuropathy is not a well known clinical presentation as acute toxicity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12718377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "The course of organophosphate-induced delayed polyneuropathy (OPIDP) in humans has not been quantitatively measured in epidemiologic studies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843436",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1443,
                    "text": "The persistence of deficits in motor strength in all severely poisoned patients regardless of pesticide type was unexpected, and may reflect persistent cholinergic blockade or intermediate syndrome, neuropathy, or a combination of these.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843436",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1517,
                    "offsetInEndSection": 1679,
                    "text": "The findings showed a strong association between exposure to OP concentrate and neurological symptoms, but a less consistent association with sensory thresholds. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11600725",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 734,
                    "text": "Following accidental or suicidal exposure, these anticholinesterases lead to three well defined neurological syndromes i.e. initial life threatening acute cholinergic crisis which often requires management in intensive care unit, intermediate syndrome in which cranial nerve palsies, proximal muscle weakness and respiratory muscle weakness are common and patients often require respiratory support and delayed organophosphate induced polyneuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11146591",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "[Late onset polyneuropathy due to exposure to organophosphates].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10528323",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 236,
                    "text": " Less often a polyneuropathic syndrome of late onset may occur.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10528323",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 1051,
                    "text": "On electromyography there was sensomotor peripheral polyneuropathy, which was primarily axonal and predominantly motor and distal. Peripheral nerve biopsy confirmed the presence of 'dying back' type axonopathy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10528323",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1367,
                    "text": "Agricultural workers chronically exposed to organophosphate insecticides, without adequate protection, have an increased risk of developing late onset neuropathy due to organophosphates. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10528323",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 750,
                    "text": "Epidemiologic studies on pesticides have found associations with long-term effects on health mainly in three fields: cancer (especially hematological cancer), neurotoxic effects (polyneuropathy, neuro-behavioral hazards, Parkinson's disease), and reproductive disorders (infertility, birth defects, adverse pregnancy outcomes, perinatal mortality). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9592856",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 839,
                    "offsetInEndSection": 1015,
                    "text": "EMG studies showed evidence of partial denervation of the anterior tibial group of muscles and flexor digiti minimi in 2 of the 30 workers (6.7%) who underwent EMG examination.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9311548",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 737,
                    "text": "Neurological symptoms consist in cerebro-organic disfunctions, locomotory disorders reminiscent of multiple sclerosis or M. Parkinson, and sensory, motoric and vegetative polyneuropathy, leading, for instance, to cardiovascular regulatory disorder like sympathicotonia or, orthostatic hypotonia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7787373",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 972,
                    "text": "Thirty percent of patients had definite or possible exposure to organophosphate pesticides, and the peak use coincides with the peak incidence of Guillain-Barr\u00e9 syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7998771",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1045,
                    "offsetInEndSection": 1289,
                    "text": "These results suggest that previously reported cases of organophosphate-induced delayed polyneuropathy may represent only the worst disease in a spectrum of impairment, a sequela of exposure that may be much more common than previously thought.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8160653",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 367,
                    "text": "It is suggested that the main cause of nervous lesions in these cases was the complex effect of pesticides.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1481520",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 330,
                    "offsetInEndSection": 415,
                    "text": "Delayed polyneuropathy develops within 1 to 3 weeks and abates after 6 to 12 months. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1665780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Isolated case reports have circumstantially linked the use of the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) to polyneuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2158793",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1028,
                    "offsetInEndSection": 1117,
                    "text": "Thus, the weight of evidence indicates that 2,4-D is an unlikely cause of polyneuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2158793",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "A patient is reported presenting a cerebellar disorder developing about 5 weeks after acute exposure to an organophosphate insecticide. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2707289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 364,
                    "text": "Less well known, but more complex and idiosyncratic, is the potential for some agents to produce a delayed and progressive polyneuropathy--Organophosphorus Induced Delayed Neurotox-icity (OPIDN).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2462700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1379,
                    "offsetInEndSection": 1570,
                    "text": " It is also quite probable that human neurotoxicity may be a potential hazard from exposure to more than the handful of organophosphorus pesticides that have been described in the literature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2462700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 601,
                    "text": "In the present study the electroencephalograms of 3 of a group 10 workmen, who had been continually exposed to hexachlorcyclohexane, show pathological findings. The electromyograms of 8 of these 10 workman demonstrate a disturbance of the peripherical motoneuron. All probands, who exhibit o pathological EEG, also show a polyneuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6179111",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Many organophosphorus compounds, including the organophosphate insecticides, may cause polyneuropathy of delayed onset.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7194975",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 333,
                    "text": "Nevertheless, we describe a patient with delayed polyneuropathy after suicidal ingestion of parathion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7194975",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 186,
                    "text": "Following acute organophosphorus (OP) poisoning patients complain of numbness without objective sensory abnormalities or other features of OP induced delayed polyneuropathy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185328",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is signal transducer and activator of transcription-3 (STAT3) critical for tumor angiogenesis progression?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24042330",
                "http://www.ncbi.nlm.nih.gov/pubmed/20204067",
                "http://www.ncbi.nlm.nih.gov/pubmed/24305878",
                "http://www.ncbi.nlm.nih.gov/pubmed/24058783",
                "http://www.ncbi.nlm.nih.gov/pubmed/24200081",
                "http://www.ncbi.nlm.nih.gov/pubmed/22076197",
                "http://www.ncbi.nlm.nih.gov/pubmed/24307888",
                "http://www.ncbi.nlm.nih.gov/pubmed/17610223",
                "http://www.ncbi.nlm.nih.gov/pubmed/23848338",
                "http://www.ncbi.nlm.nih.gov/pubmed/24238495",
                "http://www.ncbi.nlm.nih.gov/pubmed/23962559",
                "http://www.ncbi.nlm.nih.gov/pubmed/23848964",
                "http://www.ncbi.nlm.nih.gov/pubmed/20052595",
                "http://www.ncbi.nlm.nih.gov/pubmed/18498667",
                "http://www.ncbi.nlm.nih.gov/pubmed/15665295",
                "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
                "http://www.ncbi.nlm.nih.gov/pubmed/24178245",
                "http://www.ncbi.nlm.nih.gov/pubmed/24005169",
                "http://www.ncbi.nlm.nih.gov/pubmed/16061629",
                "http://www.ncbi.nlm.nih.gov/pubmed/23903834",
                "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
                "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
                "http://www.ncbi.nlm.nih.gov/pubmed/19566485",
                "http://www.ncbi.nlm.nih.gov/pubmed/24231788",
                "http://www.ncbi.nlm.nih.gov/pubmed/9091577",
                "http://www.ncbi.nlm.nih.gov/pubmed/24116074"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10788344",
                    "o": "C39238"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1514955",
                    "o": "http://linkedlifedata.com/resource/umls/label/A10788344"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1514955",
                    "o": "http://linkedlifedata.com/resource/umls/label/A10788344"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10788344",
                    "o": "Stat3 Signaling Pathway"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1514955",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7663266"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7663266",
                    "o": "C39238"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/Q7Z4H9",
                    "o": "http://purl.uniprot.org/citations/12853948"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/12853948",
                    "o": "Nature"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51375A34483900F",
                    "o": "STAT3-interacting protein as a repressor"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/12853948",
                    "o": "http://purl.uniprot.org/pubmed/12853948"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/12853948",
                    "o": "http://purl.uniprot.org/medline/22737999"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q7Z4H9",
                    "o": "http://linkedlifedata.com/resource/#_51375A34483900F"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInCellLine",
                    "s": "http://purl.uniprot.org/uniprot/Q3ZN08",
                    "o": "http://purl.uniprot.org/tissues/597"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q3ZN08",
                    "o": "http://linkedlifedata.com/resource/#_51335A4E30380015"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/597",
                    "o": "Breast tumor"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/597",
                    "o": "Mammary tumour"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q3ZN08",
                    "o": "http://linkedlifedata.com/resource/#_51335A4E30380014"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51335A4E30380014",
                    "o": "STAT3-interacting protein as a repressor"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51335A4E30380015",
                    "o": "Acrosomal protein ACPIN1"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/597",
                    "o": "Mammary tumor"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/597",
                    "o": "Mammary gland tumor"
                }
            ],
            "ideal_answer": [
                "(STAT3) is a latent cytoplasmic transcription factor, originally discovered as a transducer of signal from cell surface receptors to the nucleus. It is activated by tyrosine phosphorylation at position 705 leading to its dimerization, nuclear translocation, DNA binding, and activation of gene transcription. Under normal physiological conditions, STAT3 activation is tightly regulated. However, compelling evidence suggests that STAT3 is constitutively activated in many cancers and plays a pivotal role in tumor growth and metastasis. It regulates cellular proliferation, invasion, migration, and angiogenesis that are critical for cancer metastasis"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/STAT3_MOUSE",
                "http://www.biosemantics.org/jochem#4243664",
                "http://www.uniprot.org/uniprot/STAT3_BOVIN",
                "http://www.uniprot.org/uniprot/STAT3_CHICK",
                "http://www.uniprot.org/uniprot/STAT3_HUMAN",
                "http://www.uniprot.org/uniprot/STAT3_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043925",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045766",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045765",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050796",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001525",
                "http://www.uniprot.org/uniprot/STAT3_PIG",
                "http://www.uniprot.org/uniprot/STATC_DICDI",
                "http://www.disease-ontology.org/api/metadata/DOID:162"
            ],
            "type": "yesno",
            "id": "533d0f44c45e13371400000e",
            "snippets": [
                {
                    "offsetInBeginSection": 50,
                    "offsetInEndSection": 345,
                    "text": " (STAT3) is critical for cancer progression by regulating tumor cell survival, proliferation, and angiogenesis. Herein, we investigated the regulation of STAT3 activation and the therapeutic effects of Icaritin, a prenyl flavonoid derivative from Epimedium Genus, in renal cell carcinoma (RCC). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1205,
                    "offsetInEndSection": 1377,
                    "text": " Overall, these results suggest that Icaritin strongly inhibits STAT3 activation and is a potentially effective therapeutic option for the treatment of renal cell carcinoma",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 664,
                    "text": "we have reviewed important signaling pathways that are closely related to radiosensitization, such as cell cycle arrest, tumor angiogenesis, JAK/STAT3 signaling pathway and Mismatch repair",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24307888",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 270,
                    "text": "Interleukin-27 signaling is mediated by the JAK-STAT pathway via activation of STAT1 and STAT3, which have tumor suppressive and oncogenic activities, respectively. Epithelial-mesenchymal transition (EMT) and angiogenesis are key processes in carcinogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1813,
                    "offsetInEndSection": 1909,
                    "text": "The inhibition of STAT3 activation had no effect on the development of the epithelial phenotype.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 254,
                    "text": "STAT3 plays a vital role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and is reported to be a critical mediator of the oncogenic effects of EGFR mutations. STAT3 activation is mediated through JAK family kinases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24238495",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1551,
                    "offsetInEndSection": 2061,
                    "text": " EESB treatment could significantly suppress the activation of several CRC-related pathways, including STAT3, Erk, and p38 signalings in tumor tissues, and alter the expression of multiple critical target genes such as Bcl-2, Bax, Cyclin D1, CDK4, and p21. These molecular effects lead to the induction of cancer cell apoptosis and inhibition of cell proliferation. Our findings demonstrate that SB possesses a broad range of antitumor activities because of its ability to affect multiple intracellular targets",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231788",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1554,
                    "text": "Western immunoblotting analyses of mouse lung tissues indicated significantly lower level of pSTAT3 and Mcl-1 in the carcinogen plus DMAPT group relative to the group treated with the carcinogen only. Given the evidence that STAT3 is activated in more than half of lung cancers and it regulates genes involved in cell proliferation, survival and angiogenesis, DMAPT is a promising agent for lung cancer chemoprevention in subjects who are at high risk of developing this devastating disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24200081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 51,
                    "offsetInEndSection": 702,
                    "text": "(STAT3) is a latent cytoplasmic transcription factor, originally discovered as a transducer of signal from cell surface receptors to the nucleus. It is activated by tyrosine phosphorylation at position 705 leading to its dimerization, nuclear translocation, DNA binding, and activation of gene transcription. Under normal physiological conditions, STAT3 activation is tightly regulated. However, compelling evidence suggests that STAT3 is constitutively activated in many cancers and plays a pivotal role in tumor growth and metastasis. It regulates cellular proliferation, invasion, migration, and angiogenesis that are critical for cancer metastasis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 70,
                    "offsetInEndSection": 251,
                    "text": "STAT3) signaling pathway plays important roles in oncogenesis, angiogenesis, immunity, and tumor cell invasion. In the present study, we investigated the association of interleukin ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 346,
                    "offsetInEndSection": 585,
                    "text": " Phosphorylated STAT3 (pSTAT3) regulates many genes that are necessarily expressed in cancer initiation, development, and progression, being involved in proliferation, anti-apoptosis, invasion, angiogenesis, and immune surveillance evasion",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24005169",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is SATB1 positioned close to AT-rich sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24729451",
                "http://www.ncbi.nlm.nih.gov/pubmed/24047082",
                "http://www.ncbi.nlm.nih.gov/pubmed/18408014",
                "http://www.ncbi.nlm.nih.gov/pubmed/28179318",
                "http://www.ncbi.nlm.nih.gov/pubmed/24118100",
                "http://www.ncbi.nlm.nih.gov/pubmed/10629043",
                "http://www.ncbi.nlm.nih.gov/pubmed/8049444",
                "http://www.ncbi.nlm.nih.gov/pubmed/29306014",
                "http://www.ncbi.nlm.nih.gov/pubmed/9548713",
                "http://www.ncbi.nlm.nih.gov/pubmed/27590341"
            ],
            "ideal_answer": [
                "Yes, SATB1 is preferentially located at the start of an AT-rich sequence and is associated with other, more diffuse AT- rich sequences in the genome.",
                "Special AT-rich sequence-binding protein 1 (SATB1), a DNA-binding protein expressed predominantly in thymocytes, recognizes an ATC sequence context that consists of a cluster of sequence stretches with well-mixed A's, T's, and C's without G's on one strand. SATB1 (special AT-rich sequence-binding protein-1) provides a key link between DNA loop organization, chromatin modification/remodeling, and association of transcription factors at matrix attachment regions (MARs).",
                "Special AT-rich sequence-binding protein 1 (SATB1), a DNA-binding protein expressed predominantly in thymocytes, recognizes an ATC sequence context that consists of a cluster of sequence stretches with well-mixed A's, T's, and C's without G's on one strand.",
                "We have purified and identified one of the core factors as the matrix attachment region (MAR) binding protein, SATB1, which is known to bind to AT-rich sequences with a high propensity to unwind"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d38826ea1e1595105000016",
            "snippets": [
                {
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 585,
                    "text": " Tryptic cleavage and peptide sequence analysis demonstrated that the 98-kD protein is identical to a recently cloned protein, special A-T-rich binding protein 1 (SATB1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8049444",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Special AT-rich sequence-binding protein 1 (SATB1), a DNA-binding protein expressed predominantly in thymocytes, recognizes an ATC sequence context that consists of a cluster of sequence stretches with well-mixed A's, T's, and C's without G's on one strand. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9548713",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 973,
                    "text": " We have purified and identified one of the core factors as the matrix attachment region (MAR) binding protein, SATB1, which is known to bind to AT-rich sequences with a high propensity to unwind",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10629043",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "SATB1 (special AT-rich sequence-binding protein-1) provides a key link between DNA loop organization, chromatin modification/remodeling, and association of transcription factors at matrix attachment regions (MARs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18408014",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047082",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 133,
                    "text": "pecial AT rich sequence binding protein 1 (SATB1) plays a crucial role in the biology of various types of human cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047082",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 58,
                    "text": "Loss of special AT-rich sequence-binding protein 1 (SATB1)",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24118100",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 5,
                    "offsetInEndSection": 164,
                    "text": "Special AT-rich sequence-binding protein 1 (SATB1) is a cell type-specific matrix attachment region binding protein, functioning as a global genome organizer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24118100",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "SATB1 (special AT-rich binding protein 1) is a global chromatin organizer regulating the expression of a large number of genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Special AT-rich Sequence-binding Protein 1 (SATB1) Functions as an Accessory Factor in Base Excision Repair.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27590341",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Rearrangement of the Chromatin Organizer Special AT-rich Binding Protein 1 Gene",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28179318",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "The Special AT-rich Sequence Binding Protein 1 (SATB1) exerts multiple functions, by influencing the structural organization of chromatin and interacting with several co-activators and co-repressors of transcription.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29306014",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29306014",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does burning mouth syndrome preferentially affect post-mepopausal women?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8725589",
                "http://www.ncbi.nlm.nih.gov/pubmed/17439072",
                "http://www.ncbi.nlm.nih.gov/pubmed/15055637",
                "http://www.ncbi.nlm.nih.gov/pubmed/18985004",
                "http://www.ncbi.nlm.nih.gov/pubmed/10431669",
                "http://www.ncbi.nlm.nih.gov/pubmed/12017897",
                "http://www.ncbi.nlm.nih.gov/pubmed/23772971",
                "http://www.ncbi.nlm.nih.gov/pubmed/23201368",
                "http://www.ncbi.nlm.nih.gov/pubmed/15911160",
                "http://www.ncbi.nlm.nih.gov/pubmed/3476895",
                "http://www.ncbi.nlm.nih.gov/pubmed/21685517",
                "http://www.ncbi.nlm.nih.gov/pubmed/21528120",
                "http://www.ncbi.nlm.nih.gov/pubmed/17967714",
                "http://www.ncbi.nlm.nih.gov/pubmed/20701667",
                "http://www.ncbi.nlm.nih.gov/pubmed/20230455",
                "http://www.ncbi.nlm.nih.gov/pubmed/12907696",
                "http://www.ncbi.nlm.nih.gov/pubmed/12764983",
                "http://www.ncbi.nlm.nih.gov/pubmed/19689438",
                "http://www.ncbi.nlm.nih.gov/pubmed/16142094",
                "http://www.ncbi.nlm.nih.gov/pubmed/17849966",
                "http://www.ncbi.nlm.nih.gov/pubmed/20440632",
                "http://www.ncbi.nlm.nih.gov/pubmed/8170453",
                "http://www.ncbi.nlm.nih.gov/pubmed/7838464",
                "http://www.ncbi.nlm.nih.gov/pubmed/11871678",
                "http://www.ncbi.nlm.nih.gov/pubmed/12618668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19450321",
                "http://www.ncbi.nlm.nih.gov/pubmed/22612823",
                "http://www.ncbi.nlm.nih.gov/pubmed/23050296",
                "http://www.ncbi.nlm.nih.gov/pubmed/24096230",
                "http://www.ncbi.nlm.nih.gov/pubmed/17452954",
                "http://www.ncbi.nlm.nih.gov/pubmed/17541900",
                "http://www.ncbi.nlm.nih.gov/pubmed/9237148",
                "http://www.ncbi.nlm.nih.gov/pubmed/15024358",
                "http://www.ncbi.nlm.nih.gov/pubmed/11441716",
                "http://www.ncbi.nlm.nih.gov/pubmed/21903545",
                "http://www.ncbi.nlm.nih.gov/pubmed/20597947",
                "http://www.ncbi.nlm.nih.gov/pubmed/9844361",
                "http://www.ncbi.nlm.nih.gov/pubmed/18305436",
                "http://www.ncbi.nlm.nih.gov/pubmed/21418666",
                "http://www.ncbi.nlm.nih.gov/pubmed/10478959",
                "http://www.ncbi.nlm.nih.gov/pubmed/7629360",
                "http://www.ncbi.nlm.nih.gov/pubmed/11603307",
                "http://www.ncbi.nlm.nih.gov/pubmed/19658340",
                "http://www.ncbi.nlm.nih.gov/pubmed/6589575",
                "http://www.ncbi.nlm.nih.gov/pubmed/16905808",
                "http://www.ncbi.nlm.nih.gov/pubmed/18558051",
                "http://www.ncbi.nlm.nih.gov/pubmed/15195716",
                "http://www.ncbi.nlm.nih.gov/pubmed/18625105",
                "http://www.ncbi.nlm.nih.gov/pubmed/23787507",
                "http://www.ncbi.nlm.nih.gov/pubmed/10446526",
                "http://www.ncbi.nlm.nih.gov/pubmed/16637799",
                "http://www.ncbi.nlm.nih.gov/pubmed/8469539",
                "http://www.ncbi.nlm.nih.gov/pubmed/2700889",
                "http://www.ncbi.nlm.nih.gov/pubmed/20038880",
                "http://www.ncbi.nlm.nih.gov/pubmed/22030140",
                "http://www.ncbi.nlm.nih.gov/pubmed/18278306"
            ],
            "ideal_answer": [
                "BMS is observed principally in middle-aged patients and postmenopausal women \nBMS mostly affects elderly citizens, especially postmenopausal women with prevalence up to 12-18%."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002054",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002056",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008593",
                "http://www.disease-ontology.org/api/metadata/DOID:403",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016387",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014930",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009055",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017698",
                "http://www.disease-ontology.org/api/metadata/DOID:4331"
            ],
            "type": "yesno",
            "id": "531d76a2267d7dd05300000a",
            "snippets": [
                {
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 303,
                    "text": "It is observed principally in middle-aged patients and postmenopausal women and may be accompanied by xerostomia and altered taste.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24096230",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 304,
                    "text": "It occurs more commonly in middle-aged and elderly women and often affects the tongue tip and lateral borders, lips, and hard and soft palate. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23772971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 289,
                    "text": "BMS is a chronic disorder that frequently affects women and is characterised by burning symptoms of the oral mucosa without clinical signs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22612823",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 279,
                    "text": "It mostly affects elderly citizens, especially postmenopausal women with prevalence up to 12-18%. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22030140",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is it possible to detect survivin protein expression in normal human adult tissues?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22930255",
                "http://www.ncbi.nlm.nih.gov/pubmed/14719083",
                "http://www.ncbi.nlm.nih.gov/pubmed/18425079",
                "http://www.ncbi.nlm.nih.gov/pubmed/16360419",
                "http://www.ncbi.nlm.nih.gov/pubmed/15990723",
                "http://www.ncbi.nlm.nih.gov/pubmed/17163847",
                "http://www.ncbi.nlm.nih.gov/pubmed/18376799",
                "http://www.ncbi.nlm.nih.gov/pubmed/12671708",
                "http://www.ncbi.nlm.nih.gov/pubmed/17382535",
                "http://www.ncbi.nlm.nih.gov/pubmed/18856066",
                "http://www.ncbi.nlm.nih.gov/pubmed/16619249",
                "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
                "http://www.ncbi.nlm.nih.gov/pubmed/17204284",
                "http://www.ncbi.nlm.nih.gov/pubmed/15195112",
                "http://www.ncbi.nlm.nih.gov/pubmed/23132836",
                "http://www.ncbi.nlm.nih.gov/pubmed/20520718",
                "http://www.ncbi.nlm.nih.gov/pubmed/15138808",
                "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
                "http://www.ncbi.nlm.nih.gov/pubmed/20514400",
                "http://www.ncbi.nlm.nih.gov/pubmed/10626797"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10780389",
                    "o": "Survivin"
                }
            ],
            "ideal_answer": [
                "No. Survivin is an inhibitor of apoptosis that is undetectable in normal differentiated tissues of adult human.",
                "Most normal adult tissues do not express survivin, thymus and testis are the only exceptions."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014024",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0048729",
                "http://www.uniprot.org/uniprot/BIRC5_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0009888",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006801"
            ],
            "type": "yesno",
            "id": "51680a49298dcd4e51000062",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Survivin (BIRC5) is one of the members of IAP-family apoptosis inhibitors. The BIRCS gene is expressed in most human embryonic tissues and malignant tumors but not in normal differentiated tissues of adult human.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18856066",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 399,
                    "text": "Survivin is an inhibitor of apoptosis that is undetectable in most terminally differentiated normal human tissues, strongly expressed in embryonic and fetal organs and is strongly expressed in many different human cancers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425079",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "text": "Survivin is a member of the inhibitor apoptosis family that is overexpressed in many malignancies. It has five known alternative splice forms, some of which differ in their antiapoptotic properties and expression levels in human cancers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17204284",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 458,
                    "text": "survivin is usually not expressed in normal adult tissues,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16360419",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1409,
                    "text": "AZD1152-hQPA induced caspase-dependent apoptosis of some cell lines, demonstrated by loss of mitochondrial membrane potential, activation of caspase-9, followed by activation of caspase-3. This effect was accompanied by the inhibition of survivin expression. In vivo efficacy was determined in NOD/SCID/\u03b3c(null) mice implanted with the Ramos human BL cell line. AZD1152 had anti-tumour effects in this murine xenograft model. There preclinical data suggest that the inhibition of Aurora B kinase is a potentially useful therapeutic strategy in BL and HL.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 10,
                    "offsetInEndSection": 469,
                    "text": "a novel antiapoptosis gene, i.e., survivin, was identified as a structurally unique member of the inhibitor of apoptosis protein family. Survivin expression is turned off during fetal development and not found in non-neoplastic adult human tissues but is again turned on in the most common human cancers. The antiapoptotic properties of survivin might provide a significant growth advantage in tumors and possibly also contribute to chemoresistance of cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10626797",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 630,
                    "offsetInEndSection": 1193,
                    "text": "Further comparison of the distribution of PDEF with other widely recognized cancer-associated molecules showed that PDEF has more restricted distributions than Her-2/neu, Bcl-2, survivin or telomerase in cDNA libraries from normal human tissues and more increased distribution than Her-2/neu, CA-125, Bcl-2, survivin and telomerase in cDNA libraries from brain (except survivin), breast, lung and ovarian tumors. These data together show a better tumor-association for PDEF and suggest that PDEF is a more suitable target for developing specific cancer therapies.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14719083",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1053,
                    "offsetInEndSection": 1750,
                    "text": "we identified decreased FHIT expression resulting in apoptosis inhibition and decreasing apoptosis associated with abnormal levels of some pro- and anti-apoptotic proteins (Bax, Bcl-2 and Survivin) by TUNEL and TMA. Our results demonstrated that the mutation in the FHIT gene significantly reduced FHIT expression in human CRC. Both TUNEL and TMA experiments demonstrated significantly inhibited apoptosis by down-regulation of Bax and up-regulation of Survivin and Bcl-2. Collectively, these studies identify the mechanism by which an important tumor suppressor gene, FHIT, inactivated specifically in human CRC, and contributes to our understanding of the mechanism of colorectal carcinogenesis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382535",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is lucatumumab a polyclonal antibody?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22861192"
            ],
            "ideal_answer": [
                "No, lucatumumab is a a monoclonal antibody against CD40."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c6582207c78d69471000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22861192",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "In this open-label, multicentre, phase 1 study a fully human anti-CD40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed/refractory multiple myeloma (MM).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22861192",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does deflazacort have more side effects than prednisone?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19488064"
            ],
            "ideal_answer": [
                "Deflazacort produces fewer side effects than Prednisone in DMD patients."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5a7726989e632bc06600000c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is lambrolizumab effective for treatment of patients with melanoma ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23724846",
                "http://www.ncbi.nlm.nih.gov/pubmed/24416617",
                "http://www.ncbi.nlm.nih.gov/pubmed/23847357",
                "http://www.ncbi.nlm.nih.gov/pubmed/24089441",
                "http://www.ncbi.nlm.nih.gov/pubmed/24499550",
                "http://www.ncbi.nlm.nih.gov/pubmed/23970885",
                "http://www.ncbi.nlm.nih.gov/pubmed/24516336",
                "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
                "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
                "http://www.ncbi.nlm.nih.gov/pubmed/23997828"
            ],
            "ideal_answer": [
                "Lambrolizumab, a programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibody, has been shown to be effective for treatment of patients with melanoma. High rate of sustained tumor regression with mainly minimal adverse effects in melanoma patients treated with lambrolizumab has been reported. Because of all these reasons PD-1/PD-L1 antibodies are considered 'drug of the year.",
                "Yes. In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018328",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018326",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016896",
                "http://www.disease-ontology.org/api/metadata/DOID:1909",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008545"
            ],
            "type": "yesno",
            "id": "530cefaaad0bf1360c000008",
            "snippets": [
                {
                    "offsetInBeginSection": 683,
                    "offsetInEndSection": 1181,
                    "text": "However, through parallel efforts that have showcased the efficacy of small-molecule BRAF and MAP-ERK kinase (MEK) inhibitors, as well as the immune checkpoint inhibitors, namely ipilimumab and the anti-PD1/PDL1 antibodies (lambrolizumab, nivolumab, MPDL3280), an opportunity exists to transform the treatment of melanoma specifically and cancer generally by exploring rational combinations of molecularly targeted therapies, immunotherapies, and molecular targeted therapies with immunotherapies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24089441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. The most mature results have been obtained in advanced melanoma patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Merck's lambrolizumab (MK-3475) monoclonal antibody received \"Breakthrough Therapy\" designation from the U.S. Food and Drug Administration in April for treating patients with advanced melanoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23847357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 263,
                    "text": "The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23724846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1745,
                    "offsetInEndSection": 1995,
                    "text": "In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23724846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 946,
                    "offsetInEndSection": 1031,
                    "text": "Because of all these reasons PD-1/PD-L1 antibodies are considered 'drug of the year'.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16998490",
                "http://www.ncbi.nlm.nih.gov/pubmed/18957701",
                "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                "http://www.ncbi.nlm.nih.gov/pubmed/25340765",
                "http://www.ncbi.nlm.nih.gov/pubmed/21092253"
            ],
            "ideal_answer": [
                "Yes. Interestingly, human ultraconserved elements (UCEs) have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs). These elements may be interpreted as hallmarks for dose-sensitive genes, particularly for those genes whose gain or loss may be directly implied in neurodevelopmental disorders. Therefore, their presence in genomic imbalances of unknown effect might be suggestive of a clinically relevant condition"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056915"
            ],
            "type": "yesno",
            "id": "55413142182542114d000002",
            "snippets": [
                {
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 794,
                    "text": "We have demonstrated that nonexonic UCEs are depleted among segmental duplications (SDs) and copy number variants (CNVs) and proposed that their ultraconservation may reflect a mechanism of copy counting via comparison. Here, we report that nonexonic UCEs are also depleted among 10 of 11 recent genomewide data sets of human CNVs, including 3 obtained with strategies permitting greater precision in determining the extents of CNVs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 578,
                    "text": "Interestingly, human UCEs have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1449,
                    "offsetInEndSection": 1763,
                    "text": "We propose that these elements may be interpreted as hallmarks for dose-sensitive genes, particularly for those genes whose gain or loss may be directly implied in neurodevelopmental disorders. Therefore, their presence in genomic imbalances of unknown effect might be suggestive of a clinically relevant condition",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 579,
                    "text": "Interestingly, human UCEs have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 581,
                    "text": "We have demonstrated that nonexonic UCEs are depleted among segmental duplications (SDs) and copy number variants (CNVs) and proposed that their ultraconservation may reflect a mechanism of copy counting via comparison.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 580,
                    "text": "We have demonstrated that nonexonic UCEs are depleted among segmental duplications (SDs) and copy number variants (CNVs) and proposed that their ultraconservation may reflect a mechanism of copy counting via comparison",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 566,
                    "text": "Interestingly, human UCEs have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 716,
                    "text": "Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 639,
                    "text": "The depletion of UCEs among copy number variation as well as the significant under-representation of single-nucleotide polymorphisms (SNPs) within UCEs have also revealed their evolutional and functional importance indicating their potential impact on disease, such as cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are piRNAs involved in gene silencing?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23465540",
                "http://www.ncbi.nlm.nih.gov/pubmed/20559422",
                "http://www.ncbi.nlm.nih.gov/pubmed/20080197",
                "http://www.ncbi.nlm.nih.gov/pubmed/25842866",
                "http://www.ncbi.nlm.nih.gov/pubmed/20439430",
                "http://www.ncbi.nlm.nih.gov/pubmed/26302790",
                "http://www.ncbi.nlm.nih.gov/pubmed/23392610",
                "http://www.ncbi.nlm.nih.gov/pubmed/23124062",
                "http://www.ncbi.nlm.nih.gov/pubmed/17872506",
                "http://www.ncbi.nlm.nih.gov/pubmed/25336588",
                "http://www.ncbi.nlm.nih.gov/pubmed/23625890",
                "http://www.ncbi.nlm.nih.gov/pubmed/25313140",
                "http://www.ncbi.nlm.nih.gov/pubmed/24288375",
                "http://www.ncbi.nlm.nih.gov/pubmed/26472911",
                "http://www.ncbi.nlm.nih.gov/pubmed/21764773",
                "http://www.ncbi.nlm.nih.gov/pubmed/21775629",
                "http://www.ncbi.nlm.nih.gov/pubmed/18809914",
                "http://www.ncbi.nlm.nih.gov/pubmed/24939875",
                "http://www.ncbi.nlm.nih.gov/pubmed/26279487",
                "http://www.ncbi.nlm.nih.gov/pubmed/23132912",
                "http://www.ncbi.nlm.nih.gov/pubmed/24178563"
            ],
            "ideal_answer": [
                "Piwi induces piRNA-guided transcriptional silencing and establishment of a repressive chromatin state. piRNA-guided slicing of transposon transcripts enforces their transcriptional silencing via specifying the nuclear piRNA repertoire. Transcriptional silencing implies a piRNA-mediated formation of repressive chromatin which diminishes the transcriptional capacity of the target locus."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0016458",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020868"
            ],
            "type": "yesno",
            "id": "56c6f6005795f9a73e000009",
            "snippets": [
                {
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 304,
                    "text": "In Drosophila ovaries, the nuclear Piwi protein is required for transcriptional silencing of transposons, though the precise mechanisms by which this occurs are unknown.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26472911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 643,
                    "text": "Here we show that the CG9754 protein is a component of Piwi complexes that functions downstream of Piwi and its binding partner, Asterix, in transcriptional silencing. Enforced tethering of CG9754 to nascent messenger RNA transcripts causes cotranscriptional silencing of the source locus and the deposition of repressive chromatin marks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26472911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 644,
                    "offsetInEndSection": 878,
                    "text": "We have named CG9754 \"Panoramix,\" and we propose that this protein could act as an adaptor, scaffolding interactions between the piRNA pathway and the general silencing machinery that it recruits to enforce transcriptional repression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26472911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "piRNA-guided slicing of transposon transcripts enforces their transcriptional silencing via specifying the nuclear piRNA repertoire",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26302790",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 298,
                    "text": "Caenorhabditis elegans piRNAs interact with both transposon and nontransposon mRNAs to initiate sustained silencing via the RNAi pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26279487",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 460,
                    "text": "To assess the dysregulation of gene silencing caused by lack of piRNAs, we restored RNA silencing in RNAi-defective animals in the presence or absence of piRNAs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26279487",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1010,
                    "text": "Thus, by reanimating RNAi, we uncovered a role for piRNAs in protecting essential genes from RNA silencing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26279487",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 464,
                    "text": "In different organisms, small RNAs were shown to be implicated in the posttranscriptional degradation of mRNA and/or transcriptional repression of the homologous locus. In Drosophila, the mechanism of piRNA-mediated silencing is still far from being understood",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24178563",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Analyses of piRNA-mediated transcriptional transposon silencing in Drosophila",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24178563",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 617,
                    "text": "Transcriptional silencing implies a piRNA-mediated formation of repressive chromatin which diminishes the transcriptional capacity of the target locus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24178563",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 371,
                    "offsetInEndSection": 572,
                    "text": "In mice, piRNA-guided transposon repression correlates with establishment of CpG DNA methylation on their sequences, yet the mechanism and the spectrum of genomic targets of piRNA silencing are unknown",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24939875",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 430,
                    "text": "Using a candidate gene KD-approach, we identified differences in the spatio-temporal requirements of the piRNA pathway components for piRNA-mediated silencing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24288375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Spatio-temporal requirements for transposable element piRNA-mediated silencing during Drosophila oogenesis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24288375",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1110,
                    "offsetInEndSection": 1286,
                    "text": "In contrast, piRNA-mediated silencing is strong in germline stem cells in which TE mobilization is tightly repressed ensuring the continued production of viable germline cysts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24288375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Piwi induces piRNA-guided transcriptional silencing and establishment of a repressive chromatin state.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23392610",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "In germ cells, early embryos, and stem cells of animals, PIWI-interacting RNAs (piRNAs) have an important role in silencing retrotransposons, which are vicious genomic parasites, through transcriptional and post-transcriptional mechanisms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23132912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1148,
                    "text": "Our results show that the piRNA pathway can be used as a tool for sequence-specific gene silencing in germ cells and support the idea that the piRNA generating regions serve as traps for retrotransposons, enabling the host cell to generate piRNAs against active retrotransposons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23132912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1627,
                    "offsetInEndSection": 1820,
                    "text": " Our observations confirm the pivotal role of piRNA-mediated silencing in defending the genome against selfish transposition, yet also suggest limits to the optimization of host genome defense.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625890",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Analysis of piRNA-mediated silencing of active TEs in Drosophila melanogaster suggests limits on the evolution of host genome defense",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625890",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "The Piwi-interacting RNA (piRNA) pathway defends animal genomes against the harmful consequences of transposable element (TE) infection by imposing small-RNA-mediated silencing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625890",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "A novel organelle, the piNG-body, in the nuage of Drosophila male germ cells is associated with piRNA-mediated gene silencing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21775629",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "Proteins of the PIWI subfamily Aub and AGO3 associated with the germline-specific perinuclear granules (nuage) are involved in the silencing of retrotransposons and other selfish repetitive elements in the Drosophila genome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21775629",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 256,
                    "text": "Telomeric retroelements HeT-A, TART and TAHRE, which are involved in telomere maintenance in Drosophila, are also the targets of piRNA-mediated silencing",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764773",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Mechanism of the piRNA-mediated silencing of Drosophila telomeric retrotransposons.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764773",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Gene silencing mechanisms mediated by Aubergine piRNA complexes in Drosophila male gonad.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17872506",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "The epigenetic trans-silencing effect in Drosophila involves maternally-transmitted small RNAs whose production depends on the piRNA pathway and HP1.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20559422",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 798,
                    "text": "Here, we show that mutations in squash and zucchini, which are involved in the piwi-interacting RNA (piRNA) silencing pathway, strongly affect TSE",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20559422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 62,
                    "text": "MVH in piRNA processing and gene silencing of retrotransposons",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439430",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "piRNA-mediated silencing in Drosophila germlines.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080197",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1110,
                    "text": "These have shed light not only on the molecular mechanisms of gene silencing mediated by piRNAs and PIWI proteins, but also on their intriguing relationship with cellular genes that have been shown to be important for gametogenesis and fertility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080197",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 630,
                    "offsetInEndSection": 794,
                    "text": "The most abundant piRNAs were those corresponding to antisense transcripts of Suppressor of Stellate [Su(Ste)] genes known to be involved in Stellate gene silencing",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17872506",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 478,
                    "text": "To determine the capacity of piRNA-mediated silencing, we introduced reporter genes into Drosophila OSS cells, which express microRNAs (miRNAs) and piRNAs, and compared the Piwi pathway to the Argonaute pathway in gene regulation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336588",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "PIWI-interacting small non-coding RNAs (piRNAs) are genetic and epigenetic regulatory factors in germline cells, where they maintain genome stability, are involved in RNA silencing and regulate gene expression",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25313140",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 318,
                    "text": "The piNG-body contains ribonucleoprotein complexes involved in piRNA-silencing of genome repeats including transposons in premeiotic spermatocytes with aid of short piRNAs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25842866",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1147,
                    "text": "Our results show that the piRNA pathway can be used as a tool for sequence-specific gene silencing in germ cells and support the idea that the piRNA generating regions serve as traps for retrotransposons, enabling the host cell to generate piRNAs against active retrotransposons",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23132912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 375,
                    "text": "Recent studies have revealed not only the biogenesis of piRNAs and their roles in transposon silencing, but also the function of the Piwi-piRNA pathway in epigenetic and post-transcriptional regulation of gene expression",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23465540",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 541,
                    "text": "A growing number of studies on piRNAs have investigated piRNA-mediated gene silencing, including piRNA biogenesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23124062",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1109,
                    "text": "These have shed light not only on the molecular mechanisms of gene silencing mediated by piRNAs and PIWI proteins, but also on their intriguing relationship with cellular genes that have been shown to be important for gametogenesis and fertility",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080197",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 258,
                    "text": "Telomeric retroelements HeT-A, TART and TAHRE, which are involved in telomere maintenance in Drosophila, are also the targets of piRNA-mediated silencing. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764773",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "text": "MVH in piRNA processing and gene silencing of retrotransposons.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439430",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 480,
                    "text": "To determine the capacity of piRNA-mediated silencing, we introduced reporter genes into Drosophila OSS cells, which express microRNAs (miRNAs) and piRNAs, and compared the Piwi pathway to the Argonaute pathway in gene regulation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336588",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1213,
                    "offsetInEndSection": 1356,
                    "text": "Therefore piRNA-mediated transcriptional mode of silencing is involved in the control of retrotransposon expression in the Drosophila germline.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764773",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "text": "Panoramix enforces piRNA-dependent cotranscriptional silencing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26472911",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 631,
                    "offsetInEndSection": 796,
                    "text": "The most abundant piRNAs were those corresponding to antisense transcripts of Suppressor of Stellate [Su(Ste)] genes known to be involved in Stellate gene silencing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17872506",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1468,
                    "offsetInEndSection": 1602,
                    "text": "Our results indicate that piRNAs are involved in a posttranscriptional gene-silencing mechanism resulting in RNA nuclear accumulation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18809914",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is arimoclomol a co-inducer of the heat shock response?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22591194",
                "http://www.ncbi.nlm.nih.gov/pubmed/18551622",
                "http://www.ncbi.nlm.nih.gov/pubmed/20582873",
                "http://www.ncbi.nlm.nih.gov/pubmed/19183864",
                "http://www.ncbi.nlm.nih.gov/pubmed/17656567",
                "http://www.ncbi.nlm.nih.gov/pubmed/24853414",
                "http://www.ncbi.nlm.nih.gov/pubmed/23978556",
                "http://www.ncbi.nlm.nih.gov/pubmed/18673445",
                "http://www.ncbi.nlm.nih.gov/pubmed/19938902",
                "http://www.ncbi.nlm.nih.gov/pubmed/23393146"
            ],
            "ideal_answer": [
                "Yes, arimoclomol is a hydroxylamine derivative, a group of compounds which have unique properties as co-inducers of heat shock protein expression, but only under conditions of cellular stress."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56f7d9dd09dd18d46b000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Arimoclomol is a hydroxylamine derivative, a group of compounds which have unique properties as co-inducers of heat shock protein expression, but only under conditions of cellular stress. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978556",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 805,
                    "text": "In this review we summarize the evidence for the neuroprotective effects of enhanced heat shock protein expression by Arimoclomol and other inducers of the Heat Shock Response. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978556",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1061,
                    "offsetInEndSection": 1121,
                    "text": "arimoclomol, a co-inducer of the heat shock stress response,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393146",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1329,
                    "offsetInEndSection": 1440,
                    "text": "The heat-shock response (HSR) was activated in P23H retinae, and this was enhanced with arimoclomol treatment. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 246,
                    "text": " We also assessed these functions in mice treated with a known heat shock protein inducer, arimoclomol.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22591194",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 897,
                    "text": " Under conditions of excessive stress, arimoclomol induces amplification of the cytoprotective heat shock response in order to protect motor neurons from death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20582873",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 487,
                    "text": "Although both arimoclomol and celastrol induced the expression of Hsp70",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19183864",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "text": "Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19938902",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1337,
                    "offsetInEndSection": 1485,
                    "text": "The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673445",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18551622",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 554,
                    "text": "Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17656567",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has small pox been eradicated from the world?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22566811",
                "http://www.ncbi.nlm.nih.gov/pubmed/11808015",
                "http://www.ncbi.nlm.nih.gov/pubmed/10742580",
                "http://www.ncbi.nlm.nih.gov/pubmed/14969309",
                "http://www.ncbi.nlm.nih.gov/pubmed/23436190",
                "http://www.ncbi.nlm.nih.gov/pubmed/12822115",
                "http://www.ncbi.nlm.nih.gov/pubmed/7013291",
                "http://www.ncbi.nlm.nih.gov/pubmed/11503361",
                "http://www.ncbi.nlm.nih.gov/pubmed/22185830"
            ],
            "ideal_answer": [
                "smallpox is now eradicated.",
                "Yes, small pox has been eradicated.",
                "smallpox is now eradicated",
                "small pox has been eradicated."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:8736",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012899",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012900"
            ],
            "type": "yesno",
            "id": "58a1da4e78275d0c4a000059",
            "snippets": [
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 183,
                    "text": "small pox has been eradicated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742580",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 837,
                    "offsetInEndSection": 863,
                    "text": "smallpox is now eradicated",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808015",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 1144,
                    "text": "In May 1980 the World Health Assembly in Geneva announced in solemn form the world-wide eradication of the small-pox and gave recommendations to the member countries for concluding measures concerning the small-pox vaccination, the foundation of vaccine reserves and the control of the epidemiological situation in the world.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7013291",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 182,
                    "text": "As a result of vaccination, diseases such as polio and measles have been controlled and small pox has been eradicated",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742580",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 277,
                    "text": "Small pox eradication from the world is the perfect example of the role of mass vaccination of the entire community of the universe. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436190",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 914,
                    "offsetInEndSection": 1057,
                    "text": "The French owe a lot to this Central Committee of Vaccine, which greatly contributed to fighting small pox and eradicating the disease finally.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11503361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 276,
                    "text": "Small pox eradication from the world is the perfect example of the role of mass vaccination of the entire community of the universe.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436190",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 868,
                    "text": "Also, the vaccine that Jenner used, which decreased the prevalence of Small Pox worldwide in his own time, and later was used to eradicate Small Pox altogether, is discussed in light of recent data..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22566811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 760,
                    "text": "the only known cases of smallpox happened from an outbreak in Birmingham, England caused by a laboratory accident in the year of 1979. On May the 8 th 1980 the disease was declared as eliminated from the world by the WHO (WHO-Resolution 33.33).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12822115",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}